Characterising Heterogeneity of Glioblastoma using Multi-parametric Magnetic Resonance Imaging by Li, Chao
Characterising Heterogeneity of 
Glioblastoma using Multi-parametric 
Magnetic Resonance Imaging 
 
   
Chao Li 
Cambridge Brain Tumour Imaging Laboratory,  
Division of Neurosurgery, Department of Clinical Neurosciences 
University of Cambridge 
This dissertation is submitted for the degree of 
Doctor of Philosophy 
 




I would like to dedicate this thesis to my loving families … 
  
Declaration 
I hereby declare that except where specific reference is made to the work of others, the contents 
of this dissertation are original and have not been submitted in whole or in part for consideration 
for any other degree or qualification in this, or any other University. This dissertation is the 
result of my own work and includes nothing which is the outcome of work done in 
collaboration, except where specifically indicated in the text. This dissertation contains less 
than 60,000 words including appendices, bibliography, footnotes, tables and equations and has 




   
Contents 
 
Acknowledgements ................................................................................................................... i 
Abstract ................................................................................................................................... iii 
Abbreviations ........................................................................................................................... v 
Chapter 1 Glioblastoma Heterogeneity: A Multifaceted View ........................................ 1 
1.1 Overview ..................................................................................................................... 1 
1.2 Heterogeneous nature of glioblastoma ........................................................................ 1 
1.3 Significance ................................................................................................................. 3 
1.4 Histology ..................................................................................................................... 3 
1.5 Molecular markers....................................................................................................... 4 
1.5.1 IDH mutations ...................................................................................................... 5 
1.5.2 MGMT promoter methylation status ................................................................... 6 
1.6 Genomics ..................................................................................................................... 7 
1.7 Mathematical models .................................................................................................. 8 
1.8 Magnetic resonance imaging ....................................................................................... 9 
1.8.1 Advantages of the imaging approach ................................................................... 9 
1.8.2 Limitations of conventional MRI....................................................................... 10 
1.8.3 Perfusion imaging .............................................................................................. 12 
1.8.4 Diffusion imaging .............................................................................................. 16 
1.8.5 Magnetic resonance spectroscopy ...................................................................... 21 
1.9 Tumour habitat imaging ............................................................................................ 26 
1.10 Radiomics and radiogenomics ............................................................................... 28 
1.10.1 Definition and advantages.................................................................................. 28 
1.10.2 Workflow ........................................................................................................... 28 
1.10.3 Radiogenomics ................................................................................................... 32 
1.10.4 Challenges and opportunities ............................................................................. 33 
1.11 Summary ................................................................................................................ 35 
Chapter 2 Hypothesis ......................................................................................................... 37 
2.1 General hypothesis .................................................................................................... 37 
2.2 Hypotheses Tested..................................................................................................... 37 
Chapter 3 General Methods .............................................................................................. 40 
3.1 Patient population ...................................................................................................... 40 
3.1.1 Inclusion and exclusion criteria ......................................................................... 40 
3.1.2 Treatment and response evaluation .................................................................... 41 
3.2 Assessment of molecular markers ............................................................................. 42 
3.2.1 IDH-1 mutation .................................................................................................. 42 
3.2.2 MGMT promoter methylation status ................................................................. 42 
3.3 MRI acquisition ......................................................................................................... 43 
3.3.1 Pre-operative sequences ..................................................................................... 43 
3.3.2 Imaging parameters ............................................................................................ 43 
3.4 MRI processing ......................................................................................................... 45 
3.4.1 Brain extraction .................................................................................................. 46 
3.4.2 DTI processing ................................................................................................... 47 
3.4.3 DSC image processing ....................................................................................... 49 
3.4.4 MRS processing ................................................................................................. 51 
3.4.5 Imaging co-registration ...................................................................................... 53 
3.4.6 Tumour segmentation ........................................................................................ 54 
3.4.7 Image analysis .................................................................................................... 58 
Chapter 4 Intra-tumoural Heterogeneity of Glioblastoma Infiltration Revealed by 
Joint Histogram Analysis of Diffusion Tensor Imaging ..................................................... 62 
4.1 Abstract ..................................................................................................................... 62 
4.2 Introduction ............................................................................................................... 64 
4.3 Methods ..................................................................................................................... 65 
4.3.1 Study design ....................................................................................................... 65 
4.3.2 Pre-operative MRI acquisition ........................................................................... 65 
4.3.3 Image processing ............................................................................................... 66 
4.3.4 Histogram analysis ............................................................................................. 66 
4.3.5 Evaluation of treatment response and tumour progression ................................ 68 
4.3.6 Statistical analysis .............................................................................................. 68 
4.4 Results ....................................................................................................................... 69 
4.4.1 Patients ............................................................................................................... 69 
4.4.2 Diffusion signatures of contrast-enhancing and non-enhancing regions ........... 72 
4.4.3 Multivariate survival analysis ............................................................................ 73 
4.4.4 Incremental Prognostic Value of Joint Histogram Features .............................. 74 
4.4.5 Stepwise Multivariate Cox Model Selection ..................................................... 76 
4.4.6 Correlations with tumour progression rate ........................................................ 77 
4.5 Discussion ................................................................................................................. 80 
4.6 Conclusion ................................................................................................................. 82 
Chapter 5 Low Perfusion Compartments in Glioblastoma Quantified by Advanced 
Magnetic Resonance Imaging and Correlated with Patient Survival ............................... 83 
5.1 Abstract ..................................................................................................................... 83 
5.2 Introduction ............................................................................................................... 85 
5.3 Methods ..................................................................................................................... 86 
5.3.1 Patient cohort ..................................................................................................... 86 
5.3.2 MRI acquisition ................................................................................................. 87 
5.3.3 Image processing ............................................................................................... 88 
5.3.4 Regions of interest and volumetric analysis ...................................................... 88 
5.3.5 Multi-voxel MRS processing ............................................................................. 89 
5.3.6 DTI invasive phenotypes ................................................................................... 90 
5.3.7 Statistical analysis .............................................................................................. 92 
5.4 Results ....................................................................................................................... 92 
5.4.1 Patients ............................................................................................................... 92 
5.4.2 Multiparametric MRI identifies two low perfusion compartments ................... 93 
5.4.3 Low perfusion compartments displayed hypoxic and pro-inflammatory 
metabolic signatures ........................................................................................................ 95 
5.4.4 Low perfusion compartments exhibited diverse effects on tumour invasion .... 96 
5.4.5 The ADCL-rCBVL compartment of minimally invasive tumours is less hypoxic
 96 
5.4.6 Low perfusion compartments exhibited diversity in treatment response .......... 97 
5.5 Discussion ............................................................................................................... 100 
5.6 Conclusion ............................................................................................................... 102 
Chapter 6 Multi-parametric and Multi-regional Histogram Analysis of MRI: 
Modality Integration Reveals Imaging Phenotypes of Glioblastoma.............................. 103 
6.1 Abstract ................................................................................................................... 103 
6.2 Introduction ............................................................................................................. 105 
6.3 Methods ................................................................................................................... 106 
6.3.1 Patients ............................................................................................................. 106 
6.3.2 Pre-operative MRI acquisition ......................................................................... 106 
6.3.3 Image processing ............................................................................................. 106 
6.3.4 Histogram features ........................................................................................... 106 
6.3.5 Multi-view feature selection and clustering ..................................................... 107 
6.3.6 Leave-one-out cross validation of the clustering ............................................. 109 
6.3.7 Feature ranking ................................................................................................ 109 
6.3.8 Statistical analysis ............................................................................................ 109 
6.4 Results ..................................................................................................................... 110 
6.4.1 Patients ............................................................................................................. 110 
6.4.2 Identification of patient clusters....................................................................... 111 
6.4.3 Leave-one-out cross-validation of patient clustering ....................................... 112 
6.4.4 Clinical relevance of patient clusters ............................................................... 113 
6.4.5 Metabolic signatures of patient clusters ........................................................... 115 
6.4.6 Feature ranking and feature subset selection ................................................... 119 
6.4.7 Multivariate prognostic performance of selected features ............................... 120 
6.5 Discussion ............................................................................................................... 122 
6.6 Conclusion ............................................................................................................... 124 
Chapter 7 Decoding the Inter-dependence of Multi-parametric Magnetic Resonance 
Imaging to Unravel Patient Subgroups Correlated with Survivals ................................ 125 
7.1 Abstract ................................................................................................................... 125 
7.2 Introduction ............................................................................................................. 127 
7.3 Theory ..................................................................................................................... 128 
7.3.1 Challenges in analysing the inter-dependence of random variables ................ 128 
7.3.2 Empirical copula .............................................................................................. 129 
7.3.3 Clustering model specification ........................................................................ 130 
7.3.4 Methodology design......................................................................................... 130 
7.3.5 Remark ............................................................................................................. 132 
7.4 Methods ................................................................................................................... 132 
7.4.1 Patients ............................................................................................................. 132 
7.4.2 MRI acquisition ............................................................................................... 132 
7.4.3 Image processing ............................................................................................. 133 
7.4.4 Copula transform and patient clustering .......................................................... 133 
7.4.5 Leave-one-out cross-validation of the clustering ............................................. 134 
7.4.6 Statistical analysis ............................................................................................ 135 
7.5 Results ..................................................................................................................... 135 
7.5.1 Patient population ............................................................................................ 135 
7.5.2 Patient clustering .............................................................................................. 135 
7.5.3 Leave-one-out cross-validation of patient subtypes ........................................ 139 
7.5.4 Survivals of patient subtypes ........................................................................... 140 
7.6 Discussion ............................................................................................................... 143 
7.7 Conclusions ............................................................................................................. 145 
Chapter 8 Radiomic Features from Multimodal MRI Show Improved Accuracy in 
Predicting MGMT Promoter Methylation in Glioblastoma ............................................ 146 
8.1 Abstract ................................................................................................................... 146 
8.2 Introduction ............................................................................................................. 148 
8.3 Methods ................................................................................................................... 149 
8.3.1 Development cohort ......................................................................................... 149 
8.3.2 Pre-operative MRI acquisition ......................................................................... 149 
8.3.3 Image processing ............................................................................................. 149 
8.3.4 Radiomic feature extraction ............................................................................. 150 
8.3.5 Feature ranking ................................................................................................ 151 
8.3.6 Classification scheme....................................................................................... 151 
8.3.7 Permutation test ............................................................................................... 152 
8.3.8 Independent validation cohort.......................................................................... 152 
8.3.9 Statistical analysis ............................................................................................ 152 
8.4 Results ..................................................................................................................... 153 
8.4.1 Patients and regions of interest ........................................................................ 153 
8.4.2 Feature Ranking and Classification Performance ............................................ 154 
8.4.3 Diagnostic Validation of Radiomics Features ................................................. 156 
8.4.4 Prognostic Values of Radiomic Features ......................................................... 157 
8.5 Discussion ............................................................................................................... 158 
8.6 Conclusion ............................................................................................................... 160 
Chapter 9 General Conclusions and Limitations .......................................................... 161 
9.1 Summary of findings ............................................................................................... 161 
9.2 Limitations of studies .............................................................................................. 163 
9.2.1 Patient inclusion criteria .................................................................................. 163 
9.2.2 Single centre cohort ......................................................................................... 163 
9.2.3 Sample size ...................................................................................................... 164 
9.2.4 Effects of dexamethasone ................................................................................ 164 
9.2.5 Pseudoprogression ........................................................................................... 164 
9.2.6 Lack of histological validation......................................................................... 165 
9.3 Future directions ...................................................................................................... 165 
9.3.1 Image-guided biopsy to validate imaging biomarkers ..................................... 165 
9.3.2 Improving the reproducibility and robustness of the radiomics approach ....... 166 
9.3.3 Incorporating radiomics and habitat imaging into prospective and longitudinal 
cohort study .................................................................................................................... 166 
Chapter 10 List of Publications ..................................................................................... 168 
References ............................................................................................................................. 171 
 
Acknowledgements 
Firstly, I would like to express my sincere gratitude to my PhD supervisor, Mr Stephen Price, 
for his guidance to my PhD projects, for his motivation during my research. He not only offered 
me the opportunity of studying in Cambridge, but also showed me into the career path as an 
academic clinician. His great patience and guidance have helped me to overcome the 
difficulties throughout my research. He has created such an excellent research environment as 
a group leader, with his immense knowledge and encouragement. The door to Mr Price’s office 
is always open to me whenever I have difficulties or need discussion, by which he steered me 
to the right direction in my PhD study.  
I would like to thank my second supervisor, Dr Florian Markowetz, for his generous support 
and guidance. He opened the door for me of learning bioinformatics techniques, which broaden 
my horizons from various perspectives. He also kindly gave me access to the research facilities 
and resources in Cancer Research UK Cambridge Institute, which allows me to have the 
opportunities of exploring the broader topic of cancer research. The CI group meeting and 
lectures are insightful and energetic, during which I can learn plenty of world-class research 
tools and ideas.  
The Cambridge Brain Tumour Imaging Laboratory: 
Dr Timothy Larkin was a senior member before I joined the lab. Although I have not had the 
chance to meet him in person, he had helped the lab to set up the pipeline of image processing 
using FSL and MATLAB functions, which we are still using in our research. I would like to 
thank Dr Natalie Boonzaier, a senior PhD student who graduated in 2016, for her great help in 
collecting and maintaining the patient database, for providing her tumour masks for the inter-
rater reliability test. She kept helping me after she left for London. I would like to thank Dr 
Jiun-Lin Yan, who arrived a year before me as a senior PhD student, for his time and efforts in 
setting up the general methodology of image processing. He is always ready to help and 
discuss, which inspired me for research ideas. In addition to the help in research, he is such a 
  ii 
 
good friend in helping me to settle down in Cambridge, as well as a neurosurgeon colleague 
for communication. I wish to thank Mr Bart van Dijken, a visiting PhD student from the 
University of Groningen, Netherlands, for his help in database correction and discussion. I wish 
to thank Dr Rohitashwa Sinha, a neurosurgeon registrar and a fellow PhD student, for his help 
in data collection and discussion. I would like to thank Dr Rory Piper, an academic foundation 
trainee, for his help in progression analysis. I also wish to thank Dr Roushanak Rahmat, a post-
doc of the lab, for her valuable discussion. 
Cancer Research UK Cambridge Institute: 
I would thank Dr Mary McLean for her helpful advice on the sequence protocols of chemical 
shift imaging and the analysis of spectra, as well as the great help in data collection. I wish to 
thank Dr Turid Torheim, a post-doc of Markowetz Lab, for her feedback and discussion. Her 
valuable questions and comments have helped me to validate and clarify my research. She also 
kindly helped me to establish the experimental pipeline. I also wish to thank Dr Andrew 
Holding, a senior research associate in Markowetz Lab and Ms Amy Cullen, a research 
assistant of Markowetz Lab, for their help in establishing tissue processing protocols, with 
great patience and kindness. I wish to thank Dr Mireia Crispin-Ortuzar for her insightful 
discussion and comments.  
The Department of Clinical Neurosciences, the Division of Neurosurgery, the Wolfson 
Brain Imaging Centre and the Department of Oncology: 
I wish to thank Professor Michael Coleman, Dr Ruma Raha-Chowdhury Dr Adrian Carpenter, 
Dr Emmanuel Stamatakis, and Mrs Shannon Tinley-Browne, for organising seminars and 
lectures, and for the considerate guidance during the PhD study. I would also like to thank Mr 
Colin Watts and Dr Raj Jena who provided me with precious suggestions for my projects. I 
wish to also thank all the radiologists, radiographers, and research nurses involved in sequence 
development and patient scanning. 
The Department of Radiology and EPSRC Centre for mathematical and statistical 
analysis of multimodal clinical imaging: 
  iii 
 
I would like to thank Dr Tomasz Matys for his help in patient recruitment, data retrieval and 
annotation. I wish to thank Professor John Aston and Professor Carola-Bibiane Schönlieb for 
their guidance in mathematical modelling. I would like to thank Dr Yuan Huang, Dr Pan Liu, 
Dr Jingjing Zou, Dr Jianmin Yuan and Mr Shuo Wang for their technical help and supports.  
The funding bodies: 
I would like to take this opportunity to thank The Cambridge Trust and the China Scholarship 
Council for providing funding for my PhD study in Cambridge. I would like to thank the British 
Neuro-Oncology Society for funding my Conference attendance. I wish to express my 
appreciation to the EG Fearnsides Trust and ISMRM who funded my attendance for 2018 
ISMRM conference in Paris. I would like to thank Clare College for funding my research.  
I would like to finally express my sincerest gratitude to the patients who participated in the 
study. Their voluntary time and efforts for the scanning have provided researchers and 




A better understanding of tumour heterogeneity is central for accurate diagnosis, targeted 
therapy and personalised treatment of glioblastoma patients. This thesis aims to investigate 
whether pre-operative multi-parametric magnetic resonance imaging (MRI) can provide a 
useful tool for evaluating inter-tumoural and intra-tumoural heterogeneity of glioblastoma. 
For this purpose, we explored: 1) the utilities of habitat imaging in combining multi-parametric 
MRI for identifying invasive sub-regions (I & II); 2) the significance of integrating multi-
parametric MRI, and extracting modality inter-dependence for patient stratification (III & IV); 
3) the value of advanced physiological MRI and radiomics approach in predicting epigenetic 
phenotypes (V). The following observations were made: 
I. Using a joint histogram analysis method, habitats with different diffusivity patterns 
were identified. A non-enhancing sub-region with decreased isotropic diffusion and increased 
anisotropic diffusion was associated with progression-free survival (PFS, hazard ratio [HR] = 
1.08, P < 0.001) and overall survival (OS, HR = 1.36, P < 0.001) in multivariate models. 
II. Using a thresholding method, two low perfusion compartments were identified, which 
displayed hypoxic and pro-inflammatory microenvironment. Higher lactate in the low 
perfusion compartment with restricted diffusion was associated with a worse survival (PFS: 
HR = 2.995, P = 0.047; OS: HR = 4.974, P = 0.005). 
III. Using an unsupervised multi-view feature selection and late integration method, two 
patient subgroups were identified, which demonstrated distinct OS (P = 0.007) and PFS (P < 
0.001). Features selected by this approach showed significantly incremental prognostic value 
for 12-month OS (P = 0.049) and PFS (P = 0.022) than clinical factors.  
IV. Using a method of unsupervised clustering via copula transform and discrete feature 
extraction, three patient subgroups were identified. The subtype demonstrating high inter-
  iv 
 
dependency of diffusion and perfusion displayed higher lactate than the other two subtypes (P 
= 0.016 and P = 0.044, respectively). Both subtypes of low and high inter-dependency showed 
worse PFS compared to the intermediate subtype (P = 0.046 and P = 0.009, respectively). 
V. Using a radiomics approach, advanced physiological images showed better 
performance than structural images for predicting O6-methylguanine-DNA methyltransferase 
(MGMT) methylation status. For predicting 12-month PFS, the model of radiomic features and 
clinical factors outperformed the model of MGMT methylation and clinical factors (P = 0.010). 
In summary, pre-operative multi-parametric MRI shows potential for the non-invasive 
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Chapter 1 Glioblastoma Heterogeneity: A 
Multifaceted View 
1.1 Overview 
Glioblastoma is the commonest primary malignant tumour in the central nervous system of 
adults. Although the overall age-standardised incidence is only 4.64/100,000 patient-years 
(Brodbelt et al., 2015), it is one of the leading cancer-related death causes in young adults, with 
a recently reported rising incidence (Johnson, 2012). Over the last decade, the standard first-
line management of this disease has been accepted as maximal safe surgical resection followed 
by concomitant and adjuvant temozolomide (TMZ) chemoradiotherapy, which has been shown 
to improve patient outcomes. However, the survival of most glioblastoma patients remains low. 
The median overall survival (OS) of optimally managed patients is only 12-15 months (Hegi 
et al., 2005a, Ricard et al., 2012).  
Glioblastoma is characterised by its diffuse infiltration into the surrounding normal brain tissue, 
which renders a total surgical resection impossible. Moreover, the high proliferation and 
resistance to adjuvant therapies often cause current treatment strategies to be ineffective. In 
addition, the heterogeneity of glioblastoma can further challenge diagnosis, prognosis 
determination and treatment planning. Thus, these tumours are associated with a high tendency 
of local recurrence and high mortality rate.  
1.2 Heterogeneous nature of glioblastoma 
Glioblastomas are highly heterogeneous tumours by nature. The heterogeneity of this disease 
was initially described according to its microscopic manifestation, such as, the various extent 
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of necrosis and haemorrhage. Other histological observations indicating heterogeneity include 
cellular pleomorphism and variations in microvascularization (Louis et al., 2016). For recent 
decades, however, it has been noticed that under the same histological diagnosis of 
glioblastoma, patients may have distinct clinical outcomes (Verhaak et al., 2010), suggesting 
that multiple phenotypes may exist under the same disease entity. With further knowledge, 
tumour heterogeneity is found not limited to histological level. Actually, tumour heterogeneity 
is a multifaceted research field, which involves multiple aspects of knowledge, including 
genomics, mathematics, radiology, and clinical oncology. 
There are two levels of tumour heterogeneity that exist. The heterogeneity of glioblastoma can 
be found not only among patients but also within an individual tumour. Many tumour sub-
populations can exist in the same tumour, which may result from the tumour clonal evolution 
and constitute a complex tumour system (Burrell et al., 2013). Therefore, for clarity, the tumour 
heterogeneity among patients is termed as inter-tumoural heterogeneity, whilst heterogeneity 
observed within individual tumours is known as intra-tumoural heterogeneity (Figure 1.1). 
 
Figure 1.1 Inter-tumoural and intra-tumoural heterogeneity. Inter-tumoural heterogeneity refers to the 
variations among patients, whereas intra-tumoural heterogeneity refers to the spatial variations existing in the 
same tumour. Sub-populations of tumour cells may co-exist in the same tumour, which may result from the 
tumour evolution. 
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1.3 Significance 
It has been established that heterogeneity is one of the hallmarks of tumourigenesis (Greaves 
and Maley, 2012). There is a pressing but unmet need for a better understanding of tumour 
heterogeneity, which is of particular importance for the personalised treatment of glioblastoma.  
Firstly, given the diverse treatment response of patients, an accurate assessment of inter-
tumoural heterogeneity of glioblastoma holds promise for outcome improvement, with the 
potential of more precise diagnosis and therapeutic stratification for patients.  
Secondly, as it is accepted that some intra-tumoural clones/sub-regions have advantages in 
migration, invasion, and treatment resistance, and therefore would be particularly responsible 
for treatment failure. Identifying these invasive clones/sub-regions before treatment and further 
understanding how they influence tumour invasiveness may lead to future treatment targets.  
Last but not least, as a result of the selective stress in tumour evolution, heterogeneity may in 
reverse facilitate the emergence of novel mutations, and thus lead to adaptable clones (Yan et 
al., 2014). Although currently a wide range of therapeutic strategies, including immunotherapy 
and gene therapy, are under development or in the clinical trial, their efficacy and safety need 
further evaluation. Knowledge about tumour heterogeneity would help the development of new 
therapeutic strategies and clinical assessment techniques. 
1.4 Histology 
In the past century, histology assessment is the gold standard for the diagnosis of glioblastoma. 
Glioblastomas were diagnosed mainly based on their microscopic histological appearances and 
the cellular morphology observed on tumour tissue sections. The common histological features 
include necrosis, microvascular proliferation, mitoses, pseudopalisades, thromboses, and 
haemorrhages (Louis et al., 2016, Habberstad et al., 2012). Among these histopathological 
criteria, necrosis and microvascular proliferation are central to the microscopic diagnosis, 
which was found to be consistently co-existing in a retrospective study of 200 primary 
glioblastoma patients (Habberstad et al., 2012).   
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The past decade witnessed substantial advances in the identification of disease-related genetic 
alterations. Efforts have been made to improve the traditional histopathological paradigm using 
molecular genetic classification. As a step forward, the ‘2016 WHO Classification of Tumours 
of the Central Nervous System’ has incorporated isocitrate dehydrogenase (IDH) mutations 
into the classification of glioblastoma (Louis et al., 2016). The significance of this version of 
WHO classification is not only to provide a novel classification for more accurate 
determination of diagnosis and prognosis, but also to mark the first attempt of combining 
molecular markers into the clinically applicable guideline (Figure 1.2). 
 
 
Figure 1.2 2016 WHO classification of the diffuse gliomas (Louis et al., 2016) 
1.5 Molecular markers 
In the last decades, knowledge of glioblastoma heterogeneity has accumulated from the genetic 
profiling of patients. Several genetic and epigenetic markers are reported to add diagnostic 
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and/or prognostic values, including IDH mutations, O6-methylguanine-DNA methyltransferase 
(MGMT) promoter methylation status, epidermal growth factor receptor (EGFR) mutations, 
tumour protein p53 (TP53) mutations, telomerase reverse transcriptase (TERT) promoter 
mutations.  Here is a brief introduction to two markers that are relevant in this thesis.  
1.5.1 IDH mutations 
IDH mutations are among one of the most frequently mutated metabolic genes identified in 
human cancers, although exactly how the aberrant enzymatic activity modulates cellular 
transformation is still unclear (Ye et al., 2013). 
IDH mutations are considered as one of the driver mutations of gliomas, with diagnostic and 
prognostic significance. The Cancer Genome Atlas (TCGA) project reported that 12% 
glioblastomas have IDH-1 mutations, which are more likely to occur in young patients (Parsons 
et al., 2008a). In secondary glioblastomas, the mutations are associated with a better survival 
(Parsons et al., 2008a). By contrast, only 5-8% primary glioblastomas were reported to have 
IDH mutations (Yen et al., 2010). In a retrospective study including 404 patients with grade II-
IV gliomas, multivariate survival analysis showed that IDH-1 mutation was a favourable 
prognostic marker, independent of other clinical factors (Sanson et al., 2009). However, 
whether the prognostic value of IDH mutations is from the gene function per se or arises from 
the better treatment response still needs further investigation (Sanson et al., 2009, Cohen et al., 
2013).  
Due to the diagnostic and prognostic values of IDH mutations in glioblastoma, the 2016 WHO 
classification separated glioblastoma into three subtypes: IDH-wildtype, IDH-mutant, and 
NOS. The diagnosis of NOS is reserved for the circumstances in which the evaluation cannot 
be performed. A comparison of the clinical characteristics of IDH-wildtype and IDH-mutant 
glioblastomas is in Table 1.1 (adapted from (Louis et al., 2016)). 
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Table 1.1 Characteristics of IDH-wildtype and IDH-mutant glioblastoma  
 IDH-wildtype IDH-mutant 
Precursor lesion 
Not identifiable; 
develops de novo 
Diffuse astrocytoma; 
Anaplastic astrocytoma 
Proportion of glioblastoma ~90% ~10% 
Median age at diagnosis ~62 years ~44 years 
Male to female ratio 1.42:1 1.05:1 
Median length of clinical history 4 months 15 months 
Median overall survival 
    Surgery + radiotherapy 9.9 months 24 months 
    Surgery + chemoradiotherapy 15 months 31 months 
Location Supratentorial Preferentially frontal 
Necrosis Extensive Limited 
  
 
1.5.2 MGMT promoter methylation status 
The gene of MGMT contains five exons and a CpG island. In normal conditions, most of the 
CpG sites within the island are unmethylated. The gene function of MGMT is central in 
maintaining genomic integrity, by encoding a DNA repair protein, which can reduce the DNA 
damage caused by TMZ (Pegg, 1990). The methylated MGMT promoter can lead to a better 
sensitivity to TMZ, by silencing the MGMT expression (Hegi et al., 2008, Hegi et al., 2005a).  
A methylated MGMT promoter was found in about 40% of primary glioblastoma, and over 
70% of secondary glioblastoma (Riemenschneider et al., 2010, Weller et al., 2010). The 
MGMT promoter methylation status is reported to be an independent prognostic marker for 
glioblastoma patients (Boots-Sprenger et al., 2013). After chemoradiotherapy, 49% methylated 
glioblastoma cases survived for more than 2 years. In comparison, only 15% unmethylated 
glioblastoma cases can survive longer than 2 years (Hegi et al., 2005a).  
1.6 Genomics 7 
 
1.6 Genomics 
With the advancement of next-generation sequencing (NGS) technique, large-scale data were 
generated through genomics, epigenomics, transcriptomics and proteomics analysis. Genomics 
can promote the understanding of tumour heterogeneity, by depicting the complicated genetic 
signatures of glioblastoma (Brennan et al., 2013). Multiple distinct molecular subtypes have 
been identified, characterised by the alterations of PDGFRA, IDH-1, EGFR and NF1. These 
four subtypes, namely proneural, neural, classical and mesenchymal subtypes, are derived from 
the transcriptional signatures (Verhaak et al., 2010). The distinct patient survivals of these four 
subtypes suggest that they may represent different entities, even under the same histological 
diagnosis of glioblastoma (Ye et al., 2012, Bhat et al., 2013).  
This classification scheme, however, did not distinguish the transcriptomes of tumour cells and 
non-malignant cells. A recent revisit of this scheme using glioblastoma-specific mRNA 
revealed that three tumour-intrinsic subtypes robustly exist: classical, proneural, and 
mesenchymal (Wang et al., 2017). The exclusion of neural subtype is possibly due to the 
contamination of non-malignant cells in original samples. Further, using paired samples from 
primary and recurrent tumours, this study found that these transcriptional subtypes were 
consistent in only 55% samples, highlighting the plasticity of this classification. The shift 
between subtypes was postulated to be mediated by the interaction between tumour cells with 
microenvironmental cues (Wang et al., 2017).  
Above evidence have established the existence of inter-tumour heterogeneity of glioblastoma. 
As we mentioned above, remarkable intra-tumour heterogeneity exists within individual 
glioblastoma. It was thus speculated that multiple subtypes may co-exist within a single 
tumour. To address this hypothesis, a fluorescence guided multisampling approach was 
developed in a previous study (Sottoriva et al., 2013a), by which multiple spatially separated 
tumour samples were collected through surgical resections. The results confirmed the existence 
of multiple subtypes within the same tumour. Further, with the phylogeny of these sample 
fragments reconstructed, it was revealed that the intra-tumoural heterogeneity may arise from 
the clonal evolution during the disease progression, which may impact patient treatment and 
thus have clinical significance (Sottoriva et al., 2013a). 
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1.7 Mathematical models 
It has been a challenge to evaluate glioblastoma heterogeneity with quantitative methods. As a 
useful tool for hypothesis testing in understanding the biological process, mathematical 
modelling shows potential in this regard. To simulate the evolution of a complex tumour 
system, many mathematical models have been proposed. The different aspects of tumour 
behaviours, i.e., the growth rate of tumour cells, tumour cellularity, angiogenesis, are 
considered in sophisticated models (McDougall et al., 2006, Frieboes et al., 2006, Swanson et 
al., 2003). More recently, with a spatial model of tumour evolution, how short-range dispersal 
and cell turnover can affect intra-tumour heterogeneity was simulated (Waclaw et al., 2015). 
These models exhibit potential in providing theoretical models for tumour heterogeneity study. 
Medical images have the unique advantage of providing global information of a tumour. Thus, 
it would be possible to infer the microscopic tumour growth, invasion and evolution using 
multi-parametric and multi-temporal imaging. Considering that glioma exhibits high abilities 
of proliferation and migration, a mathematical approach was developed to quantify net 
proliferation rate (ρ) and net diffusion factor (D), using T1-weighted and T2-weighted images 
to calculate patient-specific metrics (Swanson et al., 2008). The invasiveness metrics from this 
approach has shown correlates with patient clinical outcomes and tumour extent of resection 
(Baldock et al., 2014).  
Other studies have incorporated advanced imaging modalities into the mathematical model to 
reflect the physiological information of tumour growth (Hormuth et al., 2015). With the 
advantages of diffusion imaging in reflecting the white matter tract pathology, a model using 
diffusion tensor imaging was proposed (Jbabdi et al., 2005). This study was based on the 
hypothesis that tumour infiltration may preferentially spread along white matter tracts (Jbabdi 
et al., 2005).    
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1.8 Magnetic resonance imaging  
1.8.1 Advantages of the imaging approach  
Imaging approach plays an important role in the assessment of glioblastoma heterogeneity and 
clinical patient management. It would provide indispensable tools for the assessment of tumour 
heterogeneity. Compared to the aforementioned methods, imaging approach has several 
advantages in evaluating tumour heterogeneity.  
One of the advantages is that imaging is non-invasive or minimally invasive in the acquisition. 
Therefore, it can be performed repeatedly at different time points, with lower risks than 
invasive procedures, which can significantly facilitate the temporal evaluation of tumour 
growth and invasion. Another advantage is that tumour imaging can profile an entire tumour 
in vivo. Although histological and genetic assessments can determine tumour malignancy, they 
are based on a fraction of tumour samples obtained via surgery or biopsy, which is prone to 
sampling errors. In comparison, the spatial information from imaging is not limited by the 
tumour tissue obtained. 
Magnetic resonance imaging (MRI) is by far the most widely used imaging technique for 
glioblastoma (Sorensen, 2006, Kuzucan et al., 2012). The excellent ability of MRI in 
visualising soft tissue offers the advantage of reflecting brain structure. Further, multiple MRI 
sequences have been developed to target different tumour properties, which provide crucial 
complementary information for tumour grading, malignant assessment, diagnosis 
determination and treatment response prediction.  
Current clinical evaluation of glioblastoma is primarily based on anatomical MRI sequences, 
including post-contrast T1-weighted imaging, T2-weighted imaging, T2 fluid-attenuated 
inversion recovery (FLAIR). Among these MRI sequences, post-contrast T1-weighted imaging 
is the most widely used. A typical presentation of glioblastoma on post-contrast T1-weighted 
imaging is a contrast-enhancing mass lesion with the central non-enhancing sub-regions 
(commonly considered as ‘necrosis’), and peritumoural oedema surrounding the contrast-
enhancing lesion. These radiographical manifestations suggest that glioblastoma is highly 
heterogeneous in terms of morphological appearances. 
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T2-weighted FLAIR shows hyperintensity surrounding the contrast-enhancing tumour core. 
Compared to T2-weighted images, T2-weighted FLAIR provides the advantages of 
cerebrospinal fluid (CSF) suppression. Normally, the non-enhancing peritumoural areas 
visualised on T2-weighted FLAIR images are considered to represent a tumour region outside 
of the tumour core visualised on contrast-enhancing images, which may include both 
oedematous and infiltrative regions (Villanueva-Meyer et al., 2017).  
1.8.2 Limitations of conventional MRI 
Although widely used in clinical practice, conventional MRI sequences are considered to bear 
several limitations.  
Firstly, the enhancement on post-contrast T1-weighed imaging is used to provide references 
for tumour grading. However, evidence shows that this enhancement does not necessarily 
correlate with tumour malignancy. Some glioblastomas may not demonstrate enhancement, 
whereas some low-grade glioma or other tumour types may be contrast-enhancing (Pouratian 
et al., 2007).  
Secondly, the enhancement can facilitate the delineation of tumour margin, based on the 
process of contrast agent passing through the brain blood barrier (BBB). This leakage of the 
BBB, however, is not specific in delineating the tumour invasion area (White et al., 2005). It 
is known that current surgical resection based on conventional post-contrast T1-weighted 
imaging fails to resect the tumour effectively, due to the highly infiltrative growth of 
glioblastoma (Neira et al., 2017). This failure suggests that the invasive margin of glioblastoma 
is well beyond the region visualised on post-contrast T1-weighted images (Price et al., 2006).  
Other MRI sequences may complement the information of post-contrast T1-weighted imaging. 
Among them, T2-weighted sequences are especially sensitive to oedematous tissue. With the 
advantages of T2-weighted imaging, T2-weighted fluid-attenuated inversion recovery 
(FLAIR) sequence adds the advantage of suppressing cerebrospinal fluid signal. Therefore, T2-
weighted and T2-weighted FLAIR sequences are widely used to investigate white matter 
abnormalities and localise tumours. The Response Assessment in Neuro-Oncology (RANO) 
Working Group suggests combining these techniques into clinical assessment, to compensate 
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for the limitations of T1-weighted imaging (Wen et al., 2010). These sequences, however, are 
still considered to be non-specific for differentiating tumour infiltration from tumour-
associated oedema and delayed radiation white matter change (Wen et al., 2010). Previous 
evidence showed that FLAIR is non-specific in managing tumour with stroke patients (Green 
et al., 2002, Price et al., 2011). 
Another limitation of conventional imaging is in its weakness of differentiating 
pseudoprogression with true progression. Pseudoprogression was recognised long ago, but the 
incidence was reported to be increasing since temozolomide (TMZ) chemoradiotherapy was 
accepted as the standard of care. The possible explanation is that the increased sensitivity to 
the TMZ chemoradiotherapy may cause a higher extent of treatment-related necrosis (Bach and 
Jordan, 2005). In a cohort study which investigated 208 newly-diagnosed glioblastoma patients 
treated with the Stupp protocol of TMZ concomitant and adjuvant chemoradiotherapy, 
pseudoprogression was observed in 30% patients and significantly associated with MGMT 
methylation status (Brandes et al., 2008). Since pseudoprogression is almost indistinguishable 
from true progression on conventional imaging, the diagnosis of pseudoprogression is 
recommended to be made according to a retrospective review and should incorporate imaging 
and clinical parameters (Wen et al., 2010).  
To summarize, although magnetic resonance imaging has unique advantages in investigating 
tumour heterogeneity non-invasively, it bears many limitations in reflecting tumour physiology. 
There is a clinical demand for the improvement of imaging techniques. Further, new post-
processing techniques are in pressing demand to integrate multiple imaging techniques for 
precise patient management.  
Pre-clinical and clinical physiological imaging sequences have shown their potentials in 
compensating the limitations of conventional sequences (van Dijken et al., 2017). These 
physiological sequences are considered to be more specific in reflecting tumour physiology. 
Integrating the multiple imaging modalities may potentially provide a more comprehensive 
measurement for tumour heterogeneity. Following is the introduction of the techniques of 
advanced imaging and data analysis that will be used in this thesis.  
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1.8.3 Perfusion imaging 
Perfusion refers to the biological process in which blood supply is delivered to the organ/tissue 
through the capillary bed. The measurement of tissue perfusion is crucial to determine the 
physiological state of the organ/tissue.  
The utility of quantitative perfusion MRI in oncology is based on the commonly observed 
associations between tumour malignancy and angiogenesis (Figure 1.3). As the tumours 
progress, there is a frequent observation of mismatched energy demand and blood supply. This 
mismatch may create a hypoxic tumour microenvironment, which may lead to the activations 
of angiogenic factors that modulate the formation of new blood vessels (Wesseling et al., 1997, 
Hanahan and Weinberg, 2011a). This tumour-related neovasculature, however, is marked by 
the aberrant vascular structure, which is inefficient in delivering blood supply and may lead to 
the failure of BBB (Hanahan and Weinberg, 2011a).   
Perfusion MRI includes the imaging techniques with or without exogenous contrast agent. The 
most commonly-used in oncological imaging are those with exogenous contrast agent, i.e., 
dynamic susceptibility contrast (DSC) MRI and dynamic contrast-enhanced (DCE) MRI. With 
the diffusable tracers, the wash-in and wash-out kinetics can be detected to reflect tissue 
perfusion (Detre et al., 1992). Using these techniques, contrast-enhancing images are 
 
Figure 1.3 Abnormal Vasculature of Tumours. The dilated and tortuous tumour vasculature is characterised by 
increased permeability and higher interstitial pressure compared with normal. After anti-angiogenesis therapy, the 
vascular permeability decreased and vasculature is improved (Ellis and Hicklin, 2008). 
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dynamically acquired in every a few seconds, during and after the contrast agent administered 
intravenously. Thus, the signal change in this process is detected to reflect the hemodynamics. 
Imaging biomarkers representing microvasculature characteristics are thus calculated from the 
model fitting of the dynamics.  
1.8.3.1 Dynamic susceptibility contrast MRI 
The contrast agent in the blood vessels can lead to different susceptibility between the vessel 
and the tissue (Rosen et al., 1990). DSC imaging measures the amount of contrast agent which 
remains in the tumour vessels during the first pass of the bolus passing through the capillary 
bed. By detecting T2* signal intensity reduction in this process, a concentration-time curve of 
the contrast agent can be fitted (Paulson and Schmainda, 2008). This technique allows for the 
calculation of several imaging biomarkers from the curve, including the relative cerebral blood 
volume (rCBV), the time to peak (TTP), mean transit time (MTT) and cerebral blood flow 
(CBF) (Figure 1.4).  
Among the above biomarkers, rCBV is the most widely used and has been intensively 
documented in the literature. Normally, the blood volume in a given amount of tissue can be 
calculated from the concentration-time curve, using the area under the curve (Petrella and 
Provenzale, 2000).  However, the absolute value of CBV can be affected by a number of 
factors, including the injection time and amount of the contrast agent, the cardiac output of the 
subjects. In addition, the capillary permeability of different subjects can be various, which can 
significantly influence the blood volume calculation (Petrella and Provenzale, 2000). 
Therefore, the CBV value is normally expressed as a relative value (rCBV) to the intra-subject 
control (the contralateral whiter matter is normally used).  
Previous studies showed that rCBV is associated with tumour angiogenesis and proliferation, 
and may predict tumour grading and patient outcomes (Law et al., 2008, Santarosa et al., 2016). 
A recent study of 288 glioma patients explored the correlations between the imaging phenotype 
with the genotype. The results demonstrated that rCBV can indicate IDH mutation status, 
which was associated with the hypoxia-initiated angiogenesis (Kickingereder et al., 2015). In 
a retrospective pilot study of recurrent glioblastoma who received angiogenic-inhibiting 
chemotherapy, rCBV maps were derived from DSC perfusion imaging. The hyperperfusion 
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volume of rCBV, defined as the volume of tumour sub-regions with higher rCBV value than a 
predetermined threshold, was found to show a correlation with time to progression of patients 
(Sawlani et al., 2010). Another study, using a series of image features extracted from pre-
treatment DSC-MRI, identified a subgroup of patients with poor clinical outcomes. 
Angiogenesis and hypoxia pathways were enriched in this subgroup, which may potentially 
benefit from antiangiogenic therapies (Liu et al., 2016).  
 
Figure 1.4 Signal intensity-time curve of DSC. DSC imaging measures the amount of contrast agent which 
remains in the tumour vessels during the contrast agent passing through the capillary bed, by detecting T2* 
signal intensity reduction in this process. The significant contrast leakage caused by the disrupted blood-brain 
barrier in glioblastoma may confound the assumption of the modelling. Therefore, a leakage correction is 
required for the DSC data analysis. The leakage can display different patterns, as shown above (adapted from 
(Goo and Ra, 2017)). The T1-dominant (increases above baseline) and T2*-dominant (fails to return to 
baseline) patterns can be related to different tumour characteristics (Plaza et al., 2013).  
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Although DSC-MRI provides diagnostic and prognostic values in the above studies, the 
application of DSC-MRI is restricted by the challenges in its post-processing data analysis 
(Paulson and Schmainda, 2008). One of these challenges is caused by the permeability of the 
tumour-related neovasculature, which is often observed in solid tumours as above mentioned. 
This permeability leads to the leakage of the contrast agent into the extravascular extracellular 
space (EES), which may complicate the curve fitting of the T2* signal intensity reduction. 
Thus, it is crucial to compensate for the leakage effect in the post-processing (Paulson and 
Schmainda, 2008). A preload of contrast agent and post-processing leakage correction 
algorithms are recommended. A recent study using a single-dose and low-flip-angle method 
was reported to provide comparable measurement to the double-dose method (Kathleen M 
Schmainda, 2018).  
Since above perfusion biomarkers can be computed at a voxel by voxel basis, previous studies 
showed that the spatial heterogeneity of angiogenesis within gliomas can be characterised using 
the DSC-derived parameters (Lupo et al., 2005).  
1.8.3.2 Dynamic contrast-enhanced MRI 
Although DCE-MRI is not used in this thesis, it is widely used in cancer imaging research and 
should be briefly introduced. The T1-weighted technique measures the relaxivity effects of the 
paramagnetic contrast agent, which may cause a shortening of T1 relaxation time and lead to 
higher signals on T1-weighted images (Petrella and Provenzale, 2000). DCE-MRI can detect 
the T1-weighted signal increase, during the process of contrast agent passing through from the 
intravascular space into EES. The signal intensity-time curve can be estimated after injecting 
the contrast agent. As the images are dynamically acquired every a few seconds, this curve can 
reflect the kinetics of contrast agent efflux, which is an overall effect of the tissue perfusion, 
permeability of blood vessels and the volume of EES (Essig et al., 2013). This curve is then 
converted into a time-concentration curve, for the calculation of imaging biomarkers. As the 
relaxivity effects are normally stronger than the susceptibility effects, DCE-MRI requires a 
smaller dose of contrast agent in the acquisition, compared to DSC-MRI (Petrella and 
Provenzale, 2000).  
1.8 Magnetic resonance imaging 16 
 
The differences in the mechanisms of contrast enhancement result in different analysis methods 
between DCE-MRI and DSC-MRI. To interpret the curve of DCE-MRI, pharmacokinetic 
models are developed considering two compartments: blood plasma and EES. Parameters can 
be calculated from the compartment-based pharmacokinetic models (Asselin et al., 2012, Tofts 
and Kermode, 1991), including contrast transfer coefficient (Ktrans), fractional blood plasma 
volume (vp), and the volume of EES (ve). Among these markers, K
trans is most-frequently used, 
which reflects the combined effects of blood flow and microvascular permeability. Due to the 
dilated and tortuous tumour vasculature, tumours usually demonstrate significantly higher 
permeability than normal tissue. As the anti-angiogenic therapy is considered to reduce 
neovasculature and permeability, Ktrans is reported to be useful in treatment response (Sorensen 
et al., 2009).  
1.8.4 Diffusion imaging  
Diffusion imaging is used to measure the mobility of water molecules in brain tissue, based on 
the flux of protons in water (Sabatke and Burge, 2002). Normally, the water molecules move 
in Brownian motion resulting from their thermal energy. Thus, water molecules conform to a 
Gaussian distribution in brain tissue, provided there is no barrier restricting their movement. In 
brain tissue, however, the movement of these water molecules displays as the interaction with 
the microstructure including fibres, cellular structures or macromolecules. By detecting water 
molecule movement, diffusion imaging can quantify the overall diffusivity of water molecules 
observed at voxel levels using statistical models, which thus would provide information to the 
brain microstructure (Le Bihan et al., 2001). Therefore, diffusion imaging has potentials in 
measuring the highly heterogeneous microstructure in glioblastoma, which is influenced by the 
tumour cellular proliferation and destruction. MRI is the only imaging method that detects 
diffusion so far. 
Diffusion imaging has evolved into several techniques, among which the simplest is diffusion 
weighted imaging, from which apparent diffusion coefficient (ADC) can be calculated. 
Diffusion weighted imaging (DWI) is acquired through a spin-echo planar sequence. After two 
gradient field applied, the movement of protons is sensitised, leading to the signal loss due to 
dephasing, which can be detected and the degree of diffusion is thus calculated. The higher 
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degree of diffusion, the greater signal loss. Diffusion gradients are characterised by b-value 
(s/mm2), defined as:  
𝑏 =  γ2G2𝛿2(∆ −  δ/3） 
where γ  represents the gyromagnetic ratio and diffusion gradient is characterised by G 
(amplitude), ∆ (duration) and δ (interval) (Huisman, 2010). The most commonly used b-values 
are 0 and 1000 s/mm2 (Huisman, 2010). 
Therefore, after gradient application, the diffusion coefficient can be calculated as: 
𝑆
𝑆0
=  𝑒−𝑏𝐷 
where 𝑆0 is the signal before applying the gradient, while 𝑆 is the signal after the gradient. The 
diffusion coefficient 𝐷 can thus be calculated from each voxel in the images. To interpret the 
resultant images, ADC is calculated with the assumption that diffusion is unrestricted, which 
is a three-dimensional isotropic Gaussian distribution model, using the following equation:  




In real biological tissue, the microscopic diffusion process is a much more complicated process 
than the simple equation described above, which is measured at the macroscopic voxel level  
(Le Bihan, 2013). Additionally, the diffusion measured at voxel level has integrated the effects 
of both microscopic diffusion and microvascular perfusion (Le Bihan et al., 1988). Therefore, 
it has been suggested that ADC represents the ‘apparent’ diffusion coefficient, instead of the 
‘true’ diffusion coefficient represented by 𝐷.  
The value of ADC is well documented in previous literature. It is reported to have a negative 
correlation with tumour cellularity in a meta-analysis of 729 patients (Chen et al., 2013a). One 
previous study, using the post-mortem human brain with meningioma, compared ADC value 
with cellularity at a voxel-by-voxel basis. The result showed that ADC values below a threshold 
of 0.929  10-3 mm2/s in the peritumoural FLAIR hyperintense region could indicate higher 
cellularity than other peritumoural FLAIR hyperintense regions (LaViolette et al., 2014). This 
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study however also found that the necrotic regions with extremely restricted diffusion had 
lower ADC values than hypercellularity area (LaViolette et al., 2014). Besides the correlation 
with tumour cellularity, the significance of ADC in patient survival prediction was also 
reported by previous studies. In a retrospective study, higher pre-treatment ADC histogram 
features can be used to stratify bevacizumab-treated recurrent glioblastoma patients according 
to the 6-month progression-free survival (Pope et al., 2009). Another retrospective study of 112 
patients also reported incremental prognostic values from ADC histogram features over 
MGMT methylation status (Choi et al., 2016).  
Although the above studies suggested the clinical utility of ADC in the determination of tumour 
malignancy, ADC values should be treated with caution, considering that other factors may 
influence its value. For example, vasogenic oedema may demonstrate an increase in ADC 
where protons accumulate, while cytotoxic oedema shows a decrease in ADC because of the 
loss function of Na/K-ATPase leading to water accumulating inside cells. One recent study 
reported the non-linear relation between ADC values with levels of lactate and lipids as 
measured by MR spectroscopy, suggesting the need to better elucidate the physiological 
meaning of this imaging marker (Gadda et al., 2017). 
Diffusion, however, is intrinsically a three-dimensional process. Hence, there is a need to 
address the directionality in diffusion measurement. The brain microstructure is established to 
be fibrillary, which means the neuronal tissue is normally organised in bundles (Hagmann et 
al., 2006). This structural pattern thus constrains the movement of water molecules. As a result, 
the diffusion of the water molecules is not isotropic. Since the diffusion parallel to the white 
matter tracts is faster than the perpendicular direction, this anisotropy of the diffusion can be 
used to indicate the overall direction of the white matter tract (Le Bihan et al., 2001). By 
applying gradients along three orthogonal directions (𝐷𝑥𝑥, 𝐷𝑦𝑦, 𝐷𝑧𝑧) and average the three 
images, the average directionality of diffusion can be calculated.  
The assumption of isotropic Gaussian distribution is too simplistic to reflect the fibrillary brain 
microstructure. With the assumption of anisotropic Gaussian distribution, a diffusion tensor 
can be resulted from the model fitting, in the form of a 3 × 3 matrix that characterises the 
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diffusion in three-dimensional space. The eigenvectors and eigenvalues (𝜆1 ≥ 𝜆2 ≥ 𝜆3) of the 
tensor can be calculated from the following tensor: 





With this method, the tensor is decomposed into three eigenvalues which describe the size of 
axes, and three eigenvectors which describe their directions (Figure 1.5). It is of note that the 
assumption that the water molecules conform to Gaussian diffusion is not sufficient to reflect 
the complicated brain structure, including the fibre cross and merge, which means multiple 
fibres orientations may exist in one single voxel. This is particularly important for the study of 
brain structure connectivity. Therefore, more complicated tensor distribution functions were 
proposed to better model the model the diffusion process (Leow et al., 2009, Zhan et al., 2009, 
Nir et al., 2017).  
 
Figure 1.5 Tensor Decomposition of Diffusion Imaging (Vorona and Berman, 2015). 
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The tensor is usually represented as an ellipsoid, with three principle orthogonal axes 
corresponding to the eigenvectors. The eigenvector corresponding to the largest eigenvalue 
(𝜆1) represents the principal diffusion direction. If the eigenvalues are similar to each other, 
the diffusion is isotropic; if the eigenvalues are distinct with each other, the diffusion is 
anisotropic. From the eigenvalues, mean diffusivity (MD) is therefore calculated as: 
𝑀𝐷 =
𝜆1 + 𝜆2 + 𝜆3
3
 
With each eigenvalue compared to the mean value of all eigenvalues (𝐷) , the fractional 
















𝜆1 + 𝜆2 + 𝜆3
3
 
According to the equation, FA measures the ratio of the anisotropic component to the full 
tensor. RA represents the ratio of the anisotropic component to the isotropic component. 
Despite the improvement for better characterisation of the magnitude of diffusion, these scalars 
are affected by both isotropic and anisotropic components, as described in the equations. 
Therefore, various studies have reported that it is insensitive to detect the changes after stroke 
(Green et al., 2002), and fails to differentiate the peritumoural region of infiltrating and non-
infiltrating regions in brain metastases (Lu et al., 2003). 
To improve above scalars, a tensor decomposition technique was proposed (Pena et al., 2006a). 
Based on this method, a decomposition of p:q was proposed to describe the tensor with an 
isotropic component (p) and anisotropic component (q). The values are calculated with the 
equations below:  
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 𝑝 =  √3 𝐷 =
𝜆1 + 𝜆2 + 𝜆3
√3
 
𝑞 =  √(𝜆1 − 𝐷)2  +  (𝜆2 − 𝐷)2 +  (𝜆3 − 𝐷)2 
These indices are considered sensitive to the subtle disruption of white matter tracts caused by 
tumour infiltration. Using 35 glioma patients and seven normal volunteers, one previous study 
showed that the p:q decomposition can characterise tissue signature of the brain. An increase 
in the isotropic component (p) may indicate tumour infiltration and a reduction in the 
anisotropic component (q) indicates fibre disruption (Price et al., 2004). In a subsequent image-
guided biopsy study, this decomposition technique achieved a sensitivity of 98% and 
specificity of 81% in differentiating gross tumour with tumour infiltration, while T2 is non-
specific in comparison (Price et al., 2006). 
This decomposition also demonstrates advantages in the graphical representation of the tensor 
(Pena et al., 2006a). In a follow-up study of glioma patients, three DTI patterns can be 
identified, according to the comparison of p and q maps, with one map superimposed to the 
other map (Price et al., 2007). This technique can predict patterns of tumour recurrence (Price 
et al., 2007) and patient progression-free survival (Mohsen et al., 2013).  Later it was reported 
that IDH-1 mutation was significantly associated with a minimally invasive phenotype 
determined by this technique (Price et al., 2017). 
To summarise, diffusion imaging provides crucial information about tumour microstructure. 
To better interpret the diffusion tensor, different decomposition techniques of full tensor into 
scalar maps were proposed. The isotropic and anisotropic components revealed using the 
decomposition could be a useful tool to depict the tumour microstructure changes caused by 
tumour invasion and infiltration, thus would provide information for measurement of tumour 
heterogeneity and patient stratification.  
1.8.5 Magnetic resonance spectroscopy 
Magnetic resonance spectroscopy (MRS) is an important in vivo method that detects the 
metabolites. Proton nuclei (1H) signals are commonly used for measurement due to the 
abundance of protons in human tissues (Raschke et al., 2015b). MRS is based on the chemical 
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shift properties of the atom, which means the interaction between the electric shell of the 1H 
nucleus with surrounding molecules may cause the altered spin frequency of the atom when 
experiencing altered external magnetic field (B0) (Bertholdo et al., 2013). The corresponding 
change can be detected through the chemical shift imaging (CSI) and expressed as parts per 
million (ppm). Although not quantitative, this technique shows potential in reflecting the 
metabolite profiles and metabolic state according to the spectra peaks attributed to the 
metabolites. 
Single voxel and multi-voxel techniques can be applied for MRS acquisition. The typical 
spatial resolution of MRS is between 1-10 cm3, whereas the typical achievable resolution of 
MRI is 1-10 mm3 (Blüml, 2013). Although currently the spatial resolution of CSI still needs 
further improvement, the biochemical and metabolic information that CSI confers can provide 
extra information to the anatomical information of conventional MRI (Soares and Law, 2009b).  
The amount of metabolites that are measurable by MRS partially depends on the echo time 
(TE). Generally, short TE (i.e. 30 ms) can facilitate the measurement of more metabolite 
compared to long TE (i.e. 136 ms) (Howe et al., 2003). A short TE, however, may cause a 
water shoulder that brings difficulties in measurement, which may be compensated using an 
intra-subject normalisation. Another challenge posed by shorter acquisition time is that the 
resolution of CSI is low, compared to structural images.   
A series of metabolites can be quantified using MRS technique and have clinical significance, 
including N-acetylaspartate (NAA), choline (Cho), creatine (Cr), myo-inositol (mIns), 
glutamate + glutamine (Glx), lactate (Lac), lipids (Lip) and macromolecule (MM). A 
description of the peak resonance and significance of the metabolites is in Table 1.2.  
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Choline (Cho) 3.2 Marker of cell membrane turnover 
Creatine/phosphocreatine (Cr) 3.0 Marker of cellular energetic metabolism 
N-acetylaspartate (NAA) 2.0 Neuronal marker 
Glutamate + Glutamine (Glx) 2.1 - 2.6 Excitatory neurotransmitter 
Lipids (Lip) 0.9 – 1.4 Tissue damage/destruction 
Lactate (Lac) 1.3 Marker of anaerobic glycolysis 
Myo-inositol (mIns) 3.5 Potential glial marker 
Macromolecule 0.87-3.8 Marker of amino acids of cytosolic proteins 
 
Creatine (including signals from creatine and phosphocreatine) is a component of cell 
membrane and a marker of cellular energetic metabolism, which is relatively constant in the 
healthy brain. Therefore, it is normally used as a reference metabolite, providing an intra-
subject normalisation (Lowry et al., 1983). However, the normalisation to Cr is prone to the 
variability of this metabolite caused by the pathological change, i.e., the oedema effect caused 
by tumour infiltration, as well as the regional variation caused by receive coil sensitivity. To 
compensate these biases, previous studies proposed to use the Cr in the same voxel as a 
normalisation (Price et al, 2016).  
Choline is a precursor of acetylcholine and a marker of the cell membrane. Several choline-
containing compounds exist in tissue, including choline, phosphocholine (PCh), and 
glycerophosphocholine, among which PCh is associated with cellular proliferation (Bulik et 
al., 2013a), which can be observed in malignant cell dividing, gliosis or inflammation, and thus 
is considered as non-specific (Bertholdo et al., 2013). 
N-acetylaspartate (NAA) is the acetylated derivative of aspartate acid, which is produced in 
the mitochondria of neurons. Thus, NAA is considered as a neuronal marker. A decline of this 
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marker indicates the loss or dysfunction of neurons (Howe et al., 2003), which may be caused 
by the tumour destructive growth in glioblastoma.  
The common pattern of metabolic changes in glioblastoma is an elevation in Cho level and a 
decrease in NAA level (Soares and Law, 2009a). Specifically, NAA may display significant 
decline when neurons are destructed during glioblastoma progression (Figure 1.6). At the same 
time, Cho may be elevated in glioblastoma due to cell proliferation. Therefore, the Cho/NAA 
ratio may be used as an indicator of tumour-related abnormality (Norska and Barker, 2010). In 
a previous study, a Cho-NAA index (CNI) was proposed to better interpret the tumour-related 
abnormality, integrating these two spectral peaks (McKnight et al., 2001). A linear regression 
of the choline versus NAA was performed to calculate the proposed CNI. Using 
histopathological validation from image-guided biopsy, a CNI threshold of 2.5 was shown to 
distinguish tumour tissue from other non-tumour tissue, with a sensitivity 90% and a specificity 
of 86% (McKnight et al., 2002).  
 
Figure 1.6 Single voxel spectroscopy of normal brain and glioblastoma (Bulik et al., 2013b). 
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Other metabolites can also be measured by MRS. In the normal brain, myo-inositol is a 
potential glial marker that is associated with glial proliferation (Soares and Law, 2009b). 
Glutamate is the major excitatory neurotransmitters in the brain. Since glutamate and glutamine 
are difficult to differentiate in spectroscopy, they are normally measured as Glx (Yahya et al., 
2008). Lactate is a marker of anaerobic glycolysis that is associated with hypoxia or ischemia, 
whereas lipids may indicate the tissue damage which may be caused by anaerobic glycolysis 
(Moller-Hartmann et al., 2002). Previously, Glx and lactate + lipids were reported to be helpful 
in distinguishing high-grade and low-grade gliomas (Chawla et al., 2007). 
Although not fully understood, most macromolecule (MM) peaks may be attributed to the 
amino acids of cytosolic proteins (Povazan et al., 2015). The MM peaks in the range 0.9-4.0 
ppm overlap with other metabolite peaks, which poses significant challenges for evaluating the 
concentration of MM (Opstad et al., 2008, Povazan et al., 2015).  As the lipids peak at 0.9 ppm 
is very difficult to separate with the MM peak at 0.87 ppm, they are normally expressed as a 
single measure (ML9) (Opstad et al., 2004, Opstad et al., 2008). Using an MM + lipids profiles, 
glioblastoma was reported to be differentiated from brain metastases with a specificity and 
sensitivity of 80% (Opstad et al., 2004).  
The significance of MRS techniques in assessing tumour histology subtypes, malignancy 
grades and treatment response has been demonstrated in previous studies (Padhani and Miles, 
2010, Howe et al., 2003, Julia-Sape et al., 2015). Using a tissue type basis set, the proportions 
of tumour tissue can be decomposed from the 1H spectra in grade II and grade IV glioma 
patients, which would potentially be used to estimate tumour extent and delineation (Raschke 
et al., 2015a), suggesting the potential of this technique in  tumour heterogeneity study. 
Furthermore, attempts have been made to integrate MRS technique into clinical practices. 
Incorporating with structural MRI, 1H MRS has shown values in radiation and surgical 
planning (Norska and Barker, 2010). 
Because of the heterogeneous cellular structure and metabolic status, glioblastoma normally 
displays highly heterogeneous metabolic patterns. This metabolic heterogeneity can be 
observed not only among patients, but also within each individual tumour. For example, in 
some tumour regions, due to the lack of blood supply, glioblastoma tends to undergo cell death 
because of hypoxia and displays higher proportions of necrosis. Thus, in these regions, a higher 
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level of Lac and Lip is frequently observed (Bulik et al., 2013b).  Therefore, multi-voxel MRS 
will complement other MRI modalities in the evaluation of tumour heterogeneity, by providing 
important metabolic information.  
1.9 Tumour habitat imaging 
Although emerging advanced imaging techniques are developed, traditional imaging 
interpretation fails to address intra-tumoural heterogeneity comprehensively. Until recently, 
medical images are mainly qualitatively assessed by clinicians in common practice. 
Quantitative assessment of some imaging markers normally relies on the averaged values 
within the regions of interest. As such, the spatial information carried by tumour imaging may 
not be considered, which significantly limits the characterisation of tumour heterogeneity. 
Therefore, there is a rising clinical demand for developing quantitative imaging interpretation 
approach, which can be leveraged to address spatial and temporal tumour heterogeneity. The 
following sections will focus on the emerging post-processing analytic methods that show 
potential in the measurement of spatial tumour heterogeneity.  
As discussed above, heterogeneity of glioblastoma may be caused by the intra-tumoural 
evolutional dynamics (Sottoriva et al., 2013a). Moreover, tumour microenvironment may also 
exhibit heterogeneity in microanatomy, constituents and metabolism (Lathia et al., 2011). In 
tumour biology, specialised compartments in the microenvironment are termed as tumour 
niches, which can not only harbour distinct tumour clones, but also facilitate clonal interaction 
and tumour evolution (Hambardzumyan and Bergers, 2015b). Multiple tumour niches exist 
within individual glioblastoma, including perivascular niche, hypoxic niche, and invasive niche 
(Hambardzumyan and Bergers, 2015a). These niches may display diversity in their biological 
characteristics and functional behaviours. Particularly, in the hypoxic niche, stem-like tumour 
cells may arise, mediated by hypoxia-inducible factors (HIF). These stem-like tumour cells are 
known to be resistant to treatment to other differentiated cells and may later contribute to 
tumour progression and aggressiveness (Hambardzumyan and Bergers, 2015a, Barcellos-Hoff 
et al., 2013, Plaks et al., 2015).  
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Tumour habitat imaging is a rising field that attempts to identify tumour sub-regions using 
multiple imaging modalities (Figure 1.7). The hypothesis of this approach is based on the 
different properties revealed by multiple imaging sequences. Thus, the combinations of high 
or low values of these sequences can reveal multiple tumour habitats with distinct traits, which 
were reported to be associated with signalling pathway, molecular subtype and patient survival 
of in glioblastoma patients (Dextraze et al., 2017, Lee et al., 2015). 
 
Figure 1.7 A case example of tumour habitats in glioblastoma.  Four tumour habitats are identified 
by combining post-contrast T1-weighted and FLAIR images (Zhou et al., 2014).   
In glioblastoma, angiogenesis often results in aberrant microvasculature in solid tumours, 
which is typically inefficient in resource delivery and may induce perfusion heterogeneity 
(Gillies et al., 1999). Additionally, significant variation of tumour cellularity can be observed 
within solid tumours. High or low cell densities can exist in either sufficiently or poorly 
perfused sub-regions, causing spatial variation in the tumour microenvironment (Gatenby et 
al., 2013). As we discussed above, perfusion imaging can measure the tumour vascularity, 
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which has been shown to be correlated to cellular proliferation in high-grade gliomas (Price et 
al., 2011). Diffusion weighted imaging provides information about the tissue microstructure 
(Kalpathy-Cranner et al., 2014), by measuring microscopic diffusivity of water molecules. 
Therefore, integrating physiological imaging may lead to a better characterisation of intra-
tumoural habitats. Using this approach, the invasive tumour sub-regions in the non-enhancing 
region has been reported to be associated with patient survival (Boonzaier et al., 2017b).   
1.10 Radiomics and radiogenomics  
1.10.1 Definition and advantages 
In the last decade, advances in image processing and computer vision have been achieved, 
which allows radiomics becoming a rapidly-developing area. Radiomics refers to an approach 
which can firstly extract high-throughput quantitative imaging features from subjects/regions 
of interest, and later use these features for tumour characterisation (Aerts et al., 2014b). These 
high throughput quantitative imaging features include those describing tumour shape, size, 
volume, intensity and texture characteristics (Aerts et al., 2014b, Kuo and Jamshidi, 2014). A 
large number of features allows for a more comprehensive measurement of tumours. Recent 
evidence showed that these imaging features carry important information that is correlated with 
clinical outcomes and molecular phenotypes (Li et al., 2016, Aerts et al., 2014a, Lao et al., 
2017, Zhang et al., 2017, Grossmann et al., 2017). Thus, radiomics has great potentials in 
addressing glioblastoma heterogeneity, which would provide valuable significances for patient 
management (Limkin et al., 2017, Verma et al., 2017, Lambin et al., 2017). Below is an 
introduction of radiomics workflow and challenges.  
1.10.2 Workflow 
The workflow of radiomics involves a series of techniques, including feature extraction, feature 
selection, machine learning and model validation. 
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1.10.2.1 Tumour segmentation 
Accurate segmentation of tumour regions of interest (ROIs) is central for the entire workflow. 
Segmentation includes both manual segmentation and automatic/semi-automatic 
segmentation. Although manual segmentation is commonly performed by experienced 
clinicians, it is a best practice to evaluate the consistency of the annotation, to avoid the inter-
rater variability. Automatic or semi-automatic segmentation is more reproducible than manual 
segmentation, though the accuracy still needs further improvement, compared to clinical 
experts’ annotation. Considerable efforts have been made to develop automatic algorithms to 
segment tumour regions accurately, trained by the ground truth annotated by clinical experts 
(Jones et al., 2015a, Petersen et al., 2017, Perkuhn et al., 2018).  
1.10.2.2 Feature extraction 
In general, two main radiomics feature sets can be extracted from the segmented tumour 
regions: semantic features and agnostic features (Gillies et al., 2016). Both semantic and 
agnostic radiomic features can be derived from multi-modality MRIs.  
Semantic features 
Semantic features are those descriptors used in clinical diagnosis or traditional imaging study. 
Normally these features are manually scored by clinicians using lexicons or guidelines from 
the radiology community. These features may be challenged by their reproducibility due to the 
inter-rater variability.  
Visually Accessible Rembrandt Images (VASARI) Research Project, a standardised feature 
assessment system, was developed by TCGA radiology working group 
(https://wiki.nci.nih.gov/display/CIP/VASARI/). The VASARI lexicon consists of 30 features 
that describe tumour characteristics (Mazurowski et al., 2013). The assessment is based on T1-
weighted, T2-weighted and FLAIR images. A set of features, such as tumour location, tumour 
size, the proportion of necrosis/enhancing tumour/oedema, are manually scored by clinicians. 
This feature set has been reported to predict survival and molecular subtype (Nicolasjilwan et 
al., 2015, Gevaert et al., 2015).  
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Agnostic features 
Agnostic features are those computational metrics extracted from medical images with 
mathematical or statistical algorithms. Quantitative imaging features are automatically 
computed in high-throughput from the pre-defined ROIs. The most commonly-used features 
include intensity histogram, texture, and tumour shape/size features.  
 Intensity histogram features  
Voxel intensities within a tumour can be acquired voxel by voxel from the grey-level images. 
The intensity distribution of these voxels thus is described as a series of first-order statistics, 
including maximum, minimum, standard deviation, mean, median, nth centiles, skewness and 
kurtosis. The utility of rCBV histogram features in glioma grading and survival prediction has 
been previously reported (Emblem et al., 2008). Another study reported that pre-treatment 
ADC histogram features can predict response to treatment response to bevacizumab in 
recurrent glioblastoma (Pope et al., 2009). Therefore, histogram features have potentials in 
reflecting glioblastoma heterogeneity.  
 Texture features 
Texture analysis is a method complementary to histogram analysis in assessing tumour 
heterogeneity. A variety of mathematical or statistical methods are used to measure the 
relationship of pixel groups in medical images. Therefore, texture features can provide a series 
of measures reflecting the spatial distribution of voxel groups (Davnall et al., 2012). Previously, 
texture features have been used to distinguish spatial heterogeneity caused by regional oedema, 
vascularization, and necrosis (Ryu et al., 2014). In a retrospective of 79 glioblastoma patients, 
texture features from the pre-operative post-contrast T1-weighted images were reported to be 
robust predictors of patient survival (Molina et al., 2016). 
Several types of texture metrics are commonly used: grey level co-occurrence matrix (GLCM), 
grey level run-length matrix (GLRLM), grey level size-zone matrix (GLSZM), and multiple 
grey level size-zone matrix (MGLSZM). Among them, the grey level co-occurrence features 
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are the most widely used feature set, which counts the voxel pairs of certain voxel values in 
different directions (Haralick et al., 1973). The features extracted using this method include 
homogeneity, variance, contest, energy and entropy, which can potentially quantify tumour 
heterogeneity (Haralick et al., 1973). 
 Shape features 
Shape features are developed to describe the geometrical properties of a tumour quantitatively. 
These features can be extracted from the 2D or 3D tumour volumetric structural images. The 
usefulness of shape features can be supported by the observation that the growth/invasion 
patterns lead to morphological variations of tumours and can be captured by shape-based 
features (Itakura et al., 2015). Shape features are reported to be associated with the disease 
stage and tumour invasiveness (Aerts et al., 2014b). The most commonly-used descriptors 
include tumour area, tumour perimeter, compactness, roughness, sphericity, curvature (Xu et 
al., 2012, Yap et al., 2013). 
1.10.2.3 Machine learning model 
After high-throughput features have been extracted, the feature interpretation is crucial for the 
following analysis. Machine learning algorithms are statistical methods that can be applied to 
imaging features for pattern recognition and endpoint prediction (i.e., clinical outcomes, 
molecular markers or histological subtypes) (Wang and Summers, 2012). Commonly-used 
machine learning algorithms include supervised learning and unsupervised learning (Zhou et 
al., 2018). 
Supervised learning involves a training phase in which the algorithms are trained by ground 
truth or prior knowledge to tune the parameters of predictive models. According to the outputs, 
supervised learning methods typically include regression (outputs are continuous variables) 
and classification (outputs are classified as labels) (Wang and Summers, 2012). Random forest 
(RF) and support vector machine (SVM) are among the most popular supervised learning 
algorithms (Statnikov et al., 2008). In contrast, unsupervised learning helps to explore features 
purely based on the data structure without known outputs. The most common task for 
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unsupervised learning method is clustering. Popular unsupervised learning technique includes 
k-means, which aims to separate observations into k clusters, with all observations in each 
cluster have the nearest mean (Jain, 2010). To select the optimal model parameters and reduce 
the bias of feature/model selection, cross-validation procedure is recommended.  
As discussed above, high-throughput radiomic features can be extracted from the radiographic 
images. However, a large feature number compared to the patient number may cause 
overfitting. Therefore, in the model selection stage, it is crucial to perform feature ranking and 
selection, which is an essential step before final model construction. An effective feature 
selection procedure can reduce feature redundancy and noise, providing the capability of 
selecting the most robust and informative imaging biomarkers for clinical decision making. 
1.10.2.4 Independent validation  
After the optimal models are tuned in the above process, there is a crucial need to validate the 
predictive model using another independent cohort. The purpose is to reduce the randomness 
of the model selection process. To test the generalization of the predictive model, the optimal 
independent validation cohort is from another research centre, preferably using a prospective 
clinical trial design.  
1.10.3 Radiogenomics 
Radiogenomics, which is an approach of establishing the associations between radiomics 
features with genomics features of diseases. Multiple benefits could be achieved through this 
association: firstly, the biological validation of imaging phenotypes revealed by radiomics 
approach could potentially be achieved (Gevaert et al., 2014). Secondly, by building the models 
predicting genetic markers/phenotypes, imaging features could be used as non-invasive 
surrogates for the genetic markers, which rely on the tissue obtained via the invasive procedure. 
Thirdly, since only a limited amount of samples can be taken from each individual patient, sub-
regional imaging features may potentially be used to reflect the spatial tumour evolution and 
identify the hallmark driver mutations, by establishing the association between imaging 
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features and genomic features from multiple regional tissues, obtained through image-guided 
biopsy. 
As such, radiogenomics approach can potentially provide a useful tool for intra-tumoural 
heterogeneity, since the imaging features are not limited to the sample(s) taken. In addition, it 
can facilitate longitudinal patient management in disease monitoring, and benefit patient 
evaluation by reducing the risk of invasive procedures. Further, by integrating clinical 
characteristics from large patient cohorts into the radiogenomics model, and the efficacy of 
radiomics/radiogenomics models can be significantly enhanced (Itakura et al., 2015, Aerts et 
al., 2014b).  
1.10.4  Challenges and opportunities 
1.10.4.1 Model reproducibility 
There are several possible reasons that may significantly affect the reproducibility of imaging 
features. Firstly, the imaging acquisition and reconstruction may have an impact on the 
acquired images, as the downstream analysis is typically based on the assumption that all data 
are in the standard intensity distribution. However, since most radiomics studies are using 
retrospective cohorts, the imaging protocol of each individual patient can be various. Secondly, 
the radiomics process involves multiple procedures which may cause errors, including 
segmentation variability, model testing and parameter tuning. The significant findings may be 
generated by random in the pipeline. Thirdly, since a large number of features can be extracted 
from the radiomics pipeline, overfitting can be caused in the evaluation of imaging features 
and thus the predictive models constructed using these features.  
There are several strategies which can potentially solve these challenges. Firstly, it is crucial 
to perform imaging normalisation or standardisation in the pre-processing step of the radiomics 
pipeline, to reduce the impact of heterogeneous imaging data generated from different scanners 
or protocols. Several normalisation techniques have been advanced to solve this challenge 
(Shinohara et al., 2014). A recent study evaluating the intensity normalization techniques in 
multiple sclerosis patients. The results showed that the decile based piece-wise linear 
normalization can provide a combination of better tissue discrimination and reasonable 
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computational cost (Shah et al., 2011). Developing effective methods with the consideration of 
glioblastoma heterogeneity is further needed.  
Secondly, to reduce the randomness of in the radiomics pipeline. The experimental design is 
crucial for the validation of radiomics pipeline. For tumour segmentation, it is of significance 
to include the inter-rater variability test if manual or semi-automatic segmentation methods are 
adopted, as discussed above. For a rigorous model construction, separating the patients into a 
development, test and validation set is desirable for the study design. A cross-validation is 
recommended for each phase of model development, test and validation, in the evaluation of 
the model performance. Also, pseudo-randomization achieved by permutation test can also 
help to reduce selection randomness and improve reproducibility. A standardisation of the 
pipeline is still in crucial need for best practice.  
Thirdly, to reduce the risk of overfitting, it is important to reduce the feature dimensionality 
and select the optimal features, as we mentioned above. Importantly, increasing the number of 
subjects would be helpful to improve the robustness of the model. To meet this demand, it has 
become the consensus from the community to establish imaging repository for data exchange 
or multiple centre collaboration.  
1.10.4.2 Clinical validation 
Most current radiomics/radiogenomics study are using retrospective cohorts, which limits the 
reliability of their clinical translational power. With the emergence of multiple omics, a large 
number of datasets is being generated and sophisticated research tools are being developed. 
The efficacy of these tools, however, should be tested and validated with the guidance of 
clinical criteria, including clinical prior knowledge. Further, to validate the clinical utilities of 
imaging biomarkers, it is crucial to test the models/features by considering the clinical 
hypothesis. As tumours are a complex evolving system, a clinical hypothesis-driven 
experimental design may have the potential to address clinical critical issues and meet clinical 
demands.  
Therefore, future directions with clinical perspective consideration are crucial. Firstly, multiple 
disciplinary collaboration is demanded to further translate the radiomics approach into clinical 
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practice. This involves but not limited to 1) developing imaging modality or biomarkers with 
more specific tumour biology targeting; 2) exploiting statistical algorithms of feature extraction 
and analysis with a more clinically relevant hypothesis; 3) designing more disease or organ-
specific analytic tools. Secondly, clinical trials involving standardised imaging setting, 
therapeutic regimen and outcome measure would be crucial, which would, therefore, facilitate 
the validation of imaging biomarkers with more clinical relevance. Thirdly, a prospective and 
longitudinal study design would be required for the clinical validation of radiomics approach, 
which would be critical to investigate the efficacy of radiomics features or predictive models.  
1.11 Summary 
Heterogeneity is one of the fundamental traits of glioblastoma, which poses a significant 
challenge to patient stratification. Understanding the mechanism of tumour heterogeneity is 
central for accurate diagnosis, targeted therapy and personalised treatment.  
In past decades, advances in molecular biology have been achieved for a better understanding 
of glioblastoma heterogeneity. Most of the molecular markers, however, are based on invasive 
approach, which may increase the risks of patients and be prone to sampling error. There is a 
pressing but unmet need for the development of a non-invasive approach that could be used to 
measure tumour heterogeneity for disease monitoring and patient management.  
Although widely used in clinical practice, conventional MRI bears the limitation of non-
specificity in reflecting tumour physiology. Multiple advanced physiological MRI modalities 
have been developed, including perfusion and diffusion MRI, and MR spectroscopy. The 
imaging parameters that are generated from these quantitative advanced MRI can be used to 
measure tumour vascularity, cellularity and metabolism, respectively. Multi-parametric MRI 
shows great potentials in providing a more comprehensive measure of tumour heterogeneity 
non-invasively. 
Tumour habitat imaging is a method that could be used for the identification of intra-tumoural 
habitats with different imaging characteristics. Radiomics is a rapidly developing research area, 
which can convert the medical images into high-throughput minable imaging features for 
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tumour characterisation. These approaches have shown diagnostic and prognostic values in 
various types of cancer, and thus would provide useful tools for heterogeneity evaluating and 
outcome prediction. 
Currently, many attempts have been made to examine the utilities of habitat imaging and 
radiomics in the measurement of tumour heterogeneity and patient stratification. Most of the 
studies, however, are using conventional imaging techniques. Further studies are needed to 
investigate whether habitat imaging and radiomics are useful in evaluating inter-tumoural and 




Chapter 2 Hypothesis 
2.1 General hypothesis 
Pre-treatment multi-parametric MRI could be useful in revealing inter-tumoural and intra-
tumoural heterogeneity in glioblastoma patients non-invasively. Such findings could provide 
biomarkers for patient survival prediction and future personalised treatment. 
2.2 Hypotheses Tested 
1. Glioblastoma may display an extensive intra-tumoural heterogeneous diffusion pattern. 
Particularly, tumour infiltration may be facilitated by white matter tracts and cause 
disruption. As discussed in Section 1.8.4, DTI is sensitive in detecting tumour 
infiltration by detecting water mobility, which can be decomposed into isotropic and 
anisotropic components. We hypothesised that a joint histogram analysis of isotropic 
and anisotropic diffusion components could differentiate tumour regions into sub-
regions with different diffusion patterns, which may be useful for a better understanding 
of intra-tumoural heterogeneity of tumour infiltration.  (Chapter 4) 
2. As discussed in Section 1.9, intra-tumoural habitats can be revealed by multi-parametric 
MRI. Previous evidence showed that adaptive and resistant clones may exist in the low 
perfusion sub-regions, which cause treatment failure. As discussed Section 1.8, 
perfusion imaging can quantify tumour perfusion, whereas diffusion can reflect cellular 
structure by measuring water mobility. We hypothesised that two low perfusion 
compartments could be visualised and quantified using multi-parametric quantitative 
MRI. They both have lower perfusion but with different diffusivity. The tumour 
habitats identified using this approach may display different properties that could 
correlate with patient prognosis. (Chapter 5) 
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3. Multi-parametric MRI can not only reveal the intra-tumoural habitats, but also provides 
crucial information about inter-tumoural heterogeneity to reflect interpatient variation. 
With multiple imaging modalities developed, an effective method to integrate these 
modalities is lacking. We hypothesised that a multi-view feature selection and machine 
learning approach could effectively integrate histogram features from quantitative 
multi-parametric MRI. The selected imaging features using this approach may offer 
incremental values in survival prediction.  (Chapter 6) 
4. As we discussed in Section 1.8, multiple imaging modalities provide complementary 
information regarding tumour biology. Limited studies have addressed the overall inter-
dependence between perfusion and diffusion imaging, which may help understand the 
tumour invasiveness. We hypothesised that the inter-dependence of perfusion and 
diffusion imaging can be characterised, which would provide useful information for 
evaluating tumour microenvironment. The imaging phenotypes revealed by this 
approach could be of prognostic value. (Chapter 7)  
5. As discussed in Section 1.10, radiomics is can characterise a tumour using a large 
number of features extracted from the images. This approach has shown potential to 
predict the tumour genetic markers. As epigenetic change is crucial for tumour 
progression and may be impacted by tumour microenvironment, we hypothesised that 
using radiomics approach, physiological MRIs may provide improved accuracy than 
conventional structural MRIs, for the prediction of MGMT promoter methylation 
status. The predictive models constructed using the selected radiomic features could 
improve the prognostic performance. (Chapter 8) 
 
We will test above hypotheses using a cohort which has been prospectively recruited for pre-
operative multi-parametric MRI scanning. The imaging protocol included structural imaging 
(T1-weighted, T2-weighted, and FLAIR), perfusion, diffusion and MR spectroscopy. This 
cohort has been treated and followed up in Addenbrooke’s Hospital. With available patient 
treatment response and outcome measures, this cohort would facilitate the hypothesis testing 
regarding tumour heterogeneity.  
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The details of patient recruitment and imaging protocol are detailed in Chapter 3. The general 
imaging processing pipeline is also detailed in Chapter 3, including brain extraction, DTI, DSC 
and spectroscopy processing, image co-registration, tumour segmentation, feature extraction 
and machine learning algorithms are introduced. The clinical details of the patients, including 
treatment regimen, evaluation of molecular markers, the extent of resection, post-operative 
response and progression are also introduced in Chapter 3. 
In Chapter 4-8, multiple post-processing analytic techniques were applied to test the usefulness 
of tumour habitat imaging (Chapter 4-5), modality integration (Chapter 6), modality inter-
dependence (Chapter 7) and radiomics (Chapter 8) in revealing intra-tumoural and inter-
tumoural heterogeneity. In Chapter 9, a summary of the general limitations of this thesis and 
future directions are discussed.  
  
 
Chapter 3 General Methods 
3.1 Patient population 
This study was approved by the local Institutional Review Board (ethics reference No.: 
10/H0308/23). Acquisition of patients’ data was granted by the NIHR funded “Magnetic 
Resonance Imaging to Characterise Invasive Phenotypes in Cerebral Gliomas” study 
(ISRCTN62033854). Informed written consent was obtained from all patients. Patient 
characteristics are demonstrated in Appendix A. 
We included two patient cohorts in this thesis using the same inclusion and exclusion criteria. 
The main cohort was used in Chapters 4-7. In Chapter 8, we included another validation cohort 
to validate the radiomics model developed from the primary development cohort. The scanning 
parameters of the validation cohort are different from the primary development cohort.  
3.1.1 Inclusion and exclusion criteria 
Inclusion: 
 Radiological diagnosis of supratentorial glioblastoma 
 Age ≥ 18 years and ≤ 75 years 
 Pre-operative World Health Organization performance status 0-1 (Karnofsky 
performance score ≥ 70) 
 Suitable for craniotomy or biopsy 
 Likely to receive concomitant chemoradiotherapy 
Exclusion: 
 Previous history of cranial surgery or cranial radiotherapy/chemotherapy 
 Unsuitable for contrast-enhanced MRI scan 
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 Unconfirmed post-operative pathological diagnosis of GBM 
 Pregnancy or plan for pregnancy 
 Allergic to aminolevulinic acid or suffering from porphyria 
 
3.1.2 Treatment and response evaluation 
3.1.2.1 Treatment 
To achieve maximal safe resection, surgery was performed with the guidance of neuro-
navigation (StealthStation, Medtronic, Fridley, MN, USA) and 5-aminolevulinic acid 
fluorescence (5-ALA, Medac, Stirling, UK). The extent of resection was assessed according to 
the post-operative MRI scans acquired within 72 hours, and was classified as complete 
resection, partial resection of enhancing tumour or biopsy (Vogelbaum et al., 2012). 
Concomitant temozolomide chemoradiotherapy (CCRT) and adjuvant chemotherapy (Stupp 
regimen) (Stupp et al., 2009) was performed after surgery as soon as possible, given patients’ 
conditions were stable. During radiotherapy, concomitant TMZ chemotherapy was 
administered with a dose of 75mg/m2/day, adjusted if patients’ body weight changed. After 
radiotherapy, TMZ chemotherapy was continued for six circles, with the dose of 150-
200mg/m2/day for 5 days followed by a 28-day break. Other patients received short-course 
radiotherapy or best supportive care. 
3.1.2.2 Evaluation of treatment response  
Treatment response was evaluated according to the Response Assessment in Neuro-Oncology 
criteria (Wen et al., 2010), which incorporates clinical and radiological changes to identify 
progression. Pseudoprogression was suspected where new contrast enhancement appeared 
within first the 12 weeks after completing chemoradiotherapy. In such cases, treatment was 
continued and pseudoprogression was identified if later response occurred. As a result, in some 
cases, true progression was determined retrospectively.  
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In Chapter 4, to evaluate the progression volume in a subset of patients, available follow-up 
post-contrast T1-weighted images were collected by Dr Jiun-Lin Yan. The progression was 
determined on post-contrast T1-weighted images, excluding pseudoprogression according to 
above criteria. A volumetric analysis of the tumour progression was calculated after imaging 
co-registration, using a previously proposed approach (van der Hoorn et al., 2016). 
For survival analysis of patients, relevant covariates, including IDH-1 mutation, MGMT 
promoter methylation status (assessments of IDH-1 mutation and MGMT methylation are 
detailed in Section 3.2), sex, age, the extent of resection and contrast-enhancing tumour 
volume, were accounted. Patients who were alive at the last known follow-up were censored. 
Following instances occurred in this patient cohort due to uncontrollable reasons: 1) some 
patients were lost in follow-up; 2) in some patients, MGMT promoter methylation status was 
missing.  
3.2 Assessment of molecular markers 
3.2.1 IDH-1 mutation 
IDH-1 R132H mutation was firstly determined via immunohistochemistry. After the paraffin 
was removed and a heat-induced antigen retrieval was performed, IDH-1 R132H mutation-
specific antibody (Dianova, Hamburg, Germany) was applied at a 1:20 dilution on slices. A 
secondary antibody avidin-based detection system was used. In patients for whom IDH-1 
R132H mutation was not detected by immunohistochemistry, tumour DNA was extracted from 
tumour-rich tissue and sequenced for other rare IDH mutation in codon 132 of the IDH-1 gene 
and codon 172 of the IDH2 gene using the targeted next-generation sequencing (Ion AmpliSeq 
Cancer Hotspot Panel v2 and Ion PGM System, Thermo Fisher Scientific, Waltham, MA, 
USA).  
3.2.2 MGMT promoter methylation status  
MGMT promoter methylation status was evaluated as follows: DNA was extracted from the 
dissected neoplastic cell-rich tissue and was bisulphite-converted using the EpiTect Bisulphite 
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Kit (Qiagen, Hilden, Germany). Pyrosequencing of four CpG sites (CpGs 76-79) in exon 1 of 
the MGMT gene was performed using the CE-Marked therascreen MGMT Pyro Kit on a 
Pyromark Q24 System (Qiagen, Hilden, Germany). A cut-off of 10% mean methylation for the 
four CpG sites was used to determine tumours as either methylated or unmethylated, based on 
the previously published data (Collins et al., 2014, Dunn et al., 2009a). 
3.3 MRI acquisition 
Two patient cohorts were included in this thesis using different scanning protocols. All MRI 
sequences of the developmental cohort were performed at a 3-Tesla Siemens Magnetron MRI 
system (Siemens Healthcare, Munich, Germany) at Wolfson Brain Imaging Centre (WBIC) at 
Addenbrooke’s Hospital, Cambridge, UK. All MRI sequences of the validation cohort were 
performed at a 3T system (MR750, GE Healthcare, Waukesha, WI) in Magnetic Resonance 
Imaging and Spectroscopy Unit (MRIS), Department of Radiology, University of Cambridge.  
3.3.1 Pre-operative sequences 
 Anatomical sequences: pre-contrast T1-weighted, post-contrast 3D T1-weighted 
imaging, T2-weighted, Fluid-attenuated inversion recovery (FLAIR) 
 Diffusion Tensor Imaging (DTI) sequence 
 Perfusion-weighted sequence: Dynamic Susceptibility Contrast (DSC) imaging  
 MR spectroscopy (chemical shift imaging, CSI) 
3.3.2 Imaging parameters 
3.3.2.1 Structural imaging 
1. Axial precontrast T1-weighted sequence (T1W): TR/TE 500/8.6ms; flip angle 90°; 
FOV 240 × 240 mm; slice thickness: 4 mm; slice gap: 1mm; voxel size 0.75 × 0.75 × 5 
m.  
2. Post-contrast T1-weighted imaging (T1C) was acquired after intravenous injection of 
9 mL gadobutrol (Gadovist, 1.0 mmol/mL; Bayer, Leverkusen, Germany) followed by 
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a 20-mL saline flush. Scanning parameter: TR/TE/TI 2300/2.98/900 ms; flip angle 9°; 
FOV 256 × 240 mm; slice thickness: 1 mm; no slice gap; voxel size 1.0 × 1.0 × 1.0 
mm.  
3. T2-weighted sequence (T2W): TR/TE 4840-5470/114 ms; refocusing pulse flip angle 
150°; FOV 220 x 165 mm; 23-26 slices; 0.5 mm slice gap; voxel size of 0.7 × 0.7 × 5.0 
mm. 
4. T2-weighted fluid attenuated inversion recovery (FLAIR): TR/TE/TI 7840-
8420/95/2500 ms; refocusing pulse flip angle 150°; FOV 250 × 200 mm; 27 slices; 1 
mm slice gap; voxel size of 0.78 × 0.78 × 4.0 mm.  
3.3.2.2 Physiological imaging 
1. Diffusion tensor imaging (DTI) was acquired using a single-shot echo-planar sequence. 
The setting is: TR/TE 8300/98 ms; flip angle 90°; FOV 192 × 192 mm; 63 slices; no 
slice gap; voxel size 2.0 × 2.0 × 2.0 mm; 12 directions; b values: 350, 650, 1000, 1300, 
and 1600 sec/mm2; scanning time: 9 minutes 26 seconds.  
2. Dynamic susceptibility contrast-enhancement (DSC): TR/TE 1500/30 ms; flip angle 
90°; FOV 192 × 192 mm; 19 slices; slice gap 1.5 mm; voxel size of 2.0 × 2.0 × 5.0 
mm;) with 9 mL gadobutrol (Gadovist 1.0 mmol/mL) followed by a 20 mL saline flush.   
3.3.2.3 Chemical shift imaging 
Multi-voxel 2D 1H-MRS chemical shift imaging utilized a semi-LASER sequence 
(TR/TE 2000/30-35 ms; flip angle 90°; FOV 160 × 160 mm; voxel size 10 × 10 × 15-
20 mm). PRESS excitation was selected to encompass a grid of 8 rows × 8 columns on 
T2-weighted images. 
 
3.3.2.4 Imaging protocol of validation cohort 
Axial T1-weighted imaging: TR/TE/TI: 8.2/3.2/450ms; slice thickness: 1mm; flip angle 
12°; FOV 100 × 100 mm;), after intravenous injection of 9 mL gadobutrol (Gadovist,1.0 
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mmol/mL; Bayer, Leverkusen, Germany), post-contrast T1-weighted imaging was 
acquired; Axial T2-weighted imaging: TR/TE/TI: 5226/8ms; flip angle 111°; FOV 100 
× 100 mm; slice thickness: 6mm; FLAIR: TR/TE/TI: 8000/125/2158 ms; flip angle 
111°; FOV 80 × 80 mm; slice thickness: 7mm; DTI: TR/TE 8000/88ms; flip angle 90°; 
FOV 100 × 100 mm; slice thickness: 3mm; 64 directions; b values 1000 sec/mm2; DSC: 
TR/TE 2000/17 ms; flip angle 60°; FOV 100 ×100 mm; slice thickness: 6mm, with 9 
mL gadobutrol followed by a 20 mL saline flush.   
3.4 MRI processing 
After imaging acquisition, all images were anonymised and stored in the WBIC server. Data 
were firstly retrieved from the server and processed in a standardized pipeline for each subject, 
as shown in Figure 3.1.   
All images are converted from Digital Imaging and Communications in Medicine (DICOM) 
format to Neuroimaging Informatics Technology Initiative (NIFTI) format for further analysis. 
The process of downloading and sorting was routinely performed using the Shell functions in 
WBIC server.  
Different modalities were analysed separately using an in-house pipeline. For anatomical 
images, the brain extraction was performed to strip the skull for further co-registration in FSL 
(FMRIB Software Library) v5.0.8 (Smith et al., 2004, Jenkinson et al., 2012).  For perfusion 
imaging, leakage correction was performed in NordicICE (NordicNeuroLab, Bergen, Norway), 
before calculating perfusion markers. For diffusion tensor imaging, a standard processing 
pipeline was followed, according to the manual of FMRIB's Diffusion Toolbox (FDT) (Jellison 
et al., 2004).  
After processing of all imaging modalities, co-registration was performed by using T2-
weighted images as reference. Subsequently, regions of interest (ROI) were either manually 
delineated or automatically generated using algorithms on relevant modalities, according to the 
research questions addressed in each separate study. 
3.4 MRI processing  46 
 
 
Figure 3.1 Overview of the image processing pipeline 
3.4.1 Brain extraction 
Prior to the processing pipeline, the skull-stripping of all images was performed using the 
function ‘bet’ in FSL. This process was firstly done automatically, which can generate a binary 
brain mask (Figure 3.2). This mask was then manually corrected slice by slice. The raw images 
with the skull were then multiplied by the corrected binary mask, using the function ‘fslmaths’ 
in FSL.  
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Figure 3.2 A demonstration of brain extraction. After brain extraction, the skull is stripped from the T2-
weighted images (A). The brain map (B) and brain mask (C) are generated.  
3.4.2 DTI processing 
3.4.2.1 Eddy current correction 
Eddy current was caused by the strong magnetic field gradients flanked by short ramp times in 
diffusion-weighted echo-planar imaging (EPI). The eddy current can induce stretches and 
shears in the diffusion weighted images, which may cause significant image distortions and 
artefacts (Bodammer et al., 2004). Therefore, eddy current correction is crucial for the tensor 
measure and must be performed before the following DTI analysis. This process was done by 
using the function ‘eddy_correct’ in FDT. A new function ‘eddy’ has been released in the new 
version for better distortion correction. 
3.4.2.2 Diffusion tensor analysis 
Diffusion tensor was generated from the images using the function of ‘dtifit’. The default 
output parameters of this process include a series of parameters 
(https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FDT/UserGuide), including FA, L1, L2, L3, MD, MO, 
SO, V1, V2 and V3. The detailed description of these parameters can be found the Table 3.1 
and demonstrated in Figure 3.3.  
3.4 MRI processing  48 
 
Table 3.1 Outputs of DTI analysis 
Output Description 
V1, V2, V3 1st,  2nd, and  3rd eigenvectors 
L1, L2, L3 
(𝜆1, 𝜆2, 𝜆3) 
1st,  2nd, and  3rd eigenvalues 
MD mean diffusivity 
FA fractional anisotropy 
MO mode of the anisotropy (oblate ~ -1; isotropic ~ 0; prolate ~ 1) 
S0 raw T2 signal with no diffusion weighting (b0 images) 
 
 
With the function of ‘fslmaths’ built-in FSL, DTI-p and -q were calculated from the outputs of 
FDT, according to below equations (Pena et al., 2006a).  DTI-p and -q maps are generated. For 
clinical utility, ADC maps were derived directly from the scanner using b-values 0-1000 
sec/mm2.  
𝑝 =  √3 𝑀𝐷 
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Figure 3.3 A demonstration of resultant images from DTI analysis. The ADC map is directly calculated 
from the scanner and brain extraction is performed in FSL using ‘bet’ function (A). The tensor analysis is 
performed in FDT, which generates a series of outputs, including b0 map (B), FA (C) and MD map (D). DTI-
p (D) and DTI-q (E) were then calculated using ‘fslmaths’ function in FSL according to the definition 
equation. 
3.4.3 DSC image processing 
DSC data was processed using the module of perfusion analysis in NordicICE.  Brain extraction 
was firstly applied for further co-registration.  
The pre-bolus baseline images were automatically detected and defined as the entire period 
before the first pass. Spatial or temporal smoothing is not applied to reduce potential 
confounders (Hu et al., 2015). The artery input function was defined using automatic detection. 
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Contrast agent leakage correction was then applied, with Gamma variate function enabled 
(Figure 3.4).  
 
 
Figure 3.4 Perfusion analysis and leakage correction using NordicICE 
After processing, the value of relative cerebral blood volume (rCBV), relative cerebral blood 
flow (rCBF), time to peak (TTP) and mean transit time (MTT) were calculated and parametric 
maps were produced. A demonstration of the raw perfusion weighted image and perfusion-
weighted markers is in Figure 3.5. 
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Figure 3.5 An illustration of the perfusion weighted images and perfusion markers derived after leakage 
correction.  A: raw perfusion weighted image. B-F: leakage-corrected maps with NordicICE. B: rCBV; C: 
rCBF; D: MTT; E: delay map; F: leakage map. 
3.4.4 MRS processing 
Multi-voxel MR spectroscopy data were acquired using the T2-weighted slices for 
spectroscopy planning in scanning (Figure 3.6), which were visually selected by experienced 
neuro-radiologists. A grid of 8 rows × 8 columns were then superimposed to the selected T2 
slice for voxels analysis. An example of the superimposed grid on T2-space slice is shown in 
Figure 3.6. The voxels for analysis are from 5 to 12 (rows and columns). 
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Figure 3.6 A grid is superimposed on the selected T2-weighted image. 
The acquired MRS data from the multiple voxels in the grid were then processed using LC 
Model (Provencher, Oakville, Ontario) using default setting (Provencher, 2001, Raschke et al., 
2015b). All relevant spectra from MRS voxels of interest were visually assessed for artefacts 
using previously published criteria (Kreis, 2004). The LC Model processing was performed by 
Dr Natalie R Boonzaier, a previous lab member.  
The values of the Cramer-Rao lower bounds indicated by the LC Model program were used to 
evaluate the quality and reliability of MRS data and measured concentration values. The 
Cramer-Rao lower bounds values standard deviation (SD) greater than 20% were discarded 
(Price et al., 2016). For each grid, the peak size of metabolites was calculated and then 
normalised by the value of total creatine (Cr) of in the same voxel, to avoid the dilution effect 
caused by tumour-associated oedema (Wijnen et al., 2012). Therefore, the final concentrations 
of metabolites were expressed as a ratio to creatine (Cr). The selection and normalisation were 
performed by using an in-house MATLAB script written by Dr Timothy Larkin, a previous 
senior member of Cambridge Brain Tumour Imaging Laboratory. It is of note that the 
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normalisation using Cr is limited by the regional and individual variability, as well as the spatial 
variations caused by the sensitivity of receive coil.  
3.4.5 Imaging co-registration 
3.4.5.1  Pre-operative images 
Image co-registration was performed in FSL. Since all pre-operative MRIs were acquired at 
the same time point, their co-registration was performed using FMRIB's linear image 
registration tool (FLIRT) functions (Jenkinson et al., 2002). As the spectroscopy has been 
planned on T2-weighted images, all the other pre-operative images were co-registered to T2-
weighted images, using 12 degrees of freedom with affine transformation (Chapter 5- 8). In 
Chapter 4, to investigate the tenor decomposed components specifically, anatomical images 
were co-registered to DTI B0 images with an affine transformation using FLIRT. 
 Co-registration to T2 images 
In Chapter 5-8, all images were co-registered to T2 images, as CSI was planned on the T2 
slices. The co-registration scheme is as follows: FLAIR images were firstly co-registered to 
T2-weighted images. Before co-registering to T2-weighted images, the pre-contrast and post-
contrast T1-weighted images were co-registered to FLAIR images. The respective 
transformation matrix in co-registration was saved. Considering the contrast effect of T1-
weighted imaging and FLAIR are similar, this procedure may lead to a better co-registration 
quality than direct co-registering T1-weighted images to T2-weighted images. Next, the 
function ‘convert_xfm’ was used to concatenate the two transformation matrices (T1-weighted 
to FLAIR, and FLAIR to T2-weighted), to create a new transformation matrix that was applied 
to co-register T1-weighted images to T2-weighted images.  
For the co-registration of diffusion imaging, b0 image was firstly co-registered to T2-weighted 
images, with the transformation matrix saved. This matrix was later applied to ADC, MD, FA, 
p and q maps, after the DTI analysis pipeline was performed. Similarly, the co-registration of 
perfusion weighted imaging to T2-weighted images was firstly performed. The transformation 
matrix was then applied to co-register rCBV, rCBF and MTT to T2-weighted images.   
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 Co-registration to DTI images 
In Chapter 4, to investigate the effects of directional diffusivity to tumour infiltration, the raw 
tensor was firstly decomposed and the b0 images were firstly derived. To avoid the potential 
distortion of co-registration to the raw tensor. The co-registration to b0 images was performed, 
which transformed T2-weighted, T1-weighted, FLAIR, perfusion-weighted images to tensor 
space using FLIRT, with the transformation matrix. 
3.4.5.2 Progression images 
In Chapter 4, to evaluate the effects of different diffusion patterns to tumour progression rate, 
tumour progression was analysed in a subset of 57 patients with available follow-up images in 
the development cohort. The progression data were collected by Dr Jiun-Lin Yan. The true 
progression was determined by the multi-disciplinary team in Neuro-Oncology clinic, with the 
consideration of both radiological and clinical measurement. For the co-registration between 
progression images with pre-operative images, a two-stage non-linear semi-automatic co-
registration tool was applied, which was developed by previous lab members, Dr Anouk van 
der Hoorn and Dr Jiun-Lin Yan (van der Hoorn et al., 2016). Briefly, this coregistration method 
firstly calculated the transformation matrix between the pre-operative lesion and tumour cavity 
on progression images. The matrix was then applied to the brain parenchyma using the non-
linear coregistration tool of FMRIB's non-linear image registration tool (FNIRT) functions in 
FSL. Quality of the co-registration was visually inspected by the Dr Jiun-Lin Yan, Dr Anouk 
van der Hoorn and Dr Natalie R Boonzaier.  
3.4.6 Tumour segmentation 
3.4.6.1 Manual segmentation 
To delineate the tumour margin on the conventional imaging, a manual segmentation was 
performed on the post-contrast T1-weighted images and FLAIR images slice by slice, using an 
open source software 3D Slicer v4.6.2 (Surgical Planning Laboratory, Brigham and Women's 
Hospital, Boston, MA, USA; www.slicer.org), a medical image computing platform (Fedorov 
et al., 2012).   
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1. Contrast-enhancing (CE)-ROI 
The contrast-enhancing (CE) lesion on T1-weighted images was defined as all the area within 
the contrast-enhancing margin. The segmented volume is considered as the tumour core, which 
is associated with the leakage caused by neovasculature (Figure 3.7: right). 
2. FLAIR-ROI 
The FLAIR abnormality delineates the diffuse tumour invasion and oedema regions, as 
demonstrated as the hyperintense signals on T2-weighted FLAIR image (Figure 3.7: left). 
To reduce the variability of the manual segmentation, the inter-rater reliability testing was 
performed by Dr Natalie R Boonzaier, a researcher with > 4 years of brain tumour image 
analysis experience and reviewed by Dr Tomasz Matys, a neuroradiologist with > 8 years of 
experience. Inter-rater reliability testing of regions of interest (ROIs) showed excellent 
agreement between the raters, with Dice scores (mean ± standard deviation [SD]) of 0.85 ± 
0.10 and 0.86 ± 0.10 for contrast-enhancing and FLAIR ROIs respectively. 
 
Figure 3.7 Tumour are manually delineated on FLAIR and post-contrast T1-weighted 
images respectively and two tumour ROIs are obtained.  
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3. Non-enhancing (NE)-ROI 
The non-enhancing (NE)-ROI, defined as the FLAIR abnormalities outside of contrast 
enhancement, were obtained in MATLAB (MathWorks, Natick, MA, USA) by a Boolean 
subtraction on contrast-enhancing and FLAIR ROIs. This ROI is considered to delineate the 
infiltrative regions outside of CE region (Figure 3.8). 
 
Figure 3.8 Non-enhancing region is obtained from FLAIR and post-contrast T1-weighted images using 
Boolean subtraction in MATALB.  
4. Normal-appearing white matter 
A region of 10mm in diameter from the contralateral normal-appearing white matter was 
manually reviewed and determined. It is typically located in the white matter which has the 
longest distance from the tumour location and has no perceivable abnormalities. This 
procedure has provided fair controls in the previous publication (Boonzaier et al., 2017b).  
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Figure 3.9 Normal-appearing white matter (green) on structural images (left) and the normal control 
grid (white) for CSI analysis (right) 
3.4.6.2 Hypothesis-driven segmentation (tumour habitats) 
Spatial habitats were identified using the combinations of high or low pixel values of multi-
parametric physiological imaging sequences. This selection of the combinations was 
determined according to the relevant clinical hypotheses. For example, to interpret the habitats 
with different diffusion properties, multiple combinations of isotropic and anisotropic 
components of DTI were used, with a joint histogram method (Chapter 4). To reveal the low 
perfusion compartments with different diffusivity, subsets of ADC and rCBV values were used, 
with a thresholding method (Chapter 5). 
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3.4.7 Image analysis 
3.4.7.1 Volumetric analysis  
The raw volumes of the ROIs were calculated in FSL using the function ‘fslstats’. To reduce 
the bias, all masks have been binarized before used for further analysis. The proportional 
volumes were calculated as a ratio of ROI in the contrast-enhancing volume or FLAIR volume.  
3.4.7.2 Feature extraction 
1. Univariate and joint histogram features 
Histogram analysis was performed using the Statistics and Machine Learning Toolbox of 
MATLAB. Each voxel of DTI-p and -q in tumour ROIs was normalized by dividing it by the 
mean value in the contralateral normal-appearing white matter. The univariate histograms were 
constructed with the normalized voxels using 100 bins. Histogram features, i.e., mean, median, 
standard deviation, kurtosis, skewness, were then calculated from the histogram (Chapter 4 & 
6). In Chapter 4, we also proposed a joint histogram analysis, to characterise the joint 
distribution of DTI components for the identification of multiple intra-tumoural infiltrative 
habitats. The methods are detailed in Chapter 4.  
2. Radiomic features 
Radiomic features were extracted automatically in MATLAB v2017b (MathWorks, Natick, 
MA), using open-source codes available in Github (Echegaray et al., 2017). The extracted 
image features include following feature sets: shape features, margin features, intensity features 
and grey-level co-occurrence matrix (GLCM) texture features. The methods and descriptions 
of feature sets are detailed in Chapter 8.  
3.4.7.3 Machine learning 
1. Unsupervised learning 
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A supervised learning method, the Multi-View Biological Data Analysis (MVDA), was used 
in unsupervised clustering of patients (Chapter 6). This method was implemented in R and 
available from GitHub (https://github.com/angy89/MVDA).  The details of this approach are 
in Chapter 6.  
2. Supervised learning 
To select the optimal predictive models for MGMT methylation status, four supervised learning 
methods were compared in Chapter 8, including support vector machines, random forest, naïve 
Bayes, and neural network. 
Support vector machines (SVM) can transform features into a higher dimensional space and 
calculate a maximal margin hyperplane to separate data into different classes. We used a 
Gaussian radial basis function kernel-based SVM algorithm implanted in R Package ‘kernlab’.  
Random forest (RF) is a classification scheme that uses an ensemble of decision trees. The 
individual decision tree is constructed with random subsets of training sets and features, and 
then applied to test sets for classification. We used random forest algorithm implanted in R 
Package ‘ranger’.  
Naïve Bayes (NB) algorithm calculates the posterior distributions of the unknown parameters 
in the joint model of the observed data and the unknown parameters, based on Bayes' theorem. 
We used the Naïve Bayes algorithm implanted in R Package ‘naivebayes’.  
Neural network (NN) is based on a collection of artificial neurons. Each artificial neuron can 
process inputs and pass the outputs to the connected artificial neurons. The weight of the 
artificial neurons and connections are trained and applied to the testing set. We used a feed-
forward neural network with a single hidden layer implanted in Package ‘nnet’. 
3.4.7.4 Multi-voxel MRS analysis 
Since the spatial resolution between CSI and other MRI modalities are significantly different, 
it is challenging to measure the metabolic state of ROIs in T2-space. Voxels from T2-weighted 
MRIs were projected onto CSI space according to their coordinates using MATLAB. Thus, the 
metabolic status in each voxel could be matched to the voxels in the physiological images, 
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which were co-registered to T2-weighted images. The proportion of T2-space tumour voxels 
occupying each MRS voxel was calculated, and MRS voxels were selected according to the 
threshold defined in subsequent studies for further analyses. The projection of T2 space voxels 
to CSI space is demonstrated in Figure 3.10. A case example with the demonstration of spectra 
is demonstrated in Figure 3.11. 
 
Figure 3.10 An illustration of projecting T2 space voxel into CSI voxels. As the CSI was planned on T2-
weighted images, the T2-space tumour voxels (grey cubes) can be projected to CSI voxels (white cubes) 
according to their coordinates. After projection, the proportion of T2-space tumour voxels in CSI voxels can 
be calculated. A threshold can be used as the inclusion criteria. In this example, a threshold of 50% is used. 
Since only in the green CSI voxels, T2-space tumour voxels occupy more than 50%. Thus, only the green CSI 
voxels are included for further analysis, whereas orange voxels are excluded.  
T2-space tumor voxel 
CSI voxel 
Resampling of CSI voxel 
Excluded CSI voxel 
Included CSI voxel 




Figure 3.11 Illustration of multiple voxel MRS analysis.  Left: the selection criteria. The T2-space pixels 
were projected to CSI space according to their coordinates. The proportion of T2-space tumour pixels 
occupying each CSI voxel was calculated.  A criterion was applied that only those CSI voxels were included 
when the proportion of tumour voxels are over 50%. In this case, grid 1-8 met the criteria. The proportion of 
the tumour voxels in the ROI was taken as the weight of each CSI voxel in the ROI. The summed weighted 
value was used as the final metabolic value of two compartments. Right: Example spectra of two compartments, 
abnormal control (CEC) and normal control (NAWM). 






Chapter 4 Intra-tumoural Heterogeneity of 
Glioblastoma Infiltration Revealed by Joint 
Histogram Analysis of Diffusion Tensor Imaging 
4.1 Abstract 
Background 
Glioblastoma is a heterogeneous disease characterized by its infiltrative growth, rendering 
complete resection impossible. Diffusion tensor imaging (DTI) shows potential in detecting 
tumour infiltration by reflecting microstructure disruption.  
Objective 
We aimed to explore the heterogeneity of glioblastoma infiltration using a joint histogram 
analysis of DTI, to investigate the incremental prognostic value of infiltrative patterns over 
clinical factors, and to identify specific sub-regions for targeted therapy. 
Methods 
A total of 115 primary glioblastoma patients were prospectively recruited for surgery and pre-
operative MRI. The joint histograms of decomposed anisotropic and isotropic components of 
DTI were constructed in both contrast-enhancing and non-enhancing tumour regions. Patient 
survival was analysed with joint histogram features and relevant clinical factors. The 
incremental prognostic values of histogram features were assessed using receiver operating 
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characteristic curve analysis. The correlation between the proportion of diffusion patterns and 
tumour progression rate was tested using Pearson correlation.  
Results 
We found that joint histogram features were associated with patient survival and improved 
survival model performance. Specifically, the proportion of non-enhancing tumour sub-region 
with decreased isotropic diffusion and increased anisotropic diffusion was correlated with 
tumour progression rate (P = 0.010, r = 0.35), affected progression-free survival (hazard ratio 
= 1.08, P < 0.001) and overall survival (hazard ratio = 1.36, P < 0.001) in multivariate models. 
Conclusion 
Joint histogram features of DTI showed incremental prognostic values over clinical factors for 
glioblastoma patients. The non-enhancing tumour sub-region with decreased isotropic 
diffusion and increased anisotropic diffusion may indicate a more infiltrative habitat and 
potential treatment target.  
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4.2 Introduction 
As we discussed in Chapter 1, glioblastoma is characterised by its extensive heterogeneity in 
the tumour clonal composition (Sottoriva et al., 2013b, Verhaak et al., 2010). It is recognized 
that glioblastoma is also heterogeneous in its infiltrative pattern. Migratory clones within a 
tumour may result in a more infiltrative phenotype, which may be especially responsible for 
treatment failure (Giese et al., 2003). A previous study showed that the migratory phenotype 
of a subset of cells can predict tumour recurrence (Smith et al., 2016). Understanding the intra-
tumoural heterogeneity of glioblastoma infiltration is of clinical significance for targeted 
surgery and radiotherapy. 
Magnetic resonance imaging (MRI) has unique advantages in understanding spatial structural 
variations within glioblastoma. Current clinical management is primarily based on structural 
sequences, among which the post-contrast T1-weighted imaging is most widely-used. This 
approach, however, provides limited quantitative information about tumour infiltration, as 
stated in section 1.8.2. Other sequences, such as fluid attenuated inversion recovery (FLAIR), 
although integrated into clinical assessment (Wen et al., 2010), is still considered to be non-
specific for differentiating tumour infiltration from oedema and delayed radiation white matter 
change (Price et al., 2006).  
As discussed in Section 1.8.4, diffusion tensor imaging (DTI) is a method that measures the 
magnitude and direction of water molecule movement and has been shown to be sensitive in 
detecting tumour infiltration (Price et al., 2017). Glioblastoma cells may preferentially migrate 
along white matter tracts and cause disruption (Hambardzumyan and Bergers, 2015b). The 
diffusion of water molecules in the tumour and the peritumoural brain is consequently altered. 
By decomposing the tensor into isotropic (DTI-p) and anisotropic (DTI-q) components, the 
directional diffusion can be measured (Pena et al., 2006a). This approach has been found useful 
in predicting tumour progression and patient survival (Price et al., 2007, Mohsen et al., 2013). 
It remains to be discovered, however, whether integrating these components can offer a more 
comprehensive measure of tumour infiltration. Furthermore, molecular biomarkers, such as 
isocitrate dehydrogenase (IDH) mutations(Parsons et al., 2008b) and oxygen 6–
methylguanine-DNA methyltransferase (MGMT) promoter methylation (Hegi et al., 2005a), 
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are reported to be of diagnostic and prognostic significance for glioblastoma. One previous 
study has shown that IDH mutant glioblastoma is less invasive determined by DTI maps (Price 
et al., 2017). Whether the DTI markers, particularly DTI-p and -q, can provide additional 
prognostic value to molecular markers is unclear. 
The purpose of this study was to explore the heterogeneity of glioblastoma infiltration using 
joint histogram analysis of DTI, to investigate the incremental prognostic value of infiltrative 
patterns over clinical factors, and to identify specific sub-regions that may be suitable for 
targeted therapy. The hypothesis was that joint histogram analysis of diffusion parameters can 
differentiate anatomically-defined regions into sub-regions with different diffusion patterns of 
prognostic value. 
4.3 Methods 
4.3.1 Study design  
We prospectively and preoperatively recruited patients with an initial radiological diagnosis of 
supratentorial primary glioblastoma from July 2010 to August 2015. The inclusion and 
exclusion criteria are in Section 3.1.1. This study was approved by the local institutional review 
board. Signed informed consent was obtained from all patients. Patient treatment is detailed in 
Section 3.1.2.1. Assessment of IDH-1 mutation and MGMT methylation status are described 
in 3.2. 
4.3.2 Pre-operative MRI acquisition 
A 3-Tesla MRI system (Magnetron Trio; Siemens Healthcare, Erlangen, Germany) was used. 
Pre-operative DTI, post-contrast T1-weighted imaging, T2-weighted imaging and T2-weighted 
FLAIR were acquired for all the subjects pre-operatively. Sequence details are provided in 
3.3.2.2. All patient underwent MRI within 72hrs postoperatively.  
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4.3.3 Image processing 
DTI was processed with FSL v5.0.8, as described in Section 3.4.2. DTI-p and -q were 
calculated using previously described equations (Pena et al., 2006a). Anatomical images were 
co-registered to DTI with an affine transformation, using FLIRT (Jenkinson et al., 2002). 
Tumour ROIs were manually drawn as described in 3.4.6.1. 
4.3.4 Histogram analysis 
Histogram analysis was performed in the Statistics and Machine Learning Toolbox of 
MATLAB. Contrast-enhancing and non-enhancing ROIs were analysed independently. A 
demonstration of histogram analysis is shown in Figure 4.1. Each voxel of DTI-p and -q in 
tumour ROIs was normalized by dividing it by the mean value in the contralateral normal-
appearing white matter as discussed in Section 3.4.6, which has been used in previous studies 
as a robust normalisation technique (Boonzaier et al., 2017b, Yan et al., 2017). The univariate 
histograms of DTI-p and -q were constructed with the normalized voxels using 100 bins (Figure 
4.1. A & B). The mean, median, 25th and 75th percentile of the histogram were calculated.  
The joint histogram was constructed with the x-axis and y-axis representing the normalized 
DTI-p and -q values respectively, using 50 × 50 bins on both axes (Fig 4.1. C). Each voxel 
within the tumour was assigned to a corresponding bin in the 3D space, according to the DTI-
p and -q values they carried. Since the voxel values were normalized as above, the coordinator 
point (p = 1, q = 1) was designated to represent the diffusion pattern in the contralateral normal-
appearing white matter, which was calculated as the mean value of DTI-p and DTI-q in the 
regions of interest, as described above. Thus, four voxel groups describing the co-occurrence 
distribution of DTI-p and -q abnormality were obtained (Fig 1. D), namely: 
I. Voxel Group I (decreased DTI-p/decreased DTI-q, p/q)  
II. Voxel Group II (decreased DTI-p/increased DTI-q, p/q)  
III. Voxel Group III (increased DTI-p/increased DTI-q, p/q)  
IV. Voxel Group IV (increased DTI-p/decreased DTI-q, p/q)  
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The proportion of each voxel group in the ROI was used as joint histogram features, obtained 
from both contrast-enhancing and non-enhancing tumour regions, providing eight features per 
patient.  
 
Figure 4.1 Illustration of the univariate and joint histogram analysis.  Univariate histograms of DTI-p (A) 
and -q (B) were constructed using 100 bins. The joint histogram was constructed with x- and y-axis representing 
DTI-p and -q values using 50 × 50 bins. The bin height of the joint histogram represented the relative frequency 
of voxels falling into a specific DTI-p and -q range (C). Four voxel groups of DTI-p and -q abnormalities were 
obtained (D): I. Voxel Group I (decreased DTI-p/decreased DTI-q); II. Voxel Group II (decreased DTI-
p/increased DTI-q); III. Voxel Group III (increased DTI-p/increased DTI-q); IV. Voxel Group IV (increased 
DTI-p/decreased DTI-q). 
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4.3.5 Evaluation of treatment response and tumour progression 
The extent of resection and treatment response were assessed as described in 3.1.2. The time 
to tumour progression was defined as the period between surgery date and the date of first post-
contrast T1-weighted images that showed progression (as determined by a consultant 
neuroradiologist). Available progression images were reviewed with the collaboration of Dr 
Jiun-Lin Yan and Dr Rory J Piper. A two-stage semiautomatic co-registration between the 
progression images and pre-operative post-contrast T1-weighted images was performed using 
a previously reported tool (van der Hoorn et al., 2016, Yan et al., 2017). This coregistration 
method firstly calculated the transformation matrix between the pre-operative lesion and 
tumour cavity on progression images. The matrix was then applied to the brain parenchyma 
using FNIRT in FSL. After coregistration, the progression tumour volume was calculated using 
FSL function of fslmaths. The progression rate was defined as progression volume normalized 
by time to progression.  
4.3.6 Statistical analysis 
All statistical analyses were performed in RStudio v3.2.3 (Rstudio, Boston, MA, USA). 
Histogram features or tumour volume were assessed using Wilcoxon signed rank test. Survival 
was evaluated in patients who have received concurrent TMZ chemoradiotherapy followed by 
adjuvant TMZ post-operatively. Cox proportional hazards regression was performed, 
accounting for relevant covariates, including IDH-1 mutation, MGMT methylation, sex, age, 
the extent of resection and contrast-enhancing tumour volume. Patients who were alive at the 
last known follow-up were censored. For Kaplan-Meier analysis, continuous variables were 
dichotomized using optimal cutoff values, calculated by the R Package “survminer” 
(https://cran.r-project.org/web/packages/survminer/). Logistic regression models were used to 
test prognostic values of covariates for 12-, and 18-month OS and PFS. The baseline models 
were firstly constructed using all above relevant clinical covariates. Specific histogram features 
were then added one by one into the baseline model to assess their incremental prognostic 
value, by comparing the area under the receiver operator characteristics curve (AUC) using 
one-way ANOVA. To select prognostic variables, multivariate Cox regression was performed, 
using forward and backward stepwise procedures. The forward procedure started from the 
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model containing only one covariate and add one covariate in each step, whereas the backward 
procedure initiated from the model containing all covariates and delete one covariate in each 
step. For each step, the model was evaluated using the Akaike Information Criterion (AIC). 
The final models were constructed using the covariates selected by this procedure. Correlations 
between variables were tested using the Pearson correlation test. The hypothesis of no effect 
was rejected at a two-sided level of 0.05.   
4.4 Results 
4.4.1 Patients  
We prospectively recruited 136 patients into the study. After surgery, 115 (84.6%) 
histologically confirmed glioblastoma patients (mean age 59.3 years, range 22 - 76 years, 87 
males) were included. A flowchart of patient recruitment is demonstrated in Figure 4.2. Clinical 
characteristic of 115 included patients is summarized in Table 4.1.  
Of the 115 patients, 84 (73.0 %) patients received concurrent temozolomide (TMZ) 
chemoradiotherapy followed by adjuvant TMZ, post-operatively. Other patients received a 
short-course radiotherapy (17.4%, 20/115) or best supportive care (9.6%, 11/115), due to their 
poor post-operative performance status. Survival data were available for 80 of 84 (95.2%) 
patients that were treated with CCRT and 4 (4.8%) patients were lost to follow up.  
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Figure 4.2 Flowchart showing how patients were excluded. A total of 136 patients with a radiological 
diagnosis of glioblastoma were prospectively recruited and underwent surgery. Twenty-one patients were 
excluded because of non-glioblastoma pathology diagnosis. Histogram analysis was performed on the pre-
operative MRIs of 115 glioblastoma patients. Among these patients, 84 patients received concurrent 
temozolomide (TMZ) chemoradiotherapy followed by adjuvant TMZ after surgery. Four patients were lost to 
follow up. Since MGMT methylation status was missing in two patients, multivariate Cox regression and 
receiver operator characteristics curve analyses were performed on 78 patients. Twenty-seven patients who 
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Table 4.1 Clinical characteristics  
Variables Patient Number 
Age at diagnosis   
   <60 40 
   ≥60 75 
Sex  
   Male 87 
   Female 28 
Extent of resection (of enhancing tumour)  
   Complete resection  77 
   Partial resection 32 
   Biopsy 6 
MGMT-methylation status*  
   Methylated 48 
   Unmethylated 63 
IDH-1 mutation status  
   Mutant 7 
   Wild-type 108 
Tumour volumes(cm3) #  
    Contrast-enhancing  53.6 ± 33.8 
    Non-enhancing  62.5 ± 44.0 
Survival (days)  
    Median OS (range) 424 (52 -1376) 
    Median PFS (range) 262 (25-1130) 
*MGMT-methylation status unavailable for 4 patients; #mean ± SD of original data. 
SD: standard deviation; MGMT: O-6-methylguanine-DNA methyltransferase; IDH-1: 
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4.4.2 Diffusion signatures of contrast-enhancing and non-enhancing 
regions 
The diffusion signatures of ROIs are demonstrated in Table 4.2. For univariate histogram 
features, both contrast-enhancing and non-enhancing regions displayed increased DTI-p (all 
values greater than 1). A decreased DTI-q (all values less than 1) was consistently observed in 
the contrast-enhancing region, whereas non-enhancing regions displayed increased mean and 
75th percentile of DTI-q. In accordance with the univariate histogram, joint histogram analysis 
showed that Voxel Group IV (increased DTI-p/decreased DTI-q, p/q) accounted for the 
largest proportion in tumours.  
Table 4.2 Histogram features 
Variables 
contrast-enhanced region non-enhancing region 
P value 
Mean ± SD Mean ± SD 
DTI-p histogram features 
25th percentile 1.18 ± 0.23 1.11 ± 0.15 < 0.001 
Median 1.47 ± 0.38 1.32 ± 0.23 0.001 
Mean 1.57 ± 0.36 1.37 ± 0.22 < 0.001 
75th percentile 1.90 ± 0.60 1.59 ± 0.30 < 0.001 
DTI-q histogram features 
25th percentile 0.42 ± 0.14 0.71± 0.18 < 0.001 
Median 0.65 ± 0.19 0.95 ± 0.23 < 0.001 
Mean 0.71 ± 0.19 1.01 ± 0.24 < 0.001 
75th percentile 0.93 ± 0.24 1.24 ± 0.29 < 0.001 
DTI Joint histogram features (%) 
Voxel Group I 8.50 ± 10.37 5.49 ± 6.17 < 0.001 
Voxel Group II 3.83 ± 4.92 7.27 ± 8.07 < 0.001 
Voxel Group III 20.78 ± 13.65 40.33 ± 18.97 < 0.001 
Voxel Group IV 66.90 ± 16.28 46.92 ± 20.40 < 0.001 
DTI: diffusion tensor imaging; p: isotropic component; q: anisotropic component; SD: standard 
deviation; Voxel Group I: decreased DTI-p, decreased DTI-q (p/q,); Voxel Group II: decreased 
DTI-p, increased DTI-q (p/q); Voxel Group III: increased DTI-p, increased DTI-q (p/q); 
Voxel Group IV: increased DTI-p, decreased DTI-q (p/q). 
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4.4.3 Multivariate survival analysis 
The multivariate survival model of PFS and OS were fitted in 78 patients for whom all relevant 
covariates were available (Table 4.3). Five joint histogram features were significantly 
associated with survivals. Specifically, higher proportions of Voxel Group II (p/q), in both 
contrast-enhancing and non-enhancing regions, were associated with worse survival (in 
contrast-enhancing region, PFS: HR = 1.06, P = 0.036; OS: HR = 1.09, P = 0.004; in non-
enhancing region, PFS: HR = 1.08, P < 0.001; OS: HR = 1.11, P < 0.001). The Kaplan-Meier 
curves are demonstrated in Figure 4.3, with P values from the Log-rank test. 
Table 4.3 Cox multivariate modelling of survivals 
Variables 
Progression-free survival* Overall survival* 
HR 95%CI P value HR 95%CI P value 
Contrast-enhancing region 
Voxel Group I 1.02 0.990-1.049 0.205 1.03 1.000-1.064 0.049 
Voxel Group II 1.06 1.004-1.128 0.036 1.09 1.028-1.156 0.004 
Voxel Group III 1.01 0.989-1.025 0.449 1.01 0.988-1.028 0.432 
Voxel Group IV 0.98 0.968-1.001 0.061 0.98 0.960-0.996 0.015 
Non-enhancing region 
Voxel Group I 1.02 0.975-1.057 0.463 0.997 0.947-1.049 0.904 
Voxel Group II 1.08 1.041-1.128 <0.001 1.11 1.064-1.165 <0.001 
Voxel Group III 1.01 0.996-1.026 0.145 1.01 0.997-1.026 0.116 
Voxel Group IV 0.98 0.969-0.996 0.014 0.98 0.969-0.997 0.015 
*Cox models accounted for each histogram feature and all covariates of sex, age, extent of resection, 
IDH-1 mutation status, MGMT methylation status and contrast-enhancing tumour volume. MGMT: O-
6-methylguanine-DNA methyltransferase; IDH-1: Isocitrate dehydrogenase 1; HR: hazard ratio; CI: 
confidence interval; Voxel Group I: decreased DTI-p, decreased DTI-q (p/q); Voxel Group II: 
decreased DTI-p, increased DTI-q (p/q); Voxel Group III: increased DTI-p, increased DTI-q (p/q); 
Voxel Group IV: increased DTI-p, decreased DTI-q (p/q). 
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Figure 4.3 Kaplan-Meier plots of survival analysis. The proportions of voxel groups were dichotomized 
using optimal cutoff values calculated in R. Log-rank test showed higher proportion of Voxel Group II in non-
enhancing tumour region was associated with worse PFS (P = 0.008, cut off value 2.3%) (A) and worse OS (P 
< 0.001, cut off value 12.8%) (C). Lower proportion of Voxel Group IV in non-enhancing tumour region was 
associated with worse PFS (P < 0.001, cut off value 65.9%) (B) and worse OS (P = 0.005, cut off value 36.9%) 
(D). 
4.4.4 Incremental Prognostic Value of Joint Histogram Features 
The results of model comparisons are shown in Table 4.4. Six joint histogram features 
significantly improved the model (each P < 0.05): Voxel group I (p/q), Voxel group II 
(p/q), Voxel group IV (p/q) in the contrast-enhancing region, and Voxel group II (p/q), 
Voxel group III (p/q), Voxel group IV (p/q) in the non-enhancing region. Particularly, 
Voxel Group II (p/q) in the non-enhancing region significantly improved the 12-month and 
18-month survival models. 
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95% CI P value 
18 month 
AUC 
95% CI P value 
Progression-free survival 
baseline* 0.77 0.65-0.88  0.75 0.61-0.88  
Contrast-enhancing region 
+Voxel Group I 0.81 0.71-0.92 0.038 0.78 0.65-0.92 0.424 
+Voxel Group II 0.80 0.70-0.91 0.153 0.86 0.76-0.96 0.003 
+Voxel Group III 0.77 0.66-0.88 0.916 0.79 0.66-0.91 0.229 
+Voxel Group IV 0.81 0.70-0.91 0.077 0.81 0.68-0.93 0.044 
Non-enhancing region 
+Voxel Group I 0.76 0.65-0.88 0.792 0.76 0.63-0.89 0.763 
+Voxel Group II 0.80 0.70-0.91 0.096 0.86 0.74-0.97 0.017 
+Voxel Group III 0.80 0.69-0.91 0.372 0.83 0.71-0.95 0.023 
+Voxel Group IV 0.80 0.70-0.91 0.154 0.83 0.71-0.95 0.011 
Overall survival 
baseline* 0.81 0.70-0.93   0.71 0.58-0.83   
Contrast-enhancing region 
+Voxel Group I 0.82 0.69-0.95 0.070 0.75 0.63-0.87 0.091 
+Voxel Group II 0.84 0.73-0.96 0.063 0.77 0.65-0.88 0.075 
+Voxel Group III 0.81 0.70-0.93 0.746 0.73 0.60-0.85 0.443 
+Voxel Group IV 0.84 0.72-0.95 0.164 0.77 0.65-0.88 0.035 
Non-enhancing region 
+Voxel Group I 0.81 0.70-0.93 0.942 0.71 0.58-0.83 0.952 
+Voxel Group II 0.84 0.72-0.96 0.015 0.78 0.66-0.89 0.022 
+Voxel Group III 0.84 0.74-0.94 0.109 0.74 0.61-0.86 0.196 
+Voxel Group IV 0.85 0.75-0.95 0.019 0.76 0.64-0.88 0.053 
*Baseline models were built using sex, age, extent of resection, IDH-1 mutation status, MGMT 
methylation status and contrast-enhancing tumour volume. MGMT: O-6-methylguanine-DNA 
methyltransferase; IDH-1: Isocitrate dehydrogenase 1; AUC: area under receiver operator 
characteristics curve; HR: hazard ratio; CI: confidence interval; DTI: diffusion tensor imaging; 
Voxel Group I: decreased DTI-p, decreased DTI-q (p/q,); Voxel Group II: decreased DTI-p, 
increased DTI-q (p/q); Voxel Group III: increased DTI-p, increased DTI-q (p/q); Voxel Group 
IV: increased DTI-p, decreased DTI-q (p/q). 
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4.4.5 Stepwise Multivariate Cox Model Selection 
All clinical factors and histogram features that significantly improved AUC were tested (Table 
4.5). Significant prognostic variables for both PFS and OS included the extent of resection, 
MGMT methylation status and Voxel Group II (p/q) in the non-enhancing region. 
Specifically, Voxel Group II (p/q) in the non-enhancing region contributed to a worse PFS 
(HR 1.08, P < 0.001) and worse OS (HR 1.36, P < 0.001), and displayed a higher HR than 
other voxel groups.  
Table 4.5 Stepwise Cox multivariate modelling of survivals 
Variables 
Progression-free survival* Overall survival* 
HR 95%CI P value HR 95%CI P value 
Sex 1.58 0.90-2.77 0.109 / / / 
Age / / / / / / 
Extent of resection 3.25 1.67-6.34 0.001 2.13 1.12-4.06 0.022 
IDH-1 mutation status / / / / / / 
MGMT methylation status 0.50 0.29-0.86 0.013 0.51 0.27-0.97 0.040 
Contrast-enhancing volume / / / 1.02 1.01-1.03 0.001 
Voxel Group I (contrast-enhancing region) / / / 1.06 1.02-1.11 0.006 
Voxel Group II (contrast-enhancing region) / / / / / / 
Voxel Group IV (contrast-enhancing 
region) 
/ / / / / / 
Voxel Group II (non-enhancing region) 1.08 1.04-1.13 <0.001 1.36 1.16-1.59 <0.001 
Voxel Group III (non-enhancing region) / / / 1.19 1.05-1.34 0.005 
Voxel Group IV (non-enhancing region) / / / 1.18 1.05-1.32 0.005 
*All clinical factors and joint histogram features that showed incremental prognostic values in model 
comparisons were included into selection. Final models were built only using the covariates selected by the 
stepwise procedure. HR: hazard ratio; CI: confidence interval; IDH-1: Isocitrate dehydrogenase 1; MGMT: 
O-6-methylguanine-DNA methyltransferase; Voxel Group I: decreased DTI-p, decreased DTI-q (p/q); 
Voxel Group II: decreased DTI-p, increased DTI-q (p/q); Voxel Group III: increased DTI-p, increased 
DTI-q (p/q); Voxel Group IV: increased DTI-p, decreased DTI-q (p/q). 
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4.4.6 Correlations with tumour progression rate 
The correlation with tumour progression rate was tested in 57 patients who had progression 
and available MR images at progression. The progression volume (mean ± SD) outside of the 
resection cavity was 14.3 ± 22.0 cm3. The progression rate (mean ± SD) was 0.003 ± 0.013 
cm3/day. The results indicated that Voxel Group II (p/q) in the non-enhancing region had a 
significant positive correlation (P = 0.010, r = 0.35) with the progression rate, whereas Voxel 
Group IV (p/q) in the non-enhancing region (P = 0.040, r = -0.28) showed a negative 
correlation.  No significant correlations were found from other voxel groups. Two examples of 
pre-operative and progression images, as well as the annotated sub-regions of Voxel Group II 
and Voxel Group IV in the non-enhancing region, are demonstrated in Figure 4.4 & Figure 4.5.  
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Figure 4.4 The Voxel Group II (yellow) and Voxel Group IV (blue) of non-enhancing in case 1. The 63-
year-old man was radiologically diagnosed with primary glioblastoma (A & B). Volumetric analysis of pre-
operative MRI showed contrast-enhancing tumour volume was 83.6 cm3. The patient received tumour resection 
with the guidance of neuro-navigation and 5-aminolevulinic acid fluorescence with the aim of maximal 
resection, but only subtotal resection was achieved according to 72h post-operative MRI. The pathological 
assessment confirmed this was an MGMT-methylated glioblastoma and IDH mutation was negative. The 
patient received concomitant and adjuvant temozolomide chemoradiotherapy. The progression-free survival 
was 47 days and overall survival was 104 days. The post-contrast T1-weighted imaging showed the progression 
was around the resection cavity (C). Joint histogram analysis of pre-operative DTI-p (D) and DTI-q (E) maps 
showed Voxel Group II (yellow) occupied 15.5% in the non-enhancing tumour and Voxel Group IV (blue) 
occupied 28.2% of the non-enhancing tumour (F).  
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Figure 4.5 The Voxel Group II (yellow) and Voxel Group IV (blue) of non-enhancing in case 2. The 65-
year-old man was radiologically diagnosed with primary glioblastoma (A & B). Volumetric analysis showed 
contrast-enhancing tumour volume was 37.4 cm3. Gross total resection was achieved in this patient with the 
guidance of neuro-navigation and 5-aminolevulinic acid fluorescence. The pathological assessment confirmed 
an MGMT-methylated glioblastoma and IDH mutation was negative. The patient received concomitant and 
adjuvant temozolomide chemoradiotherapy. The progression-free survival was 1006 days and the patient was 
alive in the last follow-up. Post-contrast T1-weighted imaging showed a minor progression around the resection 
cavity (C). Joint histogram analysis of pre-operative DTI-p (D) and DTI-q (E) maps showed Voxel Group II 
(yellow) occupied 2.3% of the non-enhancing tumour and Voxel Group IV (blue) occupied 81.5% of the non-
enhancing tumour (F). 
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4.5 Discussion 
In this study, we found that joint histogram analysis using DTI-p and -q can reflect the 
heterogeneity of glioblastoma infiltration. The histogram features obtained using this method 
can improve the prognostic value of IDH-1 mutation and MGMT promoter methylation status. 
The non-enhancing sub-region with decreased DTI-p and increased DTI-q may indicate a more 
infiltrative tumour habitat. 
Previous studies have shown that DTI has potential in studying white matter pathology and is 
useful in detecting tumour infiltration (Zhang, 2010, Price et al., 2004, Sternberg et al., 2014). 
Using stereotactic biopsies, DTI-p and -q is demonstrated to distinguish the gross tumour and 
peritumoural region (Price et al., 2006). As the only in vivo method of describing brain 
microstructure, it confers additional information for surgical stratification (Potgieser et al., 
2014, Jones et al., 2015b). However, the interpretation of the tensor is challenging due to its 
high dimensionality (Sternberg et al., 2014). Substantial efforts have been made to simplify the 
tensor into scalar measures. Among these markers, fractional anisotropy (FA) and mean 
diffusivity (MD) are commonly used (Pena et al., 2006a). Since FA can be affected by both 
anisotropic and isotropic components (according to its definition equation), its utility is 
inconsistent. An enhanced visualization and quantification of tensor imaging was subsequently 
advanced by decomposing the raw tensor into isotropic (p) and anisotropic (q) components 
(Pena et al., 2006a). This technique has shown its utility in detecting the subtle change caused 
by tumour invasion and predicting progression (Price et al., 2017). Consistent with previous 
studies (Price et al., 2006). Our univariate results showed increased DTI-p and decreased DTI-
q can be found in the majority of the tumour area. Additionally, the non-enhancing tumour may 
display increased DTI-q, which was not observed in the contrast-enhancing region and may 
characterize the infiltrative region.   
Previous studies have shown that histogram features extracted from DTI can characterize 
tumour heterogeneity and carry diagnostic values (Wagner et al., 2016). Every intra-tumoural 
voxel bears both isotropic and anisotropic diffusion information. Neither DTI-p nor DTI-q is 
sufficient to reflect the full tensor. This rationalizes the joint histogram analysis approach of 
this study. It has been previously suggested to combine DTI measures with structural images 
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(Bammer, 2003), which is why the joint histogram analysis was performed in tumour regions 
identified on anatomical images. The results showed the Voxel Group IV (p/q) had the 
largest proportion in both contrast-enhancing and non-enhancing tumour regions. In this sub-
region, the brain microstructure is destroyed, resulting in more isotropic diffusion. There is a 
reduction in numbers of axons that facilitate tumour cell infiltration. The displacement and 
compression of fibres may also mean the ‘fast track’ to infiltrate is diminished and, thus, 
decreased anisotropic diffusion is observed. The significantly higher proportion of this 
diffusion pattern in the bulk tumour than the infiltrated tumour may suggest more substantial 
fibre damage.  
More diffusion patterns can be revealed by this approach. Particularly, the higher proportion 
of Voxel Group II (p/q) in non-enhancing regions showed increased hazard ratio in both OS 
and PFS models. Since the decreased DTI-p is thought to reflect the elevated cell density and 
increased DTI-q may indicate intact fibres which may facilitate the tumour migration, this sub-
region may represent a migratory tumour habitat. Though the proportion s relatively low, the 
significant association with patient survival and tumour progression may indicate its 
invasiveness. As shown in the case examples, some locations of this sub-region are in the 
vicinity of the surgical cavity. Our findings may allow for better targeting of radiotherapy in 
these sub-regions. Histological correlation of these findings is required. 
The joint histogram features found in our study showed clinical significance, with incremental 
prognostic values when integrated with clinical factors. Particularly, in the model of overall 
survival, contrast-enhancing tumour volume had a smaller HR than all the voxel groups 
identified. The IDH-1 mutation did not show its prognostic value in this cohort, possibly due 
to the limited patient numbers. As the more infiltrative sub-region identified, targeted resection 
and radiation therapy can perhaps be achieved, which may reduce the radiation damage to the 
normal brain and enhance the efficacy of treatment.  
There are some limitations in our study. Firstly, the patient population reported is from a single 
centre and the results were not validated by another cohort. However, since imaging setting 
may significantly impact the calculation of DTI-based metrics, this single centre study can 
reduce the confounder from the imaging setting and facilitate hypothesis test. Secondly, 
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although our current study did not have biological validation, previous studies have validated 
the histological correlates of DTI-p and DTI-q by image-guided biopsies (Price et al., 2006). 
This current study aimed to use DTI joint histogram analysis as a surrogate to investigate 
glioblastoma infiltration. The findings of this study need further validation using the tumour 
tissue biopsied from the invasive sub-regions identified.    
4.6 Conclusion 
We used a joint histogram analysis of DTI-p and -q to investigate glioblastoma infiltration. The 
results showed that this method may help to better understand the heterogeneity of tumour 
infiltration and offer incremental prognostic values over clinical factors; the non-enhancing 
region with decreased DTI-p and increased DTI-q may be able to define an infiltrative sub-
region responsible for tumour progression. This finding may be useful for targeted surgery and 





Chapter 5 Low Perfusion Compartments in 
Glioblastoma Quantified by Advanced Magnetic 




Glioblastoma exhibits profound intra-tumoural heterogeneity in blood perfusion, which may 
cause inconsistent therapy response. Particularly, low perfusion may create hypoxic 
microenvironment and induce resistant clones. Thus, developing validated imaging approaches 
that define low perfusion compartments is crucial for clinical management.  
Methods 
A total of 112 newly-diagnosed supratentorial glioblastoma patients were prospectively 
recruited for maximal safe resection. Preoperative MRI included anatomical, dynamic 
susceptibility contrast (DSC), diffusion tensor imaging (DTI) and chemical shift imaging 
(CSI). The apparent diffusion coefficient (ADC) and relative cerebral blood volume (rCBV) 
were calculated from DTI and DSC respectively. Using thresholding methods, two low 
perfusion compartments (ADCH-rCBVL and ADCL-rCBVL) were identified. Volumetric 
analysis was performed. Lactate and macromolecule/lipid levels were determined from multi-
voxel spectroscopy. Progression-free survival (PFS) and overall survival (OS) were analysed 
using Kaplan-Meier and multivariate Cox regression analyses. 
Results 
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Two compartments displayed higher lactate and macromolecule/lipid levels than normal 
controls (each P < 0.001), suggesting hypoxic and pro-inflammatory microenvironment. The 
proportional volume of ADCL-rCBVL compartment was associated with a larger infiltration 
area (P < 0.001, rho = 0.42). Lower lactate in this compartment was associated with a less 
invasive phenotype visualized on DTI. Multivariate Cox regression showed higher lactate level 
in the ADCL-rCBVL compartment was associated with a worse survival (PFS: HR = 2.995, P 
= 0.047; OS: HR = 4.974, P = 0.005). 
Conclusions 
The ADCL-rCBVL compartment represents a treatment resistant sub-region associated with 
glioblastoma invasiveness. This approach was based on clinically available imaging modalities 
and could thus provide crucial pre-treatment information for clinical decision making. 
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5.2 Introduction 
Chapter 4 has shown that diffusion imaging can provide a useful tool to reveal the intra-
tumoural infiltrative habitat. In this Chapter, we investigate the prognostic values of the intra-
tumoural habitats revealed by multi-parametric MRI. 
In a study performed by the previous group member, Dr Natalie R Boonzaier, tumour habitats 
that were highly perfused with restricted diffusion were identified and found to be correlated 
with tumour invasiveness(Boonzaier et al., 2017a). This finding is supported by the commonly 
observed angiogenesis and elevated perfusion of glioblastoma, associated with a more invasive 
phenotype (Hanahan and Weinberg, 2011b), as stated in Section 1.8.3. However, a potent 
angiogenesis inhibitor failed to demonstrate consistent benefits in clinical trials of de novo 
glioblastoma (Chinot et al., 2014). A possible explanation is the profound intra-tumoural 
perfusion heterogeneity in glioblastomas, which is due to the aberrant microvasculature and 
inefficient nutrient delivery. This heterogeneity can give rise to regions within tumours where 
the demand and supply of nutrients are mismatched (Komar et al., 2009). Consequently, the 
sufficiently perfused sub-regions may hold the advantages for progression and proliferation, 
whereas the insufficiently perfused sub-regions may have a hypoxic microenvironment (Gillies 
et al., 1999), which may preferentially induce adaptive and resistant clones in the low perfusion 
sub-regions (Pistollato et al., 2010). It is therefore important to understand the function of low 
perfusion sub-regions and evaluate their effects on treatment resistance. 
Current clinical practice infers the low perfusion regions as the non-enhancing regions within 
contrast enhancement on post-contrast images, which can lead to non-specific results using the 
conventional weighted images (O'Connor et al., 2008, O'Connor et al., 2015), as discussed in 
Section 1.8.2. Multiparametric imaging may allow for a more comprehensive evaluation of 
tumour physiology, compared to the morphological heterogeneity seen with structural MRIs. 
Here we sought to quantify the low perfusion compartments in glioblastoma using multi-
parametric physiological magnetic resonance imaging (MRI). The relative cerebral blood 
volume (rCBV) calculated from perfusion weighted imaging measures tumour vascularity (Liu 
et al., 2016). The apparent diffusion coefficient (ADC) calculated from diffusion imaging 
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provides information about tumour microstructure by measuring the movement of water 
molecules (Pope et al., 2012). Thus, the two low perfusion compartments we visualized have 
distinct properties: one compartment with restricted diffusivity that may represent cellular sub-
regions adapting to hypoxic acidic conditions (Gatenby et al., 2013), and one compartment 
with increased diffusivity that may represent necrotic sub-regions with diminishing cellular 
structure. We studied the metabolic signatures in each compartment using MR spectroscopy 
and the impact it has on patient survival. Using multivariate survival analysis, we demonstrate 
that the volume and lactate level of these two compartments are clinically important.  
5.3 Methods 
5.3.1 Patient cohort  
Patients with a radiological diagnosis of primary supratentorial glioblastoma suitable for 
maximal safe surgical resection were prospectively recruited from July 2010 to April 2015. 
The inclusion and exclusion criteria are in Section 3.1.1. This study was approved by the local 
institutional review board. Signed informed consent was obtained from all patients. Patient 
treatment is detailed in Section 3.1.2.1. Assessment of IDH-1 R132H Mutation and MGMT 
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Figure 5.1 Flow diagram of the study design and patient recruitment. Nineteen patients were excluded due 
to pathological non-glioblastoma diagnosis. Due to the criteria of multiple voxel selection, patients with 
missing Lac/Cr and ML9/Cr data were excluded in MRS analysis. DTI invasive phenotypes were correlated 
with the 64 patients overlapping with a previously reported cohort. Patient survival was reviewed 
retrospectively to exclude pseudoprogression and was only analysed in those who received standard 
chemoradiotherapy. 
 
5.3.2 MRI acquisition  
Pre-operative MRI sequences in this study included: post-contrast T1-weighted, T2-weighted, 
T2-weighted fluid attenuated inversion recovery (FLAIR), dynamic susceptibility contrast-
enhancement (DSC), diffusion tensor imaging (DTI) with inline ADC calculation, and multi-
voxel 2D 1H-MRS chemical shift imaging (CSI). Sequence details are provided in 3.3.2.2. All 
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patient underwent MRI within 72hrs postoperatively as a clinical routine scanning to evaluate 
extent of resection.  
5.3.3 Image processing 
For each subject, all images were co-registered to T2-weighted images with an affine 
transformation, using the linear image registration tool (FLIRT) functions (Jenkinson et al., 
2002) in FSL v5.0.0 (Oxford, UK) (Smith et al., 2004).  
DTI was processed as described in Section 3.4.2 (Behrens et al., 2003). The decomposition into 
isotropic (p) and anisotropic (q) components was performed as previously described (Pena et 
al., 2006b). DSC was processed as described in Section 3.4.3. The relative cerebral blood 
volume (rCBV), mean transit time (MTT) and relative cerebral blood flow (rCBF) maps were 
calculated. CSI data were processed as described in 3.4.4.  
5.3.4 Regions of interest and volumetric analysis 
Conventional tumour regions of interest (ROIs) were manually drawn as described in 3.4.6.1. 
ADC-rCBV ROIs were further generated using quartile values in Matlab (v2016a, The 
MathWorks, Inc., Natick MA). The procedure is illustrated in Figure 5.2. Firstly, ADC and 
rCBV values were obtained from each voxel within the contrast-enhancing (CE) ROI and 
pooled together as described previously (Boonzaier et al., 2017a). The lowest quartile of the 
pooled rCBV values (rCBVL) was interpreted as low perfusion regions. Then the first quartile 
(ADCL) and last quartile (ADCH) of ADC map were respectively overlaid on rCBVL maps. 
Finally, two intersections of ADCL-rCBVL and ADCH-rCBVL ROIs were obtained. Other 
regions within CE outside the two ADC-rCBV ROIs were taken as abnormal controls (CE 
control, CEC). Raw volumes of ROIs were calculated in FSL (Smith et al., 2004). Proportional 
volumes (%) of two ADC-rCBV ROIs were calculated as the ratio of the raw volumes to CE 
volume. 
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Figure 5.2 Illustration of the pipeline to identify two ADC-rCBV compartments.  Both ADC and rCBV 
maps are co-registered to the T2 weighted images and tumour regions are segmented manually. Low perfusion 
tumour regions are partitioned using a quartile threshold. Similarly, two ADC sub-regions are partitioned using 
high and low ADC quartile thresholds respectively. The spatial overlap between the thresholded rCBV and 
ADC maps defined two compartments ADCH-rCBVL and ADCL-rCBVL. MR volumetric and metabolic 
analyses of both compartments are performed and interrogated in invasive phenotype and patient survival 
analysis models. 
5.3.5 Multi-voxel MRS processing 
Only those MRS voxels that were completely within the delineated tumour were included in 
further analyses. The weight of each MRS voxel was taken as the proportion of the ADC-rCBV 
compartments in that MRS voxel. The sum weighted value was used as the final metabolic 
value. This method provides an objective method for MRS voxel selection (Figure 5.3). 
 
5.3 Methods 90 
 
 
Figure 5.3 Illustration of multiple voxel MRS analysis.  Left: the selection criteria. The T2-space pixels 
are projected to MRS space according to their coordinates. The proportion of T2-space tumour pixels occupying 
each MRS voxel is calculated. A criterion is applied that only those MRS voxels are included when this voxel 
is completely within the delineated tumour. In this case, grid 1-6 met the criteria. A weighted average metabolite 
content for each region is calculated from the metabolite content of each voxel within it weighted by that voxel’s 
percentage of (ADCH-rCBVL [blue]: grid 1,2 and 4 are counted; ADCL-rCBVL [yellow], grid 3 and 5 are 
counted; abnormal control [CEC]: grid 1-6 are counted). Right: Example spectra of ROIs. Each spectrum 
corresponds to the grids on the left. Grid 2: lactate/Cr ratio 13.2, ML9/Cr ratio: 10.4; grid 3: lactate/Cr ratio 
28.4, ML9/Cr ratio: 22.7; grid 6: lactate/Cr ratio 8.9, ML9/Cr ratio: 16.6; grid 7 (NAWM): lactate/Cr ratio 0.37, 
ML9:1.36. 
5.3.6 DTI invasive phenotypes 
We investigated DTI invasive phenotypes of 64 patients which overlap with a previously 
reported cohort and have been correlated to isocitrate dehydrogenase (IDH) mutation status 
(Price et al., 2017). Three invasive phenotypes were classified using previously described 
criteria (Price et al., 2007) based on the decomposition of diffusion tensor into isotropic (p) and 
anisotropic components (q).  This approach classified glioblastoma into three phenotypes: (a) 
diffuse invasive phenotype, where the p abnormality is larger than the q abnormality in all 
directions; (b) localised invasive phenotype, where p abnormality exceeds the q abnormality in 
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one particular direction; and (c) minimal invasive phenotype: where p abnormality is similar 
to the q abnormality (Figure 5.4). Previous studies showed this approach can predict tumour 
recurrence pattern (Price et al., 2007).  
 
Figure 5.4 Examples of DTI invasive phenotypes. (A), (C), (E): DTI-p maps with abnormality outlined by 
the blue line; (B), (D), (F): DTI-q maps with abnormality outlined by the green line. All the delineation were 
manually performed by clinical experts. (A) & (B) show a minimal invasive phenotype. The isotropic 
abnormality is similar to the anisotropic abnormality. (C) & (D) show a localised invasive phenotype. The 
isotropic abnormality is larger than the anisotropic abnormality in one direction. (E) & (F) show a diffuse 
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invasive phenotype. The isotropic abnormality is larger than the anisotropic abnormality in more than one 
direction. 
5.3.7 Statistical analysis 
All analyses were performed with RStudio v3.2.3. Continuous variables were tested with 
Welch Two Sample t-test. MRS data or tumour volume, were compared with Wilcoxon rank 
sum test or Kruskal-Wallis rank sum test (multiple comparisons), using Benjamin-Hochberg 
procedure for controlling the false discovery rate in multiple comparisons. Spearman rank 
correlation was used to model the relation between the volume of two ADC-rCBV ROIs and 
the volume of CE and FLAIR ROIs. Kaplan-Meier using log-rank test and Cox proportional 
hazards regression analyses were performed to evaluate patient survival. For the Kaplan-Meier 
analysis, the volumes of ROIs and MRS variables were dichotomized using the function of 
‘surv_cutpoint’ in R Package “survminer”. Patients who were alive at the last known follow-
up were censored. Multivariate Cox regression with forward and backward stepwise 
procedures was performed, accounting for relevant covariates, including IDH-1 mutation, 
MGMT methylation, sex, age, the extent of resection and contrast-enhancing tumour volume. 
The forward procedure started from the model with one covariate. The backward procedure 
initiated from the model including all covariates. For each step, the Akaike Information 
Criterion (AIC) was used to evaluate the model performance. The final multivariate model was 
constructed using the covariates selected by the stepwise procedures. The hypothesis of no 
effect was rejected at a two-sided level of 0.05.   
5.4 Results 
5.4.1  Patients 
After surgery, 19 (14.5%) patients were excluded due to non-glioblastoma pathological 
diagnosis and 112 patients (mean age 59.4 years, range 22-76, 84 males; Overview: Table 5.1) 
were included. Among them, 82 (73.2%) patients received a standard dose of radiotherapy plus 
temozolomide concomitant and adjuvant chemotherapy post-operatively. Eighty of 112 
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(71.4%) patients had survival data available. The median progression-free survival (PFS) of 
these patients was 265 days (range 25-1130 days) and overall survival was 455 days (range 52-
1376 days). 
 

















Age at diagnosis 








≥60 74 58.6±35.7 119.5±63.8 6.3±4.8 2.5±2.4 
Sex 








Female 28 48.5±30.0 107.7±57.8 5.4±4.4 1.9±1.8 
Extent of resection 








Partial 37 67.4±40.8 128.3±66.1 7.5±5.2 2.6±2.8 
MGMT-methylation status* 








Unmethylated 60 55.8±32.1 121.1±57.9 6.1±4.5 2.4±2.0 
IDH-1 mutation status 








Wild-type 105 52.9±33.1 114.1±61.2 5.6±4.6 2.3±2.2 
*MGMT-methylation status unavailable for 4 patients. CE: Contrast-enhancing; cm: centimetres; FLAIR: 
fluid attenuated inversion recovery; ADCL-rCBVL: region of low-ADC and low-rCBV; ADCH-rCBVL: region 
of high-ADC and low-rCBV; IDH-1: Isocitrate dehydrogenase1; MGMT: O-6-methylguanine-DNA 
methyltransferase; SD: Standard deviation.  
 
 
5.4.2 Multiparametric MRI identifies two low perfusion compartments 
The volumes of ROIs for patient subgroups are compared in Table 5.1. The ADCH-rCBVL 
compartment (volume 5.7 ± 4.6 cm3) was generally larger than the ADCL-rCBVL compartment 
(volume 2.3 ± 2.2 cm3) (P < 0.001). Completely resected tumours had smaller CE volume (P 
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= 0.006) and smaller ADCH-rCBVL compartment (P = 0.002). Figure 5.5 (A, D) shows the two 
compartments for two cases. 
 
 
Figure 5.5 Two hypoxic compartments and MRS characteristics. Case 1: A-C; Case 2: D-F. A & D show 
the location of ADCL-rCBVL (yellow) and ADCH-rCBVL (blue) compartments. B & E demonstrate the Lac/Cr 
ratios of the two compartments. C & F demonstrate the ML9/Cr ratios in the two compartments. The colour 
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bar shows the level of metabolites (red: high, blue: low). Note that case 1 shows greater tumour volume and 
higher lactate level. G & H demonstrate the MRS characteristics of the compartments over the patient cohort. 
Yellow: ADCL-rCBVL; blue: ADCH-rCBVL; black: contrast-enhancing control (CEC); grey: normal-appearing 
white matter (NAWM). G: mean Lac/Cr level; H: mean ML9/Cr. ***: P < 0.001. 
5.4.3 Low perfusion compartments displayed hypoxic and pro-
inflammatory metabolic signatures 
The ADCH-rCBVL compartment showed a significantly higher lactate/creatine (Lac/Cr) ratio 
than NAWM (P < 0.001), as well as an increased ML9/Cr ratio compared to NAWM (P < 
0.001). Similarly, the ADCL-rCBVL compartment displayed higher Lac/Cr ratio and ML9/Cr 
ratio than NAWM (both P < 0.001). Although not significant, the Lac/Cr and ML9/Cr ratios in 
the ADCH-rCBVL compartment were higher than the ADCL-rCBVL compartment (Table 5.2). 
Figure 5.5 shows overlays between the rCBV-ADC compartments in two example cases and 
the metabolite levels of the two compartments.   
Table 5.2 Metabolic characteristics measured by MRS. 
Lac/Cr 
 Descriptive ADCL-rCBVL CEC NAWM 
ROI Mean ± SD 95% CI P P P 
ADCH-rCBVL 12.3±15.4 7.9-16.7 0.427 0.411 < 0.001 
ADCL-rCBVL 9.4±9.8 6.6-12.2 / 0.407 < 0.001 
CEC 8.5±8.9 5.9-11.0 / / < 0.001 
NAWM 0.10±0.28 0.02-0.17 / / / 
ML9/Cr 
 Descriptive ADCL-rCBVL CEC NAWM 
ROI Mean ± SD 95% CI P P P 
ADCH-rCBVL 28.0±71.6 9.2-46.9 0.650 0.529 < 0.001 
ADCL-rCBVL 21.5±31.2 13.3-29.7 / 0.492 < 0.001 
CEC 19.7±29.3 12.0-27.4 / / < 0.001 
NAWM 0.87±0.68 0.70-1.05 / / / 
ROI: region of interest; ADCL-rCBVL: ROI of low-ADC and low-rCBV; ADCH-rCBVL: ROI of high-ADC 
and low-rCBV; CEC: contrast enhancement control; NAWM: normal appearing white matter; Lac: lactate; 
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5.4.4 Low perfusion compartments exhibited diverse effects on tumour 
invasion 
The contrast-enhancing (CE) tumour volume was significantly correlated with the Lac/Cr ratio 
in the ADCL-rCBVL (P = 0.018, rho = 0.34). Interestingly, the volume of tumour infiltration 
beyond contrast enhancement, which was delineated on FLAIR images and normalised by CE 
volume, showed a moderate positive correlation with the proportional volume of the ADCL-
rCBVL compartment (P < 0.001, rho = 0.42) and a negative correlation with the proportional 
volume of the ADCH-rCBVL compartment (P < 0.001, rho = -0.32).  
5.4.5 The ADCL-rCBVL compartment of minimally invasive tumours is 
less hypoxic 
The minimally invasive phenotype displayed a lower volume of ADCL-rCBVL compartment 
than the localised (P = 0.031) and diffuse phenotype (not significant), and a higher volume of 
ADCH-rCBVL compartment than the localised (P = 0.024) and diffuse phenotype (not 
significant), suggesting the effects of the two low perfusion compartments to tumour 
invasiveness were different. Of note, the minimally invasive phenotype displayed lower Lac/Cr 
ratio compared to the localised (P = 0.027) and diffuse phenotype (P = 0.044), indicating that 
the ADCL-rCBVL compartment experienced less hypoxic stress in the minimally invasive 
tumours. A full comparison between the three invasive phenotypes can be found in Table 5.3. 
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Table 5.3 Comparison of the three DTI invasive phenotypes. 
  Diffuse Localised Minimal Comparisons 


















P value P value P value 
CE Volume (cm3)  53.8±35.0 39.7±16.0 52.7±36.2 0.388 0.406 0.390 
FLAIR Volume (cm3)  116.7±57.3 82.0±31.5 85.2±68.4 0.067 0.062 0.490 
ADCH-
rCBVL 
Volume#  0.10±0.04 0.08±0.03 0.12±0.04 0.036 0.140 0.024 
ADCL-
rCBVL 
Volume# 0.04±0.03 0.06±0.03 0.03±0.02 0.080 0.104 0.031 
ADCH-
rCBVL 
Lac/Cr 12.9±20.3 12.9±12.3 3.5±3.8 0.206 0.182 0.190 
ADCL-
rCBVL 
Lac/Cr 9.0±9.1 10.0±8.9 1.8±2.3 0.407 0.044 0.027 
CEC Lac/Cr 8.8±9.2 8.8±7.6 2.7±2.7 0.218 0.080 0.073 
*raw volumes; #proportional volumes; ROI: region of interest; CE: contrast enhancement; cm: centimeters; 
FLAIR: fluid attenuated inversion recovery; ADCL-rCBVL: ROI of low-ADC and low-rCBV; ADCH-rCBVL: 




5.4.6 Low perfusion compartments exhibited diversity in treatment 
response 
First, we used multivariate Cox regression to analyse all relevant clinical covariates. The results 
showed that extent of resection (EOR) (PFS: hazard ratio [HR] = 2.825, P = 0.003; OS: HR = 
2.063, P = 0.024), CE tumour volume (OS: HR = 2.311, P < 0.001) and FLAIR tumour volume 
(OS: HR = 0.653, P = 0.031) were significantly associated with survivals. 
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Next, we included the volumes of two compartments and their Lac/Cr ratios into the survival 
models. The results using stepwise procedure showed that higher volumes of the two 
compartments were associated with better PFS (ADCH-rCBVL: HR = 0.102, P = 0.049; ADCL-
rCBVL: HR = 0.184, P = 0.033), whilst the higher Lac/Cr ratio in the two compartments was 
associated with worse PFS (ADCH-rCBVL: HR = 6.562, P = 0.002; ADCL-rCBVL: HR = 2.995, 
P = 0.047). Further, the higher Lac/Cr ratio in the ADCL-rCBVL compartment was also 
associated with worse OS (HR = 4.974, P = 0.005). In contrast, the Lac/Cr ratio in the contrast-
enhancing control regions was associated with better survivals (PFS: HR = 0.053, P = 0.001; 
OS: HR = 0.090, P = 0.007). The results of the Cox proportional hazards models are described 
in Table 5.4 and the Kaplan-Meier curves using log-rank test are shown in Figure 5.6. 
 
Figure 5.6 Kaplan-Meier plots of survival analysis. Log-rank tests show larger proportional volume of 
ADCL-rCBVL compartment is associated with better PFS (P = 0.041) (A), while higher Lac/Cr ratio in this 
compartment is associated with worse PFS (P =0.040) (B) and OS (P = 0.038) (C). Higher Lac/Cr ratio in the 
ADCH-rCBVL compartment is associated with worse PFS (P = 0.025) (D). 
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Table 5.4 Univariate and multivariate modelling of survivals  
 PFS OS 
Factor 
Multivariate Stepwise Multivariate Stepwise 
HR 95%CI P HR 95%CI P HR 95%CI P HR 95%CI P 
Age 1.007 0.979-1.035 0.645    1.002 0.971-1.033 0.911 0.927 0.860-0.998 0.045 
Sex (M) 1.499 0.838-2.681 0.172 5.043 1.063-23.91 0.042 1.252 0.662-2.365 0.490    
extent of resection (partial) 2.825 1.417-5.635 0.003 4.531 1.002-20.49 0.050 2.063 1.099-3.874 0.024 12.18 2.701-54.91 0.001 
MGMT methylation status* 0.624 0.366-1.063 0.083 0.392 0.125-1.233 0.109 0.647 0.358-1.167 0.148 0.231 0.070-0.762 0.016 
IDH mutation status 0.902 0.278-2.926 0.864    0.900 0.256-3.170 0.870    
CE volume 1.291 0.861-1.935 0.216 6.760 0.696-65.63 0.099 2.311 1.527-3.499 <0.001 3.080 1.487-6.383 0.002 
Flair volume 0.775 0.519-1.157 0.212 2.008 0.818-4.926 0.128 0.653 0.444-0.961 0.031    
ADCL-rCBVL volume    0.184 0.039-0.874 0.033       
ADCH-rCBVL volume    0.102 0.011-0.992 0.049       
Lac/Cr in ADCH-rCBVL    6.562 2.023-21.29 0.002    2.367 0.825-6.790 0.109 
Lac/Cr in ADCL-rCBVL    2.995 1.012-8.861 0.047    4.974 1.608-15.39 0.005 
Lac/Cr in CEC    0.053 0.010-0.295 0.001    0.090 0.016-0.520 0.007 
*MGMT-methylation status unavailable for 4 patients. PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval; IDH-1: Isocitrate 
dehydrogenase1; MGMT: O-6-methylguanine-DNA methyltransferase; CE: Contrast-enhancing; FLAIR: fluid attenuated inversion recovery; Lac: lactate; ADCL-rCBVL: region of 
low-ADC and low-rCBV; ADCH-rCBVL: region of high-ADC and low-rCBV; CEC: contrast enhanced control. 




This study combined perfusion and diffusion parameters to quantify low perfusion 
compartments that may be responsible for treatment resistance. The non-invasive approach 
using physiological imaging may potentially improve on the commonly-used weighted 
structural imaging.  
The clinical values of the individual markers have been assessed previously. Among them, 
rCBV is reported to indicate IDH mutation status and associated with hypoxia-initiated 
angiogenesis (Kickingereder et al., 2015). Decreased ADC is considered to represent higher 
tumour cellularity/cell packing (Chen et al., 2013b) and associated with shorter survival 
(Shiroishi et al., 2016). Here we integrated the two markers to identify two low perfusion 
compartments with hypoxic stress. With similar perfusion levels in these two compartments, 
the higher cellularity (ADCL) in the ADCL-rCBVL compartment suggests it may display a 
higher degree of mismatch between supply and demand of nutrients.  
We measured the lactate, macromolecule and lipid levels at 0.9 ppm (ML9) in the spectra, as 
increased lactate indicates hypoxia, while ML9 is associated with pro-inflammatory microglial 
response (Pardon et al., 2016). The elevated ML9/Cr ratios may suggest both compartments 
displayed elevated inflammation response (Pardon et al., 2016), potentially due to the 
recruitment of inflammatory cells by necrosis (Galluzzi and Kroemer, 2008), The positive 
correlation between tumour volume and lactate levels in the ADCL-rCBVL compartment could 
indicate the acquired hypoxia as the tumour grows. When evaluating the non-enhancing 
peritumoural regions, we found that tumours with large infiltration tended to have smaller 
ADCH-rCBVL and larger ADCL-rCBVL compartments, suggesting the latter might be more 
responsible for infiltration. This was supported by our findings that minimally invasive 
phenotypes displayed significantly lower lactate levels in the ADCL-rCBVL compartment. 
We further investigated the effects of two compartments to patient survivals. Interestingly, a 
higher Lac/Cr ratio in the two compartments was related to worse outcomes (HR > 1) while 
this ratio in other tumour regions showed a reduced hazard (HR < 1). This suggests that the 
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resistant phenotypes induced by hypoxia mainly reside in the two compartments. As the ADCL-
rCBVL compartment was associated with tumour infiltration area, diffusion invasiveness, and 
significantly affected both PFS and OS, this compartment may be more responsible for 
treatment resistance.  
We found that the higher volume of both compartments was significantly associated with better 
survivals, while higher Lac/Cr ratios were associated with worse survivals. These results 
suggested that the extent of low perfusion, indicated by volume, and the intensity of hypoxia, 
indicated by lactate level, have different clinical implications. Specifically, the higher 
proportion of the low perfusion compartments may represent a relatively lower proliferative 
phenotype, while the more intensive hypoxia in these compartments may represent a more 
aggressive phenotype.  
Our findings have clinical significance. Our identification of possibly resistant regions could 
inform the choice of treatment target. Additionally, recent studies postulated that 
antiangiogenic agents failed to demonstrate consistent response because they can induce the 
adaptive clones and thus cause treatment resistance (Liu et al., 2016, Hu et al., 2012). Our 
findings may provide indications for antiangiogenic therapy. Particularly, more attention might 
be needed for patients with larger volumes of the ADCL-rCBVL compartment when considering 
antiangiogenic agents.  
There are limitations in our study. Due to the MRS spatial resolution, the multivariate analysis 
was based on a subset of patients. Similarly, survival analyses were performed on patients who 
received post-operative chemoradiotherapy. The cut-off values defining the two compartments 
were based on the quartiles of rCBV and ADC distributions, rather than optimizing for 
threshold specifically. Lastly, although the imaging markers are validated histologically from 
other studies (Price et al., 2006), a full biological validation can only be achieved with a multi-
region sampling of each tumour. 
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5.6  Conclusion 
We showed that multi-parametric imaging could identify two low perfusion compartments. 
This approach may help optimize the current clinical routine which is mainly based on non-
specific conventional imaging. The compartment demonstrating both low perfusion and 
restricted diffusion may indicate a habitat resistant to adjuvant therapies. This could provide 
crucial information for treatment choice in personalized treatment. As our analyses were based 
on clinically available imaging modalities, this approach could easily be implemented, and 
potentially extended to other system. 
 
 
Chapter 6 Multi-parametric and Multi-regional 
Histogram Analysis of MRI: Modality Integration 
Reveals Imaging Phenotypes of Glioblastoma 
6.1 Abstract 
Purpose 
Integrating multiple imaging modalities is crucial for MRI data interpretation. The purpose of 
this study is to determine whether the proposed multi-view approach can effectively integrate 
histogram features from multimodal MRI and whether selected features can offer incremental 
prognostic values. 
Methods 
Eighty primary glioblastoma patients underwent surgery and chemoradiotherapy. Histogram 
features of diffusion and perfusion imaging were extracted from contrast-enhancing (CE) and 
non-enhancing (NE) regions independently. Unsupervised patient clustering was performed by 
the proposed multi-view approach. Kaplan-Meier and Cox proportional hazards regression 
analyses were performed to evaluate the relevance of clustering to survival. The metabolic 
signatures of patient clusters were analysed by multi-voxel spectroscopy. The prognostic 
values of histogram features were evaluated by survival and receiver operator characteristics 
curve analyses.  
Results 
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Two patient clusters were generated, consisting of 53 and 27 patients respectively. Cluster 2 
demonstrated better overall survival (OS) (P = 0.007) and progression-free survival (PFS) (P 
< 0.001) than Cluster 1. Cluster 2 displayed lower N-acetylaspartate/creatine ratio (P = 0.013), 
and higher glutamate + glutamine/Cr (Glx/Cr) ratio (P = 0.027) in NE region. Higher mean 
value of anisotropic diffusion in NE region was associated with worse OS (HR = 1.40, P = 
0.020) and PFS (HR = 1.36, P = 0.031). Seven features selected by this approach showed 
significantly incremental value in predicting 12-month OS (P = 0.020) and PFS (P = 0.022).  
Conclusions 
The multi-view clustering method can provide an effective integration of multimodal MRI. The 
histogram features selected may be used as potential prognostic markers. 
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6.2 Introduction 
As shown in Chapter 4 & 5, integrating multi-parametric MRI can reveal the intra-tumoural 
habitats, which suggests that advanced MRI may confer physiological information and 
compensate for the non-specificity of structural imaging. In this chapter, we will investigate if 
integrating multi-parametric MRI reflects the inter-tumoural heterogeneity.  
As shown in Chapter 4, histogram features can characterize tumour heterogeneity by measuring 
the distribution of voxels within the tumour, and were reported to be related with tumour 
malignancy and patient survival (O'Connor et al., 2015). As emerging advanced MRI 
modalities, including diffusion and perfusion imaging markers, are developed to reflect tumour 
physiological properties, increasing numbers of features can be generated. It remains a 
challenge to effectively incorporate the physiological information to reflect the multifaceted 
characteristics of the tumour. Further, selecting optimal features for clinical decision making 
is crucial. 
Although machine learning algorithms have been successful in stratifying patients (Parmar et 
al., 2015), classical machine learning techniques may not be effective in integrating the 
complementary information that multimodal advanced MRI confers, with all imaging features 
merged at an early stage. The multi-view approach is a data integration method that was 
initially developed to jointly analyse multiple genomic data derived from different molecular 
experiments, i.e., gene expression, copy number variation. Given the success of this approach 
in integrating multiple omics data to understand the complex biological system (Serra et al., 
2015), we hypothesized that it could be applied to multi-parametric advanced MRI for more 
stable clustering results and better insights into tumour characterization (Fratello et al., 2017, 
Sun et al., 2014). Therefore, the purpose of this current study was to determine whether the 
multi-view approach can effectively integrate histogram features of multiple quantitative 
advanced MRI, and whether the selected features can offer incremental values in survival 
prediction.  
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6.3 Methods 
6.3.1  Patients 
This study was approved by the local institutional review board. Signed informed consent was 
obtained from all patients. Patient inclusion and exclusion criteria are in Section 3.1.1. Patient 
treatment is detailed in Section 3.1.2.1. Assessment of IDH-1 R132H Mutation and MGMT 
Methylation Status are described in 3.2. 
6.3.2  Pre-operative MRI acquisition 
MRI sequences were acquired on a 3-Tesla MRI system (Magnetron Trio; Siemens Healthcare, 
Erlangen, Germany) with a standard 12-channel receive-head coil. MRI sequences included: 
post-contrast T1-weighted, T2-weighted FLAIR, DSC sequence, DTI, and multi-voxel 2D 1H-
MRS. Sequence details are provided in 3.3.2.2. 
6.3.3  Image processing 
All images were co-registered to T2-weighted images, using FLIRT (Jenkinson et al., 2002). 
DTI was processed as described in Section 3.4.2. The decomposition into isotropic (p) and 
anisotropic (q) components was performed as previously described (Pena et al., 2006b). DSC 
was processed as described in Section 3.4.3. The relative cerebral blood volume (rCBV), mean 
transit time (MTT) and relative cerebral blood flow (rCBF) maps were calculated. CSI data 
were processed as described in 3.4.4. Only CSI voxels containing more than 50% tumour T2-
voxels were included for further analysis. Tumour regions of interest (ROIs) were manually 
drawn as described in 3.4.6.1. 
6.3.4  Histogram features 
The study design is summarized in Figure 6.1. Histogram features were extracted using the 
Statistics and Machine Learning Toolbox of MATLAB (version 2016a). Perfusion images 
(rCBV, MTT and rCBF) and diffusion images (DTI-p and DTI-q) were analysed separately. 
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The CE and NE ROIs in each map were also analysed independently. Therefore, four categories 
of feature sets (CE-diffusion, NE-diffusion, CE-perfusion, NE-perfusion) can be obtained, 
considering features extracted from multiple modalities and regions. Intensity histograms were 
constructed using 100 bins. A total of 10 features were calculated, including mean, standard 
deviation (SD), median, mode, skewness, kurtosis, and 5th (Prc5), 25th (Prc25), 75th (Prc75), 
95th (Prc95) percentiles of intensity histograms. Therefore, altogether 100 features were 
extracted from each subject. 
 
Figure 6.1 Study design. DTI-p and DTI-q maps are generated from diffusion tensor imaging (DTI). The 
relative cerebral blood volume (rCBV), mean transit time (MTT) and relative cerebral blood flow (rCBF) maps 
are generated from dynamic susceptibility contrast (DSC) imaging. Histogram features extracted from the 
multiple modalities and regions (contrast-enhancing and non-enhancing) are treated as four independent views. 
Each view is first clustered to select centroid features, which are later used to cluster patients. The resulting 
clusters from each view are integrated to yield two patient clusters. A leave-one-out cross-validation is 
performed. Patient clusters are assessed in survival analysis and their metabolic signatures are compared. The 
centroid features are ranked according to the importance in the clustering and selected features are used to build 
the multivariate prognostic model. 
6.3.5 Multi-view feature selection and clustering 
The analysis was performed using a multi-view late integration methodology called Multi-
View Biological Data Analysis (MVDA), implemented in R and available from GitHub 
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(https://github.com/angy89/MVDA). As perfusion and diffusion characteristics were 
considered to bear different physiology information, and different tumour region may have 
different biological significance, we hypothesised that each feature set may represent a unique 
view in characterising tumour properties. Therefore, we treated four categories of feature sets 
as different views to maximize tumour characterization in each case. We applied this analytic 
tool into imaging analysis, considering that the multi-view approach allows analysing each 
view independently and then merging the results using a late integration methodologies 
(Pavlidis et al., 2001). This offer the advantage to avoid representing bias in feature selection 
compared to classical feature selection and machine learning methods. 
The analysis was divided into multiple steps: I. To reduce the dimensionality and remove noisy 
information, the features were first clustered using the hierarchical ward clustering method for 
each view. The number of feature clusters was determined by the previously proposed VAL 
index (Serra et al., 2015). Clustering solutions with high correlation within each cluster and 
low correlation between the clusters were preferred. The number of features was reduced by 
selecting the centroids of the feature clusters which represent the features of each view. II. For 
each view, the patients were clustered by applying a hierarchical ward clustering method using 
the features selected from the previous step. The number of patient clusters was also determined 
by the VAL index (Serra et al., 2015). III. The clustering results of each view were integrated 
into a late integration method. The vector of clustering assignment of each view was 
transformed into a binary membership matrix, with patients on the rows and clustering on the 
columns. These matrices were transposed and stacked vertically to create a larger matrix X 
with L rows (the clusters) and N columns (the patients). This matrix was then factorized to 
obtain two matrices P (with L rows and k columns) and H (with k rows and N columns), 
minimizing the difference between X and PH. In this settings, H represented the membership 
matrices of the N patients to the final multi-view clusters. The number of multi-view clusters 
was set to 2 to dichotomize patients into two clusters with better or worse survivals 
respectively.  
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6.3.6 Leave-one-out cross validation of the clustering 
To validate patient clustering was not obtained by random, a leave-one-out cross-validation 
(LOOCV) procedure was applied. Briefly, all steps of the MVDA approach were repeated by 
leaving one patient out of the cohort at each repetition. The consensus analysis was performed 
in the 80 clustering results obtained from the LOOCV approach. An 80 ×80 co-occurrence 
consensus clustering matrix M was created, where M (i, j) indicating percentage of times that 
the patients i and j were clustered together across the 80 dataset perturbations.  
6.3.7 Feature ranking 
To estimate the contribution of each centroid feature in the clustering, the variable importance 
evaluation function ‘varImp’ in the R package ‘Caret’ was used (Kuhn, 2008). The patient 
clustering result was firstly used to train a logistic regression model, which then was used to 
evaluate the importance of each feature, according to the model performance. The feature 
importance was scored and scaled by the function with a maximum value of 100.  
6.3.8 Statistical analysis 
All statistical analyses were performed in RStudio v3.2.3. CSI data were compared with the 
Wilcoxon rank sum test using the Benjamin-Hochberg procedure for controlling the false 
discovery rate in multiple comparisons. Kaplan-Meier and Cox proportional hazards regression 
analyses were performed to evaluate patient survival. For Cox proportional hazards regression, 
all relevant covariates, including IDH-1 mutation status, MGMT methylation status, sex, age, 
the extent of resection and contrast-enhancing tumour volume were considered. For Kaplan-
Meier analysis using the Log-rank test, each feature was dichotomized using optimal cutoff 
values calculated by ‘surv_cutpoint’ function in the R Package “survminer”. Patients who were 
alive at the last known follow-up were censored. Logistic regression was used to test prognostic 
values of covariates for 12-month overall survival (OS) and progression-free survival (PFS). 
The baseline models were constructed using all relevant clinical covariates, including IDH-1 
mutation status, MGMT promoter methylation status, the extent of resection sex, age, contrast-
enhancing tumour volume. Histogram features were subsequently added into baseline models 
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to construct OS and PFS models. The incremental prognostic values of imaging features were 
determined according to the area under the receiver operator characteristics curve (AUC), 
which was compared using one-way ANOVA. The hypothesis was accepted at a two-sided 
significance level of alpha = 0.05.   
6.4 Results 
6.4.1 Patients  
We included 80 patients who received CCRT and had available survival data into the study. 
Patient characteristics and two patient clusters were summarized in Table 6.1.  
Table 6.1 Clinical characteristics  
Variables Patient Number 
P Value 
 Total (n = 80) Cluster 1 (n = 53) Cluster 2 (n = 27) 
Age at diagnosis 
   <60 35 18 16 
0.058 
   ≥60 45 35 11 
Sex 
   Male 58 41 17 
0.201 
   Female 22 12 10 
Extent of resection (of enhancing tumour) 
   Complete resection  56 35 21 
0.267    Partial resection 22 17 5 
   Biopsy 2 1 1 
MGMT-methylation status* 
   Methylated 37 24 13 
0.929 
   Unmethylated 41 27 14 
IDH-1 mutation status 
   Mutant 7 4 3 
0.622 
   Wild-type 73 49 24 
Pre-operative Tumour volumes(cm3) # 
    Contrast-enhancing  49.7 ± 28.1 50.2 ± 28.4 50.4 ± 28.1 0.823 
    Non-enhancing  64.7 ± 48.3 48.7 ± 27.9 92.8 ± 53.5 0.007 
Survival (days) 
    Median OS (range) 461 (52-1259) 424 (52-839) 689 (109-1259) 0.020† 
    Median PFS (range)  264(25-1130) 248 (25-607) 318 (279-1130) <0 .001† 
*MGMT-methylation status unavailable for 2 patients; #mean ± SD of original data. †Log-Rank test; SD: 
standard deviation; MGMT: O-6-methylguanine-DNA methyltransferase; IDH-1: Isocitrate dehydrogenase 
1; cm: centimeters; OS: overall survival; PFS: progression-free survival. 
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6.4.2 Identification of patient clusters 
From the four views, 5, 4, 7 and 6 centroid features were respectively selected (Figure 6.2, 
Table 6.2). Using the centroid features and optimal cluster numbers determined in the 
algorithm, patients were firstly divided into 7, 8, 9 and 10 clusters in each view, using 
hierarchical ward clustering. Late integration of four views yielded a final clustering of two 
patient clusters, with 53 and 27 patients in each cluster respectively.  
 
Figure 6.2 Multi-view feature selection In each view, all features are clustered using the hierarchical ward 
clustering method. The centroid features (marked by yellow stars) are selected to represent each view. A: view 
1 (CE-DTI); B: view 2 (NE-DTI); C: view 3 (CE-PWI); D: view 4 (NE-PWI). 
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6.4.3 Leave-one-out cross-validation of patient clustering 
After leave-one-out cross-validation, the co-occurrence consensus clustering matrix was 
computed. The result showed that the two patient clusters generated from the unsupervised 
clustering were stable. The mean values of the co-occurrence consensus clustering matrix were 
0.79 for Cluster 1 and 0.68 for Cluster 2 (Figure 6.3). 
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Figure 6.3 Leave-one-out cross-validation of patient clustering. After multi-view clustering, consensus 
analysis was performed based on the 80 clustering results obtained after the leave-one-out cross-validation. The 
mean value of the co-occurrence consensus clustering matrix was 0.79 for patient Cluster 1 and 0.68 for patient 
Cluster 2. 
6.4.4 Clinical relevance of patient clusters 
The two patient clusters showed no significant differences in clinical characteristics (Table 
6.1). Interestingly, two clusters had similar contrast-enhancing tumour volume. Cluster 1, 
however, had significantly smaller non-enhancing tumour volume (P = 0.007) than Cluster 2. 
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Further, the two clusters showed a significant difference in survival. Specifically, Cluster 2 
showed better OS (Log-rank test, P = 0.020) and better PFS (Log-rank test, P < 0.001) than 
Cluster 1 in Kaplan-Meier analysis (Table 6.1, Figure 6.4.A & 6.4.B).  
 
Figure 6.4 Survivals of patient clusters.  Log-rank test showed patient Cluster 2 displayed better OS (P = 
0.020) (A) and PFS (P < 0.001) (B). Higher man value of DTI-q in the non-enhancing region (Mean-q-NE) 
was associated with a worse OS (P = 0.002) (C) and PFS (P < 0.001) (D). 
 
Since MGMT promoter methylation status was missing in two patients, the multivariate Cox 
proportional hazards regression modelling was tested in the remaining 78 patients. The results 
showed that Cluster 2 displayed significantly better OS (P = 0.007, HR = 0.32) and PFS (P < 
0.001, HR = 0.33) than Cluster 1, considering relevant covariates. Among these covariates, 
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extent of resection (P = 0.019, HR = 2.20) and contrast-enhancing tumour volume (P < 0.001, 
HR = 1.02) significantly affected OS. Extent of resection (P = 0.003, HR = 2.84) significantly 
affected PFS. No significance was found in other clinical factors.  
6.4.5 Metabolic signatures of patient clusters 
Due to the abovementioned rules excluding CSI voxels containing less than 50% tumour, CSI 
data were missing in four patients. Our results showed N-acetylaspartate/creatine (NAA/Cr) 
ratio of Cluster 2 was significantly lower than in Cluster 1, both in the CE (P < 0.001) and NE 
region (P = 0.013). In NE region, glutamate + glutamine/Cr (Glx/Cr) ratio of Cluster 2 was 
significantly higher than Cluster 1 (P = 0.027 respectively). No other metabolites showed 
significant differences. The comparison of NAA/Cr and Glx/Cr of two patient clusters are 
detailed in Table 6.3 and demonstrated in Figure 6.5. Two example spectra are demonstrated 
by Figure 6.6. 
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Figure 6.5 NAA/Cr and Glx/Cr of two patient clusters. N-acetylaspartate/creatine (NAA/Cr) ratio in Cluster 
1 was significantly higher than in Cluster 2, both in the contrast-enhancing (CE) region (P < 0.001) (A) and 
non-enhancing (NE) region (P = 0.013) (B).  In the NE region, Cluster 1showed significantly higher 
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Figure 6.6 Example spectrum of patient clusters. T1-weighted contrast-enhanced MR images show contrast-
enhancing (CE) (blue) and non-enhancing (NE) (orange) tumour regions, with two example spectra of NAA at 
2.0 ppm and Glx at 2.05-2.50 ppm. One example from Cluster 1 (A) shows NAA/Cr ratio of 1.36 and Glx/Cr 
ratio of 1.54. The other example from Cluster 2 (B) shows NAA/Cr ratio of 0.58 and Glx/Cr ratio of 3.09. 
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Table 6.3 Metabolic statistics of patient clusters 
 Contrast-enhancing tumour region Non-enhancing tumour region 
Metabolite 
Cluster 1 Cluster 2 
P Value 
Cluster 1 Cluster 2 
P Value 
Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI 
Cho/NAA 0.60 ± 0.32 0.50-0.69 0.49 ± 0.26 0.38-0.60 0.091 0.54 ± 0.50 0.38-0.70 0.45 ± 0.19 0.37-0.53 0.689 
Cho/Cr 0.70 ± 0.24 0.63-0.77 0.63 ± 0.17 0.55-0.70 0.244 0.44 ± 0.13 0.40-0.48 0.40 ± 0.14 0.34-0.46 0.149 
NAA/Cr 0.76 ± 0.35 0.66-0.86 0.46 ± 0.27 0.35-0.58 <0.001 0.97 ± 0.32 0.86-1.07 0.76 ± 0.30 0.64-0.89 0.013 
GSH/Cr 0.31 ± 0.28 0.23-0.40 0.40 ± 0.36 0.23-0.57 0.245 0.34 ± 0.19 0.27-0.41 0.39 ± 0.27 0.26-0.51 0.687 
Glx/Cr 1.89 ± 1.11 1.56-2.23 1.85 ± 1.29 1.31-2.40 0.651 1.41 ± 0.58 1.20-1.62 1.98 ± 1.04 1.54-2.42 0.027 
mIn/Cr 1.37 ± 0.88 1.12-1.62 1.28 ± 0.77 1.08-1.99 0.657 1.14 ± 0.41 1.00-1.27 1.16 ± 0.38 1.00-1.32 0.924 
Lac/Cr 6.37 ± 5.73 4.67-8.07 4.81 ± 4.14 2.93-6.69 0.448 1.13 ± 0.98 0.75-1.52 1.45 ± 2.62 0.11-2.80 0.087 
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6.4.6 Feature ranking and feature subset selection 
Seven features with a score over 50 were selected according to the importance of centroid 
features in the clustering (Figure 6.7): Mean-p-NE (mean value of DTI-p in the non-enhancing 
tumour regions, score: 100), Mean-q-NE (mean value of DTI-q in the non-enhancing tumour 
regions, score: 82.5), Prc25-rCBV-NE (twenty-fifth percentile of rCBV in the non-enhancing 
tumour regions, score: 74.7), Kurtosis-p-NE (kurtosis of DTI-p histogram in the non-enhancing 
tumour regions, score: 66.6), Mean-q-CE (mean value of DTI-q in the contrast-enhancing 
tumour regions, score: 63.9), Prc25-p-CE (twenty-fifth percentile of DTI-p in the contrast-
enhancing tumour regions, score: 63.7), Prc95-rCBF-NE (ninety-fifth percentile of rCBF in the 
non-enhancing tumour regions, score: 61.7). 
 
Figure 6.7 Feature ranking. The centroid features were ranked according to the importance in the clustering. 
The scores were scaled with a maximum value of 100. 
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6.4.7 Multivariate prognostic performance of selected features 
The seven selected features all showed significance in survival analysis (Table 6.4). 
Particularly, higher Mean-q-NE was associated with worse OS (HR = 1.40, P = 0.020) and 
worse PFS (HR = 1.36, P = 0.031). The Kaplan-Meier curves showing the relevance of Mean-
q-NE in OS and PFS are demonstrated by Figure 6.4 C & 6.4 D. 
For prediction of 12-month OS and PFS, the AUC of baseline multivariate models were 0.81 
(confidence interval [CI]: 0.70-0.93) and 0.77 (CI: 0.65-0.88) respectively. The results of 
model comparison showed that these seven features significantly improved both OS model 
(AUC: 0.91, CI: 0.84-0.99, P = 0.020) and PFS model (AUC: 0.89, CI: 0.81-0.97, P = 0.022) 
(Figure 6.8).  
 
Figure 6.8 Receiver operating characteristic (ROC) curve analysis. Receiver operating characteristic 
(ROC) curves showed that the models of 12-month OS (left) and PFS (right) were significantly improved (P = 
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Table 6.4 Survival statistics of the selected features  
Feature 











Mean-p-NE 0.79 0.58-1.08 0.143 < 0.001 0.74 0.53-1.04 0.083 0.015 
Mean-q-NE 1.40 1.05-1.86 0.020 < 0.001 1.36 1.03-1.79 0.031 0.002 
Prc25-rCBV-NE 1.28 0.94-1.74 0.121 0.052 1.53 1.09-2.14 0.014 0.019 
Kurtosis-p-NE 1.18 0.85-1.63 0.326 0.168 1.66 1.15-2.39 0.007 0.048 
Mean-q-CE 1.17 0.90-1.51 0.245 0.029 1.17 0.89-1.55 0.268 0.197 
Prc25-p-CE 0.88 0.66-1.17 0.369 0.032 0.79 0.56-1.10 0.165 0.004 
Prc95-rCBF-NE 1.11 0.88-1.40 0.358 0.049 1.15 0.88-1.51 0.307 0.063 
*Cox models accounted for IDH-1 mutation status, MGMT methylation status, sex, age, the extent of resection and contrast-enhancing tumour volume. HR: hazard 
ratio; CI: confidence interval; CE: contrast-enhancing region; NE: non-enhancing region.  
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6.5 Discussion 
This study showed that integrating multi-parametric and multi-regional MRI histogram 
features may help to stratify patients and identify invasive tumour phenotype, using a multi-
view integration approach. Seven histogram features extracted from diffusion and perfusion 
images were particularly useful for predicting patient outcomes, as demonstrated by 
multivariable Cox regression and receiver operating characteristic curve analysis.  
Histogram analysis of quantitative MRI offers a method of characterizing tumour heterogeneity 
(O'Connor et al., 2008, Shiroishi et al., 2016). Evidence support the utility of MRI histogram 
features in heterogeneity evaluation and survival prediction (Choi et al., 2016, Andras et al., 
2011, Santarosa et al., 2016). One recent study, however,  showed that diffusion and perfusion 
histogram parameters only showed marginal prognostic values in multivariate models 
containing clinical factors (Burth et al., 2016). Here our results demonstrated that diffusion and 
perfusion histogram parameters carry prognostic values, even after accounting for relevant 
clinical covariates in the multivariate models. Moreover, features selected using the 
unsupervised algorithm can significantly improve the survival prediction performance of 
clinical models. Further studies using prospective design are needed for validating the 
prognostic value of imaging parameters.  
Limited studies have investigated both perfusion and diffusion imaging parameters in one 
cohort (Coban et al., 2015, Burth et al., 2016, Hilario et al., 2014). Moreover, most studies 
analysed perfusion and diffusion parameters separately. As perfusion and diffusion imaging 
measure different facets of tumour physiology, we hypothesized that integrating them 
effectively may lead to better tumour characterization. The multi-view approach can offer the 
advantage of a parallelized selection of features from multiple modalities, and synthesize the 
complementary information at a late stage. By doing so, it can avoid representation bias, since 
the analyses on each view are independent and integrated for final clustering (Serra et al., 
2015). With this unsupervised algorithm, we separated patients into two clusters with distinct 
survivals and metabolic signatures. Our results may suggest that appropriately integrating 
multiple modalities is crucial for tumour characterization. 
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The physiology of tumour core (CE) and peritumoural region (NE) are considered distinct, 
which is our motivation of differentiating tumour regions for feature extraction and treating 
them as independent views. Our results showed higher feature Mean-q-NE (mean value of DTI-
q in NE region) was associated with worse survivals. Correspondingly, MRS results showed 
that higher NAA/Cr and lower Glx/Cr levels in the NE region were also associated with worse 
survivals. Glioblastoma is recognized to preferentially migrate along the white matter tracts, 
which may lead to increased anisotropic movement of water molecules. Further, NAA is known 
as a marker of neuronal integrity, and glutamate is a key neurotransmitter that maintains 
neuronal function. High extracellular glutamate may be caused by structural destruction in the 
tumour (Noch and Khalili, 2009). Since the patients in our cohort received maximal safe 
surgery with the aim to resect the CE region, one possible explanation for the above findings 
is that the worse survival group may have disrupted rather than destroyed neurons in the NE 
region, which may facilitate tumour infiltration and be responsible for treatment failure. 
However, this finding is different from the previous findings that a decreased NAA within the 
tumour may indicate a more aggressive phenotype. Here our results may indicate the NAA 
profile in the non-enhancing tumour is heterogeneous, which may confound our finding. The 
findings here merit a further investigation, especially using histological validation. 
With the advances of imaging modality and computer vision, radiomics approach can extract 
high-throughput features from medical images, which are hypothesized to provide more 
comprehensive measures of tumour imaging phenotype (Itakura et al., 2015, Aerts et al., 
2014b). The increasing number of features, however, may pose the challenges of effective 
feature selection and modality integration for robust phenotyping (Verma et al., 2017, Zhou et 
al., 2018). Currently, many techniques have been developed for this purpose (Larue et al., 
2017). Considering the specific tumour biology information conferred by physiological 
imaging over structural imaging, new approaches with biological hypothesis might be needed 
to characterise the complex tumour system. Our current study investigated the feasibility of a 
genomic analytic tool in imaging studies, using histogram features considering the 
interpretability and robustness of features. Future work may potentially be extended to broader 
imaging feature sets and bioinformatics tools.  
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Our study has some limitations. Firstly, although we used a leave-one-out cross-validation, the 
patient population reported is from a single centre. Secondly, although previous studies have 
validated the histological correlation of the imaging markers, our current findings need further 
biological validation. Lastly, as the 1H-MRS voxels were larger than T2 space voxels, we had 
fewer patients with CSI data available.  
6.6 Conclusion 
Our results showed that the multi-view clustering method can provide an effective approach 
of integrating multiple quantitative MRI features. The histogram features selected from the 
proposed approach may be used as potential imaging markers in personalized treatment 
strategy and response determination. 
 
 
Chapter 7 Decoding the Inter-dependence of 
Multi-parametric Magnetic Resonance Imaging to 




Glioblastoma is highly heterogeneous in microstructure and vasculature, creating various 
tumour microenvironments among patients, and could lead to different phenotypes. The 
purpose of this study was to interrogate the inter-dependence of microstructure and vasculature 
using perfusion and diffusion imaging, and to investigate the utility of this approach in tumour 
invasiveness assessment. 
Methods  
A total of 115 primary glioblastoma patients were prospectively recruited for surgery and pre-
operative MRI scan. Apparent diffusion coefficient (ADC) was calculated from diffusion 
imaging, and relative cerebral blood volume (rCBV) was calculated from perfusion imaging. 
Empirical copula transform was applied to ADC and rCBV values in contrast-enhancing 
tumour region to obtain their joint distribution, which was then discretized to extract second-
order features for hierarchical clustering. Clinical characteristics and lactate levels obtained 
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from MR spectroscopy were compared. Survivals were analyzed using Kaplan-Meier and 
multivariate Cox regression analyses.  
Results 
Three patient subgroups were identified by unsupervised clustering. These subtypes showed 
no significant differences in clinical characteristics but were significantly different in lactate 
level and patient survivals. Specifically, the subtype demonstrating high inter-dependence of 
ADC and rCBV displayed a higher lactate level than the other two subtypes (P = 0.016 and P 
= 0.044 respectively). Both subtypes of low and high inter-dependence showed worse 
progression-free survival compared to the intermediate subtype (P = 0.046 and P = 0.009 
respectively).  
Conclusions 
The inter-dependence between perfusion and diffusion imaging may be useful in stratifying 
patients and evaluating tumour invasiveness. This approach provided overall measures of 
tumour microenvironment using multimodal MRI.  
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7.2 Introduction 
As stated in Chapter 1, remarkable heterogeneity can be found in glioblastoma (Sottoriva et 
al., 2013b, Verhaak et al., 2010). Tumour habitats of high or low cell densities can exist in 
either sufficiently or poorly perfused sub-regions, causing spatial variation in the tumour 
microenvironment (Gatenby et al., 2013). As shown in Chapter 4 & 5, tumour habitats or sub-
regions can be revealed using the combination of high/low intensities of multiple imaging 
modalities. It is shown in Chapter 6 that integrating the information of multiple MRI modalities 
is useful to identify invasive tumour phenotypes. These methods, however, tend to complement 
the information of a single modality with other modalities, providing limited information about 
the overall interaction between modalities. Validated surrogates to quantify the inter-
dependence between perfusion and diffusion imaging remains scant.  
Tumour imaging is central to depict the global prosperities of solid tumours. Multi-parametric 
imaging enables the incorporation of complementary imaging modalities. The relative cerebral 
blood volume (rCBV) calculated from perfusion weighted imaging can measure tumour 
vascularity and has been shown to correlate with cellular proliferation in high-grade gliomas 
(Price et al., 2011). The apparent diffusion coefficient (ADC) calculated from diffusion 
weighted imaging provides information about the tissue microstructure of different 
cellularity/cell packing (Kalpathy-Cranner et al., 2014), by measuring microscopic diffusivity 
of water molecules. Considering the complementary values of multi-parametric imaging, joint 
analysis of perfusion and diffusion has the potential to provide clinical insight by depicting the 
global variations of cellular structure and vasculature in solid tumours, which may potentially 
reflect tumour microenvironment.  
Here we propose an approach to characterise the overall tumour microenvironment by 
investigating the inter-dependence between diffusion and perfusion MRIs using the copula 
transform (Nelsen, 2007),  a multivariate probability distribution describing the inter-
dependence of random variables. We leveraged empirical copula transform to solve the 
challenges of parametric model fitting posed by the distinct marginal distribution of different 
modalities and then extracted features from the discrete joint distribution matrix to quantify the 
inter-dependence between ADC and rCBV. Therefore, the purpose of this study was to 
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characterise the overall tumour microenvironment by quantifying the inter-dependence of ADC 
and rCBV using copula transform, and to investigate the utility of inter-dependence 
characteristics in patient stratification.     
7.3 Theory 
7.3.1 Challenges in analysing the inter-dependence of random variables 
The existing literature involving analysis of inter-dependencies commonly originate from the 
probabilistic interpretation of Canonical Correlation Analysis (Bach and Jordan, 2005). To be 
precise, let 𝑋 = (𝑥1, … , 𝑥𝑁𝑋)and 𝑌 = (𝑦1, … , 𝑦𝑁𝑌) be random variables with dimensions 𝑁𝑋 
and𝑁𝑌 ∈ ℕ, respectively (i.e.,𝑋 ∈ ℝ
𝑁𝑋), then the following inter-dependence model can be 
introduced: 
𝑍 ∼ 𝑀𝑢𝑙𝑡(𝜃),where(𝑋, 𝑌)|𝑍 ∼ 𝒩𝑁𝑋+𝑁𝑌(𝜇𝑧, 𝛷), 
where 𝛷 represents the covariance matrix of variables 𝑋 and 𝑌.  
The normal distribution assumption in the above model fitting, however, may be challenged 
by severe model mismatch if the variables are non-normally distributed. Later, it was proposed 
that normal distribution assumption on variables could be relaxed by applying exponential 
family transforms (Klami et al., 2012). However, since most exponential transforms are not 
available in multi-dimensional settings, such method is still impractical for multidimensional 
data. 
One way to mitigate above limitations is to apply copula framework. The empirical copula can 
be used to prepare our data for later discrete feature extraction and clustering. Therefore we 
named our approach inter-dependence clustering via copula transform and discrete feature 
extraction. 
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7.3.2 Empirical copula 
In probability theory, a copula is a normalized multivariate probability distribution that 
provides a framework to quantify the inter-dependence structure between random variables. 
This framework is particularly useful when the given random variables follow non-normal 
distributions. Moreover, it can be applied to higher dimensional data, which is difficult when 
using standard joint distributions.  
We first recall the definition of the copula transform and Sklar's theorem which provides 
theoretical validation for the application of the copula transform (Sklar, 1973).  
Definition. A function 𝐶: [0,1]𝑁 → [0,1] is a 𝑁-dimensional copula if 𝐶 is a joint cumulative 
distribution function (CDF) of a 𝑁-dimensional random vector on the unit cube [0,1]𝑁 with 
uniform marginal. 
Sklar’s Theorem. Let 𝐹𝑖(𝑥): = 𝑃𝑟[𝑋𝑖 ≤ 𝑥]  are continuous marginal CDFs. Then, every 
multivariate cumulative distribution function 
𝐻(𝑥1, … , 𝑥𝑁) = 𝑃𝑟[𝑋1 ≤ 𝑥1, … , 𝑋𝑁 ≤ 𝑥𝑁] 
of a random vector (𝑋1, … , 𝑋𝑁) can be expressed in terms of its marginal 𝐹𝑖(𝑥𝑖) = 𝑃𝑟[𝑋𝑖 ≤ 𝑥𝑖] 
and a copula 𝐶, such that  
𝐻(𝑥1, … , 𝑥𝑁) = 𝐶(𝐹1(𝑥1), … , 𝐹𝑁(𝑥𝑁)). 
The copula 𝐶 describes the dependence structure between the variables 𝑋1, … , 𝑋𝑁.A wide range 
of marginal distributions, such as exponential, gamma, beta, and empirical, can be included in 
Sklar’s theorem. However, since a standard joint distribution is challenging to be obtained from 
noisy MRI data, we used the empirical copula to estimate the distribution function, namely: 
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7.3.3 Clustering model specification 
Copula examines the inter-dependence between random variables across the entire distribution. 
In particular, they capture the effects of higher-order moments, i.e., skewness or kurtosis. 
Although such effects might benefit the research in Geostatistical interpolation and spatial 
statistics, they may possibly cause issues of fat-tails and skewness of data distribution, and such 
effeteness may hence present unnecessary noises and cause a mismatch in clustering, including: 
a) The weight of the data value at each point might be altered. That is, some data points 
might be given undesired priorities by the copula transform.  
b) Spatial information of the data might be changed. The copula transform is not an 
isometric transform (Lindenstrauss and Tzafriri, 2013) and hence the data matrix may 
get deformed after the copula is applied. 
7.3.4 Methodology design 
Here we propose to use discrete feature extraction to reduce the above-mentioned noises 
elements as the spatial information is reduced in the discretization process (Wiatowski et al., 
2016). Our cluster analysis consists of the following steps: 
Step 1. By applying the empirical copula transform, we normalized the voxel values of ADC 
and rCBV to [0,1] and extracted the inter-dependence structure of the transformed ADC and 
rCBV values.  
Step 2. We discretized the resulting copula into a 10 × 10 matrix, in which each element 
𝑝(𝑖, 𝑗) represented the relative frequency of voxels within ROI falling into the corresponding 
discretized value range: 
𝑝(𝑖, 𝑗) =  
𝑃(𝑖, 𝑗)
∑ 𝑖 ∑ 𝑝(𝑖, 𝑗)10𝑗=1
10
𝑖=1
       (𝑖, 𝑗 = 1,2, … ,10) 
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respectively.  
The following quantities were also defined: 











𝜎𝑖 = ∑(𝑖 − 𝜇𝑖)





 ,       𝜎𝑗 = ∑(𝑗 − 𝜇𝑗)






The characteristic metrics of the copula matrix were calculated as second-order features 
(Haralick et al., 1973), which included Energy, Contrast, Entropy, Homogeneity, Correlation, 
SumAverage, Variance, Dissimilarity, and AutoCorrelation: 
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Step 3. A hierarchical clustering of patients was then performed based on the above features.  
7.3.5 Remark 
We should point out that in Step 2, when performing discretization, we only counted the 
relative frequency. Firstly, as frequency counting is invariant regarding weight changes of the 
data value, the extracted matrix is not affected by the possible priority shifting of the copula 
transform. Secondly, since we only computed the relative frequency of required data points 
relative to the given regions of interest, the extracted matrix is again invariant regarding 
possible deformation of the data distribution through the copula transform.  
7.4 Methods 
7.4.1 Patients  
The inclusion and exclusion criteria are in Section 3.1.1. This study was approved by the local 
institutional review board. Signed informed consent was obtained from all patients. Patient 
treatment is detailed in Section 3.2.2.1. Assessment of IDH-1 R132H Mutation and MGMT 
Methylation Status are described in 3.2. 
7.4.2 MRI acquisition 
MRI sequences in this study included: post-contrast T1-weighted, T2-weighted, dynamic 
susceptibility contrast-enhancement (DSC), diffusion tensor imaging (DTI) with inline ADC 
calculation, and multi-voxel 2D 1H-MRS chemical shift imaging (CSI). Sequence details are 
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provided in 3.3.2.2. All patient underwent MRI within 72hrs postoperatively as a clinical 
routine scanning to evaluate the extent of resection.  
7.4.3 Image processing 
DSC data were processed and rCBV maps were generated after leakage correction using 
NordicICE (NordicNeuroLab, Bergen, Norway), during which an arterial input function was 
automatically defined. For each subject, all MRI images were co-registered to T2-weighted 
images with an affine transformation, using the linear image registration tool (FLIRT) 
functions in FSL (Jenkinson et al., 2002). CSI data were processed as described in 3.4.4. Only 
CSI voxels completely in tumour T2-voxels were included for further analysis. 
7.4.4 Copula transform and patient clustering  
We applied the copula transform to the ADC and rCBV maps on each patient individually, 
with no outliers removed, using the method we proposed the analysis in Section 7.2. The study 
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Figure 7.1 Study design. All images are co-registered before tumour regions are manually segmented 
from post-contrast T1-weighted images (T1WI). Voxels are then extracted from both ADC and rCBV 
maps. Empirical copula transform is performed on the joint distribution of ADC and rCBV voxels, 
which is then discretized before extracting second-order features from the matrix. These features are 
used in patient clustering to reveal subtypes. 
 
To find the most stable and unambiguous patient clustering, we varied the number of clusters 
from 2 to 10. The optimal number of clusters was selected according to the majority vote among 
the 26 indices as implemented in the ‘Nbclust’ package in R (Charrad et al., 2014).  
7.4.5 Leave-one-out cross-validation of the clustering 
A leave-one-out cross-validation (LOOCV) procedure was applied for constructing and 
validating the patient clusters. The clustering steps were repeated by leaving one patient out of 
the cohort at each repetition. The consensus analysis was performed based on the clustering 
results obtained from the LOOCV approach. A consensus matrix M was calculated, where M 
(i, j) indicating percentage of times that the patients i and j were clustered together across the 
dataset perturbations. 
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7.4.6 Statistical analysis 
All analyses were performed in RStudio v3.2.3 (Rstudio, Boston, MA, USA). The clinical 
characteristics and CSI data of the clusters were compared with Kruskal-Wallis rank sum test, 
using the Benjamini-Hochberg procedure for controlling the false discovery rate in multiple 
comparisons. Kaplan-Meier and Cox proportional hazards regression analyses were performed 
to evaluate patient overall survival and progression-free survival. Survival analysis was based 
on the subset of patients (n = 84) who received concurrent temozolomide (TMZ) 
chemoradiotherapy followed by adjuvant TMZ post-operatively. Cox proportional hazards 
regression was performed, accounting for relevant covariates, including IDH-1 mutation, 
MGMT methylation, sex, age, the extent of resection and contrast-enhancing tumour volume.  
Patients who were alive at the last known follow-up were censored. The hypothesis of no effect 
was rejected at a two-sided level of 0.05.    
7.5 Results 
7.5.1 Patient population  
A total of 115 (84.6%) glioblastoma patients (mean age 59.3 years, range 22 - 76 years, 87 
males) were included in this study.  
7.5.2 Patient clustering  
Based on the quantitative features characterising the joint distribution of ADC and rCBV, three 
patient clusters were identified through hierarchical clustering, containing 40 patients (35 %), 
48 patients (42 %), and 27 patients (23 %) respectively (Figure 7.2). The average discretized 
matrix of ADC-rCBV joint distribution of three subtypes is demonstrated by Figure 7.3. Three 
subtypes showed no significant differences in clinical factors, as indicated in Table 7.1. The 
lactate levels of three subtypes were distinct (Table 7.2, Figure 7.4). Subtype III displayed a 
higher level of Lac/Cr ratio than Subtype II (P = 0.016) and Subtype I (P = 0.044). 
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Figure 7.2 Patient clustering. Three patient clusters are identified using the features extracted from the joint matrix 
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Table 7.1 Clinical characteristics of subtypes 
Variable 
Subtype I 
(n = 40) 
Subtype Ⅱ 
(n = 48) 
Subtype Ⅲ 
(n = 27) 
P value 
Age at diagnosis (range, yrs.) 59 (33 -76) 62 (38 -75) 55 (22 -73) 0.261 
Sex, number of patients 
Male 32 36 19 
0.663 
Female 8 12 8 
Extent of resection (of enhancing tumour), no. of patients 
Complete resection 30 30 17 
0.208 Partial resection 7 16 9 
Biopsy 3 2 1 
MGMT promoter methylation status*  
Methylated 20 17 11 
0.373 
 Unmethylated 19 30 14 
IDH-1 mutation status  
 Mutant 1 3 3 
0.354 
 Wild-type 39 45 24 
Tumour volumes(cm3) # 48.6 ± 31.4 41.0 ± 25.1 55.9 ± 33.1 0.172 
Survival (days)  
    Median OS (range) 403 (163-1077) 551 (78-1376) 407 (52-1333) 0.039† 
    Median PFS (range) 262 (93-758) 389 (25-1130) 244 (37-589) 0.025† 
*MGMT promoter methylation status unavailable for 4 patients; #mean ± SD of original data. †Log-Rank test; 
SD: standard deviation; MGMT: O-6-methylguanine-DNA methyltransferase; IDH-1: isocitrate dehydrogenase 
1; cm: centimeter; OS: overall survival; PFS: progression-free survival. P-values indicate the significance of 
comparison across all three groups. 
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Figure 7.3 Average joint distribution matrices of three subtypes. The joint distribution of transformed ADC 
and rCBV values is discretized into a 10 × 10 joint distribution matrix for each patient. This figure shows the 




Table 7.2 Lac/Cr ratio of subtypes 
 Descriptive Subtype II Descriptive Subtype II 
Subtype Mean ± SD 95% CI P value P value 
Subtype I 12.9 ± 2.7 7.2 ± 18.6 0.341 0.030 
Subtype II 9.8 ± 5.8 5.8 ± 13.8 / 0.006 
Subtype III 21.4 ± 3.4 14.3 ± 28.5 / / 
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Figure 7.4 Lac/Cr of three patient clusters. Lac/Cr ratio in Subtype III is significant higher than Subtype I 
(P = 0.030) and Subtype II (P = 0.006). Lac: lactate; Cr: creatine; *: P <0.05; **: P < 0.01. 
7.5.3 Leave-one-out cross-validation of patient subtypes 
After the leave-one-out cross-validation, the co-occurrence consensus clustering matrix was 
computed. The results showed that three patient clusters generated from the unsupervised 
clustering were highly stable (Figure 7.5). The mean values of the co-occurrence consensus 
clustering matrix were 0.91 for Subtype I, 0.95 for Subtype II and 0.98 for Subtype III. 
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Figure 7.5 Leave-one-out cross-validation of patient clusters. Consensus analysis was performed based on 
the 115 clustering results obtained from the leave-one-out cross-validation. The mean value of the co-
occurrence consensus clustering matrix is 0.91 for Subtype I, 0.95 for Subtype II and 0.98 for Subtype III. 
7.5.4 Survivals of patient subtypes 
Kaplan-Meier analysis using Log-rank test showed significantly different OS (P = 0.039) and 
PFS (P = 0.025) (Table 7.1, Figure 7.6) for the three identified subtypes. Cox regression models 
(Table 7.3) accounted for all relevant clinical covariates. In the multivariate model of OS, 
Subtype I showed significantly worse survival compared to Subtype II (HR = 3.042, P = 0.003). 
Extent of resection (HR = 2.691, P = 0.011) and tumour volume (HR = 1.019, P = 0.001) 
significantly affected OS. In multivariate modelling of PFS, Subtype I (HR = 1.992, P = 0.046) 
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and Subtype III (HR = 3.062, P = 0.009) showed significantly worse survival compared to 
Subtype II. Extent of resection (HR = 2.710, P = 0.007), and MGMT methylation status (HR 
= 0.532, P = 0.025) significantly affected PFS. Figure 7.7 demonstrates a case from Subtype 
II. 
 
Figure 7.6 Survivals of patient clusters.  Log-rank test shows that Subtype II displays better OS (P = 0.039) 
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Table 7.3 Multivariate modelling of survivals 
Factor 
OS PFS 
HR 95% CI 
P 
value 
HR 95% CI 
P 
value 
Age 1.004 0.971-1.038 0.812 1.027 0.994-1.062 0.106 
Sex (M) 1.242 0.624-2.471 0.537 1.807 0.976-3.346 0.060 
Extent of resection  2.691 1.259-5.754 0.011 2.710 1.321-5.560 0.007 
MGMT promoter methylation status* 0.565 0.307-1.040 0.067 0.532 0.306-0.924 0.025 
IDH mutation status 1.066 0.286-3.973 0.925 0.936 0.270-3.246 0.917 
Tumour volume# 1.019 1.008-1.030 0.001 1.002 0.991-1.012 0.742 
Subtype I 3.042 1.453-6.367 0.003 1.992 1.011-3.925 0.046 
Subtype III 1.857 0.790-4.367 0.156 3.062 1.327-7.062 0.009 
*MGMT promoter methylation status unavailable for 2 patients; #contrast-enhancing tumour volume. HR: 
hazard ratio; MGMT: O-6-methylguanine-DNA methyltransferase; IDH-1: isocitrate dehydrogenase 1; OS: 
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Figure 7.7 Case example of Subtype II.  Pixel-wise ADC values (A) and rCBV values (B) are overlaid on 
post-contrast T1 weighted images. After the copula transform, the joint distribution are discretized (C).  The 
matrix demonstrates a uniform distribution, which suggests a low inter-dependence of ADC and rCBV in this 
case. 
7.6 Discussion 
In this study, we characterized the inter-dependence of ADC and rCBV using copula transform 
and discrete feature extraction, and evaluated the clinical significance of the inter-dependence 
characteristics in patient outcomes. The results showed that the inter-dependence of perfusion 
and diffusion imaging can provide a useful tool for evaluating the variation of the tumour 
microenvironment. The inter-dependence between perfusion and diffusion imaging may offer 
useful information for patient stratification. 
Tumour microstructure estimated from diffusion imaging and vascularity estimated from 
perfusion imaging can describe the key characteristics associated with tumour pathogenesis. 
Although existing evidence suggests benefits from combining imaging techniques to identify 
tumour sub-regions that are responsible for treatment failure (Boonzaier et al., 2017a), 
systematic measures to integrate perfusion and diffusion imaging are lacking. Previous studies 
have validated the robustness of copula transform in estimating non-linear correlation in 
multimodal neuroimaging data analysis (Ince et al., 2017). Here we leveraged the copula 
transform to extract the joint distribution matrix to investigate the interaction between 
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perfusion and diffusion imaging. The second-order statistics calculated from the joint 
distribution matrix of transformed ADC and rCBV can yield an array of measures that describe 
the overall heterogeneity of the joint distribution. To avoid the potential weight change during 
the copula transform, we used discretized features for characterization. The subtypes revealed 
by this approach demonstrated no significance in clinical factors, but were significantly 
different in patient outcomes. This finding may suggest that the interaction between perfusion 
and diffusion imaging offer information which is complementary to clinical factors for 
evaluating tumour aggressiveness.  
The second-order features of ADC-rCBV joint distribution in Subtype III demonstrated 
diagonalised characteristics, as shown in Figure 3. This suggested high inter-dependence 
between microvasculature and microstructure in this subtype. Correspondingly, this subtype 
had a higher lactate level than the other two subtypes, indicating a more hypoxic 
microenvironment. Interestingly, although Subtype I showed the most uniform distribution 
characteristics among the three subtypes, and therefore demonstrated the less inter-dependent 
vasculature and microstructure, the survival of this subtype was worse than Subtype II. The 
higher lactate level of Subtype I implies more hypoxic microenvironment than Subtype II. This 
finding suggests that both high and low inter-dependence between vasculature and 
microstructure are associated with more hypoxic tumour microenvironment and more invasive 
phenotypes.  A possible explanation for this association could be that Subtype III may represent 
a highly proliferative phenotype with an unmet oxygen demand leading to global hypoxia, 
while Subtype I may have a less coupled microvasculature and microstructure, leading to sub-
regional hypoxia.  Both could lead to treatment resistance and poorer outcomes, as 
demonstrated by our findings.  
Our findings have clinical significance. The subtypes revealed by the inter-dependence 
between perfusion and diffusion may give insights potentially relevant for treatment selection. 
Our findings showed that both high and low inter-dependent tumour microvasculature and 
microstructure may be correlated with a higher degree of hypoxia, which may lead to resistance 
to radiation therapy.  Cytoreductive surgery may be more crucial in these phenotypes. Future 
studies using a prospective cohort study design is needed to validate the clinical significance.  
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Our approach had limitations. Firstly, the resolution of CSI was lower than the resolution of 
the anatomical imaging and 1H MR spectroscopy voxels were, therefore, larger than rCBV and 
ADC voxels. Secondly, our findings have not been validated in another independent validation 
cohort. Lastly, to reduce our cluster complexity, we applied discretization to the copula-
transformed joint matrix in this study, our future work will focus on feature extraction 
technique that incorporates the weight and continuous information of copula matrix.   
7.7 Conclusions 
In conclusion, the inter-dependence between perfusion and diffusion imaging offer useful 
information that could potentially be used for glioblastoma patient stratification, by evaluating 
variation of the tumour microenvironment. This approach provides an overall measure of 
tumour microenvironment using multimodal MRI. This approach could be extended to include 




Chapter 8 Radiomic Features from Multimodal 
MRI Show Improved Accuracy in Predicting MGMT 
Promoter Methylation in Glioblastoma 
8.1 Abstract 
Objectives 
To determine whether physiological MRI can provide improved accuracy compared to 
structural MRI in predicting O6-methylguanine-DNA methyltransferase (MGMT) promoter 
methylation status in glioblastoma, using a radiomics approach.  
Methods 
A total of 115 primary glioblastoma patients were prospectively recruited for treatment. Pre-
operative MRI included structural (T1-weighted, T2-weighted, post-contrast T1-weighted and 
FLAIR imaging) and physiological (diffusion tensor and dynamic susceptibility contrast 
imaging) sequences. Radiomic features were extracted from each modality separately. Feature 
ranking was performed on structural and physiological image features using an ensemble 
ranking method. Four supervised classifiers, including support vector machine, random forest, 
neural network and naïve Bayes, were compared. A ten-fold cross-validation was applied. An 
independent cohort including 15 primary glioblastomas was used to validate the predictive 
model. The prognostic values of MGMT methylation status and selected radiomics features 
were compared using survival models. 
Results 
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The radiomics model based on physiological images showed better performance than structural 
images in all classifiers. Neural network achieved best prediction performance (structural 
model: AUC = 0.78, accuracy = 0.71; physiological model: AUC = 0.76, accuracy = 0.84) 
compared to other classifiers. The neural network predictive model obtained similar 
performance in the validation cohort. For predicting 12-month progression-free survival, the 
model of radiomic features and clinical factors outperformed and the model of MGMT 
methylation and clinical factors (P = 0.010). 
Conclusions 
Radiomic features can predict MGMT promoter methylation status of glioblastoma using 
supervised machine learning schemes. Models based on physiological image features provide 
increased performance compared to models based on structural image features. 
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8.2 Introduction 
In previous chapters, we utilise multi-parametric MRIs to reveal the intra-tumoural and inter-
tumoural heterogeneity of glioblastoma. As we discussed in Chapter 1, Radiomics is a 
quantitative approach of tumour characterisation, with a large number of features extracted 
from the images. These features have been shown to differentiate tumour phenotypes with 
different underlying molecular pathways and patient survival time (Itakura et al., 2015). Here 
we would investigate the role of radiomics in the study of tumour heterogeneity.  
As we discussed in Chapter 1, glioblastoma is among the most lethal cancers. Concurrent TMZ 
chemoradiotherapy has considerably improved patient survival in newly diagnosed 
glioblastoma patients (Hegi et al., 2005b) and is recommended as standard of care (Stupp et 
al., 2010). Glioblastoma patients, however, display inconsistent response to TMZ. Better 
response to TMZ can be observed from a subgroup of patients with a methylated O6-
methylguanine-DNA methyltransferase (MGMT) promoter (Stupp et al., 2009). MGMT is 
central in maintaining genomic integrity by encoding a DNA repair protein. MGMT, therefore,  
helps to reduce the tumour cell DNA damage caused by TMZ (Pegg, 1990). The methylation 
of MGMT promoter can lead to increased sensitivity to TMZ by silencing the MGMT 
expression (Hegi et al., 2008). As such, the promoter methylation of MGMT has been widely 
used as an independent favourable prognostic factor in glioblastoma patients (Dunn et al., 
2009b). Pyrosequencing is reported to be reproducible and robust in assessing MGMT 
promoter methylation (Mikeska et al., 2007). This approach, however, relies on the tissue 
obtained via invasive methods. 
Recently, radiomic features were reported to reflect MGMT promoter methylation status 
(Korfiatis et al., 2016, Xi et al., 2017, Li et al., 2018). However, the features used in these 
studies were extracted from structural images only, which may be prone to be non-specific 
(O'Connor et al., 2008). The purpose of this current study is to determine whether physiological 
MRIs can provide improved accuracy in predicting MGMT promoter methylation status. We 
utilized two sets of radiomic features extracted from structural and physiological MRIs 
respectively. These radiomic features, which describe the tumour shape, margin, intensity 
histogram and texture, were used to build predictive models of MGMT promoter methylation 
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status, in which multiple classifiers were implemented. The predictive accuracies of the models 
were compared and features of particular importance in prediction were explored.  
8.3 Methods  
8.3.1 Development cohort 
The inclusion and exclusion criteria are in Section 3.1.1. This study was approved by the local 
institutional review board. Signed informed consent was obtained from all patients. Patient 
treatment is detailed in Section 3.2.2.1. Assessment of IDH-1 R132H Mutation and MGMT 
Methylation Status are described in 3.2.  
8.3.2 Pre-operative MRI acquisition 
A 3-Tesla MRI system (Magnetron Trio; Siemens Healthcare, Erlangen, Germany) with a 
standard 12-channel receive-head coil was used for pre-operative MRI scan. MRI sequences 
included structural sequences (T1-weighted [T1W], T2-weighted [T2W], pre-contrast T1-
weighted [T1C] and T2-weighted fluid attenuated inversion recovery [FLAIR]), dynamic 
susceptibility contrast (DSC) and diffusion tensor imaging (DTI). The complete scanning 
protocol is detailed in Section 3.3.2.2.  
8.3.3 Image processing 
All MRI images were co-registered to T2W images with an affine transformation, using the 
FSL linear image registration tool (FLIRT) (Jenkinson et al., 2002). Mean diffusivity (MD) 
and fractional anisotropy (FA) were obtained from DTI using FDT. The relative cerebral blood 
volume (rCBV), mean transit time (MTT) and relative cerebral blood flow (rCBF) maps were 
calculated from the DSC. Tumour ROIs were manually drawn as described in 3.4.6.1. The 
study design is summarized in Figure 8.1. 
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Figure 8.1 Study design. Structural sequences (T1-weighted, T2-weighted, post-contrast T1-weighted and 
FLAIR) and physiological sequences (MD and FA are calculated from DWI; rCBV, rCBF and MTT are 
calculated from PWI). All images are co-registered to T2-weighted images and then normalized using the 
histogram-matching method. Radiomics features are extracted from the manually segmented tumour regions. 
Features include intensity, shape, texture, and margin features. Feature ranking is performed on structural, 
physiological imaging and their combination, based on an ensemble importance score. Support vector machine, 
random forest, neural network and naïve Bayes are applied in classification using a ten-fold cross-validation. 
The optimal combination of hyperparameters in each classifier and the number of features used in the classifiers 
are tuned according to the prediction accuracy. A permutation test is performed to examine if the performance 
is achieved by chance. Prognostic value of MGMT methylation status and selected image features are compared 
in survival models. 
 
8.3.4 Radiomic feature extraction 
We defined 3D radiomic features to characterize the tumour. Features were extracted from 
structural images (T1W, T2W, FLAIR, and T1C) and physiological images (FA, MD, rCBV, 
rCBF, MTT). From each map, a total of 943 features were extracted automatically in MATLAB 
(MathWorks, Natick, MA) v2017b using open-source code available in Github (Echegaray et 
al., 2017). Image features include: (1) shape features (four Size features describing the tumour 
size; 39 Local Volume Invariant Integral [LVII] features describing the local curvature of the 
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tumour; 430 Surface Roughness features characterizing the surface of the tumour: and one 
Sphericity feature describing how similar the shape of the  tumour is to a sphere); (2) margin 
features (25 Edge Sharpness features describing intensity changes between the interior and 
exterior of the tumour); (3) intensity features (12 features describing the statistics of pixel 
values within the tumour) (4) Grey-level co-occurrence matrix (GLCM) texture features (432 
features measuring the spatial distribution of pixel intensities within the tumour).  
8.3.5 Feature ranking  
Feature ranking was performed using the R package ‘EFS’ (Neumann et al., 2017), an 
ensemble feature ranking method that incorporates eight feature selection methods for 
binary classifications. Each feature is given an importance score between 0 and 1, with 
1 indicating high importance for classification.  This method seeks to avoid the specific 
bias caused by one single feature selection method, reduce feature redundancy and 
improve the interpretability of feature reduction (Saeys et al., 2008). 
8.3.6 Classification scheme 
We implemented Support Vector Machines (SVM), Random Forest (RF), Naïve Bayes (NB) 
and Neural Network (NN) classifiers to predict MGMT methylation status. A detailed 
description of the four classifiers can be found in Section 3.4.7.3. All classifiers were trained 
and evaluated in RStudio with the package ‘Caret’ (Kuhn, 2008). The optimal combination of 
hyperparameters in each classifier and number of features selected in the classifiers were tuned 
according to prediction accuracy, with 10-fold cross validations repeated 200 times for each 
classifier. The performance of each classifier was evaluated according to the prediction 
accuracy, specificity, sensitivity and the area under the receiver operating characteristic curve 
(AUC). The performance results in the training set were reported as the average value across 
200 times. 
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8.3.7 Permutation test 
We performed a permutation test to evaluate the accuracy of the proposed methods. The test 
was performed using the R function ‘sample’ to permute the MGMT promoter methylation 
status of the entire cohort without replacement. The test was repeated 1000 times, with each 
classifier procedure running through in each repetition. The P values were calculated under the 
null hypothesis that the predicted results by the methods are random (Phipson and Smyth, 
2010). 
8.3.8 Independent validation cohort  
To further evaluate the classifier performance, another patient cohort which included 15 
glioblastoma patients were analysed using an identical pipeline for image processing, feature 
extraction and classification. A different 3T system (MR750, GE Healthcare, Waukesha, WI) 
and a different imaging protocol were used for the scanning. The imaging protocol is as 
follows: Axial T1W: TR/TE/TI: 8.2/3.2/450ms; slice thickness: 1mm; flip angle 12°; FOV 100 
× 100 mm;), after intravenous injection of 9 mL gadobutrol (Gadovist,1.0 mmol/mL; Bayer, 
Leverkusen, Germany), T1C imaging was acquired; Axial T2W: TR/TE/TI: 5226/8ms; flip 
angle 111°; FOV 100 × 100 mm; slice thickness: 6mm; FLAIR: TR/TE/TI: 8000/125/2158 ms; 
flip angle 111°; FOV 80 × 80 mm; slice thickness: 7mm; DTI: TR/TE 8000/88ms; flip angle 
90°; FOV 100 × 100 mm; slice thickness: 3mm; 64 directions; b values 1000 sec/mm2; DSC: 
TR/TE 2000/17 ms; flip angle 60°; FOV 100 ×100 mm; slice thickness: 6mm, with 9 mL 
gadobutrol followed by a 20 mL saline flush.   
8.3.9 Statistical analysis 
All analyses were performed in RStudio v3.2.3. Patient characteristics of MGMT promoter 
methylated and unmethylated group were compared using Welch Two Sample t-test. Survival 
was tested on the patients who received concurrent temozolomide (TMZ) chemoradiotherapy 
followed by adjuvant TMZ post-operatively. Patients who were alive at the last known follow-
up were censored.  
 
8.4 Results 153 
 
To further reduce the number of features and identify the optimal survival models, multivariate 
Cox regression with forward and backward stepwise selection procedures was performed, 
considering other relevant clinical covariates. Model performance for predicting 12-month 
overall survival (OS) and progression-free survival (PFS) were evaluated using Akaike 
Information Criterion (AIC). Survival models were constructed firstly using all clinical 
covariates including MGMT promoter methylation status, and then using the selected image 
features to replace MGMT promoter methylation status. The performance of the models was 
compared using the area under the receiver operator characteristics curve (AUC). The 
hypothesis of no difference was rejected at a two-sided level of 0.05.  Mean values of variables 
are presented ± standard deviation [SD]. 
8.4 Results 
8.4.1 Patients and regions of interest 
A total of 136 patients were recruited for pre-operative MRI scans. After surgery, 21 of 136 
(15.4 %) patients were excluded due to non-glioblastoma pathology diagnosis. Another four 
patients were excluded due to missing MGMT promoter methylation status. Thus, altogether 
111 of 115 (96.5 %) patients (mean age 59 years, range 22-75 years, 83 males) were included, 
and 82 of 111 (73.9 %) patients received concurrent TMZ chemoradiotherapy followed by 
adjuvant TMZ post-operatively. Other patients received short-course radiotherapy (16.2 %, 
18/111) or best supportive care (9.9 %, 11/111), due to poor post-operative status. Four of 82 
patients (4.9 %) were lost to follow up. Clinical characteristics of all patients, and 
methylated/unmethylated subgroups are summarized in Table 8.1.  
The contrast-enhancing volume of the methylated tumours was 48.4 ± 32.7 cm3 and 56.8 ± 
33.8 cm3 for unmethylated tumours (P = 0.185). The non-enhancing volume of the two groups 
were 58.9 ± 47.4 cm3 and 67.2 ± 41.9 cm3 (P = 0.341). A full comparison of the two groups 
was detailed in Table 8.1.   
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Table 8.1 Clinical characteristics of development cohort 
Variables Patient Number P value  
 
Total  
(n = 111) 
Methylated* 
 (n = 48) 
Unmethylated* 
(n = 63) 
 
Age at diagnosis 
   <60 39 32 40 0.446 
   ≥60 72 16 23  
Sex 
   Male 83 34 49 
0.415 
   Female 28 14 14 
Extent of resection (of enhancing tumour) 
   Complete resection  76 34 42 
0.642    Partial resection 31 13 18 
   Biopsy 4 1 3 
IDH-1 mutation status 
   Mutant 7 4 3 
0.464 
   Wild-type 104 44 60 
Pre-operative Tumour volumes(cm3) # 
    Contrast-enhancing  53.2 ± 33.3 48.4 ± 32.7 
56.8 ± 33.8 
0.185 
    Non-enhancing  63.6 ± 44.3 58.9 ± 47.4 67.2 ± 41.9 0.341 
Survival (days) 
   Median OS (range) 424 (52-1259) 475 (52-1259) 
422 (78-890) 
0.059† 
   Median PFS (range) 262 (25-1130) 318 (25-1130) 
246 (47-747) 
0.067† 
*Patients were subgrouped according to MGMT promoter methylation status. #mean ± SD of original data. 
†Log-Rank test. SD: standard deviation; MGMT: O-6-methylguanine-DNA methyltransferase; IDH-1: 
Isocitrate dehydrogenase 1; cm: centimeters; OS: overall survival; PFS: progression-free survival. 
 
 
8.4.2 Feature Ranking and Classification Performance 
Both structural and physiological image features were ranked according to the ensemble 
importance score. All classifiers showed fair performance in predicting MGMT methylation 
status (Table 8.2). The results showed that physiological image features resulted in higher 
prediction accuracy than the structural image features in four classifiers. A combination of 
physiological and structural features showed further improvement in accuracy. The 
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permutation test indicated that prediction accuracy obtained from the four classifiers were all 
significantly higher than by chance (all P < 0.001).  
Table 8.2 Structural features selected in neural network classifier in development cohort (n = 111) 
 
SVM RF NN NB 
 STR PHY Hybrid STR PHY Hybrid STR PHY Hybrid STR PHY Hybrid 
Feature 
number 
8 5 10 6 10 15 5 6 14 5 5 14 
Accuracy 0.71 0.74 0.78 0.68 0.74 0.77 0.71 0.76 0.84 0.69 0.74 0.75 
Sensitivity 0.74 0.79 0.82 0.74 0.83 0.83 0.72 0.80 0.83 0.65 0.79 0.77 
Specificity 0.67 0.69 0.74 0.60 0.62 0.69 0.71 0.71 0.86 0.75 0.68 0.73 
PPV 0.75 0.77 0.80 0.71 0.74 0.78 0.76 0.78 0.89 0.77 0.76 0.79 
NPV 0.67 0.71 0.76 0.64 0.73 0.76 0.66 0.73 0.80 0.62 0.71 0.70 
AUC 0.74 0.81 0.84 0.74 0.81 0.83 0.78 0.84 0.87 0.76 0.78 0.84 
STR: structural imaging; PHY: physiological imaging; Hybrid: a combination of structural and physiological imaging. PPV: positive 
predictive value; NPV: negative predictive value; AUC: area under the receiver operating characteristic (ROC) curve; SVM: support 
vector machine; RF: random forest; NN: neural network; NB: Naïve Bayes. 
 
The performance comparison of four classifiers, based on AUC and accuracy, shows that NN 
had a higher prediction performance than other classifiers. The structural, physiological image 
features and their combination selected by the ensemble ranking and the NN classifier are 
presented in Table 8.3 - 8.5. 
Table 8.3 Structural features selected in neural network classifier in development cohort (n = 111) 
 Importance score Feature 
1 1.00 LVII _Radius_3mm_range 
2 0.89 T2_glcm_distance_1mm_energy_interquartileRange 
3 0.88 T2_glcm_distance_1mm_contrast_median 
4 0.86 T1_glcm_distance_3mm_sumMean_min 
5 0.84 T2_glcm_distance_1mm_sumMean_mean 
 
 
Table 8.4 Physiological features selected in neural network classifier in development cohort (n = 111) 
 Importance score Feature 
1 0.73 LVII_Radius_3mm_range 
2 0.69 FA_glcm_distance_1mm_contrast_min 
3 0.67 rCBF_edgeSigmoidFitting_window_median 
4 0.65 MD_glcm_distance_1mm_contrast_kurtosis 
5 0.64 MTT_glcm_distance_3mm_clusterShade_skewness 
6 0.64 MTT_glcm_distance_1mm_entropy_median 
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Table 8.5 Hybrid feature ranking in neural network classifier in development cohort (n = 111) 
 Importance score Feature 
1 0.73 LVII_Radius_3mm_range 
2 0.69 FA_glcm_distance_1mm_contrast_min 
3 0.67 rCBF_edgeSigmoidFitting_window_median 
4 0.65 MD_glcm_distance_1mm_contrast_kurtosis 
5 0.65 T2_glcm_distance_1mm_energy_interquartileRange 
6 0.64 MTT_glcm_distance_3mm_clusterShade_skewness 
7 0.64 MTT_glcm_distance_1mm_entropy_median                                    
8 0.64 T2_glcm_distance_1mm_contrast_median                
9 0.64 MD_glcm_distance_1mm_clusterTendency_skewness                           
10 0.62 T1_glcm_distance_3mm_sumMean_min   
11 0.62 MTT_glcm_distance_3mm_inverseVariance_skewness  
12 0.61 T2_glcm_distance_1mm_sumMean_mean  
13 0.60 rCBV_glcm_distance_3mm_maxProbability_kurtosis 





8.4.3 Diagnostic Validation of Radiomics Features  
Using the above selected features and NN classifier, the validation cohort achieved an AUC of 
0.73 and 0.82 respectively. The combination of structural and physiological image features 
achieved an AUC of 0.96 (Table 8.6). 
Table 8.6 Performance of NN in validation cohort(n = 15)  
 STR PHY Hybrid 
Accuracy 0.67 0.73 0.87 
Sensitivity 0.50 0.75 0.75 
Specificity 0.86 0.71 1.00 
PPV 0.80 0.75 1.00 
NPV 0.60 0.71 0.78 
AUC 0.73 0.82 0.96 
STR: structural imaging; PHY: physiological imaging; Hybrid: a 
combination of structural and physiological imaging. PPV: positive 
predictive value; NPV: negative predictive value. 
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8.4.4 Prognostic Values of Radiomic Features 
The stepwise procedure based on AIC selected four and one image features for the PFS model 
and OS model respectively (Table 8.7), from the combination of structural and physiological 
image features selected by the NN classifier.  For the prediction of 12-month PFS and OS, 
AUC of the model based on image features and clinical factors was higher than the model based 
on MGMT methylation status and clinical factors (PFS: P = 0.010; OS: not significant, Figure 
8.2).  
 
Figure 8.2 Comparison of survival models based on MGMT promoter methylation status and imaging 
features.  For the prediction of 12-month PFS and OS, AUC of the model based on image features and other 
clinical factors was significantly higher (0.87, confidence interval [CI]: 0.78-0.95) than the model with MGMT 
and other clinical factors (0.78, CI: 0.67-0.89, P = 0.010). For the prediction of 12-month PFS, AUC of the 
model with image features and other clinical factors was higher (0.84, CI: 0.72-0.95) than the model with 
MGMT and other clinical factors (0.82, CI: 0.71-0.94, not significant). 
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Table 8.7 Stepwise multivariate Cox regression in development cohort (n = 111) 
Variables 
Progression-free survival* Overall survival* 
HR 95% CI P  HR 95% CI P  
Extent of resection 4.07 
2.088-
7.941 


























0.023 / / / 
*Multivariate Cox models accounted for IDH-1 mutation status, MGMT methylation status, sex, age, the extent 
of resection and contrast-enhancing tumour volume. A stepwise procedure was performed to select optimal 
models.  HR: hazard ratio; CI: confidence interval. 
8.5 Discussion 
In this study, we sought to explore the radiomic features that could predict MGMT promoter 
methylation status of glioblastoma, and compare the predictive values of radiomic features 
extracted from structural or physiological images. Our results showed that physiological 
imaging can provide more accurate prediction compared to structural imaging; neural network 
classifier may potentially offer a reliable classification scheme for MGMT promoter 
methylation prediction.  
Previously, several studies reported the relevance of structural imaging markers in predicting 
MGMT methylation status (Romano et al., 2013, Moon et al., 2012, Li et al., 2018). One study, 
however, reported a poor correlation between imaging features with MGMT promoter 
methylation status (Carrillo et al., 2012). Since only semantic features from the radiology 
lexicon were used, the authors suggested advanced imaging post-processing techniques may 
be needed to extract more useful features, for example, textural features. Another study 
reported that ring enhancement and structural texture features were associated with MGMT 
methylation status with an accuracy of 71% in classification, and that unmethylated tumours 
had larger tumour volume than methylated tumour (Drabycz et al., 2010). Consistent with this 
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study, our structural features yielded similar accuracies, although the difference in tumour 
volume was not confirmed.  
Inconsistent results were reported regarding the usefulness of diffusion and perfusion 
parameters in MGMT methylation status prediction. The apparent diffusion coefficient (ADC) 
and rCBF were reported to achieve high accuracies in various studies (Romano et al., 2013, 
Han et al., 2018). Another study, however, showed that ADC and FA were not useful in 
differentiating methylated and unmethylated glioblastoma, whereas Ktrans values of methylated 
cases were significantly higher than in unmethylated cases (Ahn et al., 2014). In our study, we 
leveraged the radiomics approach to integrate physiological modalities. The results showed 
that physiological imaging offers higher accuracy and sensitivity in four classifiers, and higher 
specificity in two classifiers (SVM and RF), compared to structural imaging. This finding 
supports the utility of physiological imaging for predicting MGMT methylation.  
In accordance with several studies (Drabycz et al., 2010, Korfiatis et al., 2016, Xi et al., 2017), 
our results showed that texture features provide the most valuable feature set for prediction. 
Texture features can measure the tumour heterogeneity by quantifying spatial complexity in 
images (O'Connor et al., 2015). The usefulness of texture features for predicting molecular 
subtypes (Yang et al., 2015), IDH mutation status (Jakola et al., 2018) and 1p/19q co-deletion 
(Brown et al., 2008) were reported previously, suggesting the potential of texture features in 
bridging imaging phenotypes and genetic/epigenetic signatures. Further, we found that one 
tumour shape-based feature (Local Volume Invariant Integral) ranked the highest importance. 
As this feature quantifies the local curvature of the tumour, our finding implies that methylated 
and unmethylated glioblastomas may be different in tumour morphology. 
There are limitations in our study. Firstly, high numbers of radiomic features may require larger 
datasets to fully test the robustness of feature selection and classification scheme, ideally from 
multiple centres. Secondly, in the determination of MGMT promoter methylation status, we 
used a 10% threshold of four CpG islands in the MGMT promoter, which may be optimized 
by further studies. This may possibly explain the OS and PFS of the MGMT-methylated 
subgroup only showed marginally significant better OS and PFS than MGMT-unmethylated 
subgroup. Future studies will need to investigate the potential of radiomics features in 
prediction the continuous MGMT methylation percentage. Thirdly, one of the principal 
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challenges in radiomics is the robustness of predictive features. In our study, we used an 
ensemble feature selection to avoid the specific bias from any single algorithm. Many other 
efforts have been made, including a recent study using all-relevant feature selection (Li et al., 
2018). Future efforts are needed to test algorithms for clinically reproducible and applicable 
features.   
8.6 Conclusion 
Radiomic features can predict MGMT promoter methylation status of glioblastoma using 
supervised machine learning schemes. Physiological image features demonstrated higher 
prediction accuracies than structural image features. Features that measure tumour image 





Chapter 9 General Conclusions and Limitations 
9.1 Summary of findings 
The aim of this thesis was to investigate the utility of multi-parametric MRI, explored by 
habitat imaging, imaging integration techniques and radiomics approach, in patient prognosis 
determination and epigenetic prediction. The main hypotheses tested are: 
1. Joint histogram analysis of isotropic and anisotropic diffusion components could 
differentiate tumour regions into sub-regions with different diffusion patterns, 
which may be useful for a better understanding of the intra-tumoural 
heterogeneity of tumour infiltration.  (Chapter 4) 
 
In Chapter 4, we proposed a method of joint histogram analysis, using DTI 
decomposition, to explore the heterogeneity of tumour infiltration. The intra-tumoural 
habitats revealed by this approach can provide incremental prognostic values for 
patients. A non-enhancing sub-region with decreased isotropic diffusion and increased 
anisotropic diffusion was associated with worse patient outcomes (for PFS, HR = 1.08, 
P < 0.001; for OS, HR = 1.36, P < 0.001) and could possibly be a sub-region for targeted 
therapy. The findings of this study support the usefulness of DTI in revealing intra-
tumoural invasive tumour habitats.  
 
2. Low perfusion compartments could be visualized and quantified using multi-
parametric quantitative MRI. The tumour habitats identified using this approach 
could correlate with patient prognosis. (Chapter 5) 
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In Chapter 5, we integrated ADC and rCBV for the identification of low perfused 
tumour habitats with different diffusivity. Higher lactate in the low perfused habitat 
with restricted diffusivity was associated with worse survivals (PFS: HR = 2.995, P = 
0.047; OS: HR = 4.974, P = 0.005). The findings of this study support the usefulness 
of habitat imaging using multi-parametric MRI for the identification of intra-tumoural 
invasive sub-regions. 
 
3. A multi-view feature selection and machine learning approach could effectively 
integrate histogram features from quantitative multi-parametric MRI. The 
selected imaging features using this approach may offer incremental values in 
survival prediction.  (Chapter 6) 
In Chapter 6, we applied a multi-view feature selection and clustering method, which 
can provide an effective integration of multi-parametric MRI for patient prognosis 
determination (for OS: P = 0.007; for PFS: P < 0.001). The histogram features selected 
can be used as potential prognostic markers. The findings of this study suggest the 
importance of integrating multiple imaging modalities for MRI interpretation in the 
study of inter-tumoural heterogeneity. 
 
4. The inter-dependence of perfusion and diffusion imaging can be characterised, 
which would provide useful information for evaluating tumour 
microenvironment. The imaging phenotypes revealed by this approach could be 
of prognostic value (Chapter 7) 
In Chapter 7, we investigated the inter-dependence of microstructure and vasculature 
for glioblastoma characterisation, using perfusion and diffusion imaging. The patient 
subtypes revealed by this approach showed significant differences in patient survival 
(PFS: P = 0.046 and P = 0.009, respectively). The findings of this study suggest that 
the interaction of imaging modalities provides crucial information for understanding 
inter-tumoural heterogeneity. 
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5. Using radiomics approach, advanced physiological MRIs may provide improved 
accuracy than conventional structural MRIs, for the prediction of O6-
methylguanine-DNA methyltransferase (MGMT) promoter methylation status. 
The predictive models constructed using the selected radiomic features could 
improve the prognostic performance. (Chapter 8) 
In Chapter 8, we compared the values of advanced physiological MRI with structural 
MRI, in predicting MGMT promoter methylation status of glioblastoma, using a 
radiomics approach. Advanced physiological images showed better performance than 
structural images in the prediction of MGMT methylation status. The findings of this 
study suggest that physiological MRI provides more specific information for predicting 
epigenetic markers than structural MRI. 
9.2 Limitations of studies 
The limitations of experimental chapters (Chapter 4-8) have been described in each individual 
chapter. The general limitations of the project are described below. 
9.2.1 Patient inclusion criteria 
To target the patient with a diagnosis of supratentorial glioblastoma, a radiological diagnosis 
of glioblastoma was used, based on the contrast enhancement on post-contrast T1-weighted 
imaging. This may cause a bias by excluding those glioblastoma patients with non-enhancing 
lesions, although most glioblastoma is contrast-enhancing. We do exclude those non-
glioblastoma patients according to their post-operative pathology diagnosis. The generalisation 
of the findings of the thesis is therefore limited to the contrast-enhancing glioblastomas.  
9.2.2 Single centre cohort 
As we discussed in Section 1.10.2.4, to validate the imaging findings, an optimal validation 
cohort is from another independent centre, preferably from multiple centres. This purpose of 
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this procedure is not only to reduce systematic bias, but also to reduce the variance caused by 
different manufacturer/models of MRI scanners. The latter has long been known to 
significantly affect the reproducibility of imaging findings. This limitation could be improved 
by the future study using multiple centre cohorts.  
9.2.3 Sample size  
As discussed in 1.10.2.3, radiomics approach can generate a large amount of imaging feature 
for tumour characterisation. The relatively large numbers of features compared to the patient 
number may cause overfitting. The sample size of glioblastoma cohort, however, is limited by 
its relatively low incidence. To relieve this limitation, we have applied the various type of 
feature selection techniques, including the multi-view feature selection method (Chapter 6), 
ensemble feature ranking and selection method (Chapter 8) and the stepwise procedure 
(Chapter 5, 6, 8). In the future studies, multiple centre cohort may help to increase the sample 
size and improve robustness.  
9.2.4 Effects of dexamethasone 
Vasogenic oedema caused by the glioblastoma can be significantly relieved by the use of 
dexamethasone and improve patient outcomes. Therefore, it is unethical to withhold 
dexamethasone. Previous studies reported the effects of dexamethasone on rCBV (Bastin et al., 
2006), rCBF (Kirton et al., 2006), MTT (Bastin et al., 2006), MD (Sinha et al., 2004), FA 
(Sinha et al., 2004) and ADC (Minamikawa et al., 2004). A systematic literature review of 24 
articles showed that the use of dexamethasone may cause a decrease in tumour perfusion, and 
diffusion (Kotsarini et al., 2010). The patients in this thesis, however, were all in a steady dose 
of dexamethasone, which reflects the standard of patient care.   
9.2.5 Pseudoprogression 
As discussed in Section 1.9.2., the incidence of pseudoprogression is increasing since TMZ 
chemoradiotherapy was widely used. In this study, treatment response and tumour progression 
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were evaluated according to RANO criteria, which incorporates clinical and radiological 
changes. Pseudoprogression was suspected where new contrast enhancement appeared within 
first 12 weeks after completing chemoradiotherapy. In such cases, treatment was continued and 
pseudoprogression was identified where later response occurred. As a result, in some cases, 
true progression was determined retrospectively. 
9.2.6 Lack of histological validation 
Previously biopsies have been taken from the tumour, which helps to validate the correlation 
between DTI abnormalities with histological changes. The imaging findings of this thesis, 
however, still needs an image-guided biopsy. Although we included molecular biomarkers in 
Chapter 8 to show the usefulness of imaging marking in reflecting tumour biology, the 
validation of intra-tumoural habitats needs multiple biopsy and further evidence. We would 
argue that the advantage of imaging studies is to provide a non-invasive tool for clinical patient 
management. Further, we believe the findings of this study will provide a reference for 
targeting.  
9.3 Future directions 
This thesis aims to investigate the role of multi-parametric MRI and radiomics approach in the 
study of tumour heterogeneity. The work described here can be developed in the following 
directions: 
9.3.1 Image-guided biopsy to validate imaging biomarkers 
As discussed above, a lack of histological validation is one of the limitations of this thesis. 
Therefore, future work using image-guided multiple biopsies is a crucial step in future studies. 
This involves the improvement of the neuro-navigation system and clinical surgical procedure. 
To reduce the influence of brain shift during the craniotomy, a needle biopsy can be applied 
before durotomy. Using the multiple samples obtained through image-guided needle biopsy, 
genomic profiling can be applied, with the aim of 1) validating the imaging markers using 
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genomic profiling; 2) revealing intra-tumoural heterogeneity using tumour phylogenetic 
analysis; 3) investigating the integration of tumour cells with tumour microenvironment.  
9.3.2 Improving the reproducibility and robustness of the radiomics 
approach 
As we discussed in Section 1.10.4, the standardisation in radiomics workflow design is of 
crucial importance to the reproducibility of radiomics approach. The standardisation involves 
multiple processes in the radiomics approach, including imaging acquisition and 
reconstruction, data annotation, feature extraction and machine learning scheme. Particularly, 
the feature set identification has not reached consensus in the community. Different feature sets 
are being used in multiple laboratories, which may significantly influence the reproducibility 
of the radiomics approach. In future work, we aim to investigate the impact of feature definition 
in radiomics, by applying multiple feature extraction and model selection techniques. The 
robustness of feature sets will be compared for clinical validation. We have been prospectively 
recruiting an independent multi-centre cohort in a recent clinical trial called “Predicting sites 
of tumour progression in the invasive margin of glioblastomas (PRaM)”, which aims to 
investigate the robustness of imaging biomarkers from mixed scanners and imaging protocols, 
which would potentially bring benefits to the testing of reproducibility and robustness of 
radiomics.  
9.3.3 Incorporating radiomics and habitat imaging into prospective and 
longitudinal cohort study 
As we discussed in Section 1.10.4, for the clinical validation of the imaging markers identified 
using radiomics, it is crucial to involve multiple research centres and interdisciplinary 
collaboration. Our imaging study revealing invasive phenotypes showed clinical significance. 
These studies, however, were using a retrospective design, which may need further rigorous 
validation. Prospective study design, using the paradigm of clinical efficacy investigation, will 
be of importance to the clinical validation of imaging markers and habitats. Our future work 
will include a validation process incorporating the clinical and biological knowledge into 
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model testing. Longitudinal study design may also help the clinical validation of imaging 
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